masran的个人主页 - 老虎社区

masran

masran

暂无个人介绍

IP属地：未知

276关注

16粉丝

0主题

0勋章

2021-12-24

thx

抱歉，原内容已删除

2021-12-24

pls like

抱歉，原内容已删除

2021-12-24

good to hear

抱歉，原内容已删除

2021-12-23

like pls

抱歉，原内容已删除

2021-12-21

thx

Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>

2021-12-20

NIO very impressive

抱歉，原内容已删除

2021-12-18

like pls

抱歉，原内容已删除

2021-12-17

let see

抱歉，原内容已删除

2021-12-17

hurray

Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote>

2021-12-16

thx

抱歉，原内容已删除

2021-12-16

good thought

Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote>

2021-12-16

hurray

Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote>

2021-12-16

need booster

Rebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote>

2021-12-10

wow

Crypto stocks dipped in morning trading<blockquote>加密货币股票早盘下跌</blockquote>

2021-12-10

like pls

Grab and Lucid stocks plunged more than 10%<blockquote>Grab和Lucid股价暴跌逾10%</blockquote>

2021-12-02

coming up soon

Xpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价由涨转跌4%</blockquote>

2021-11-30

good

Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>新冠抗体药物受奥密克戎挑战初步检测显示</blockquote>

2021-11-30

think again

抱歉，原内容已删除

2021-11-30

enjoy wen it go up

AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票NFT赠品的AMC股票趋势</blockquote>

2021-11-24

enjoy the holiday

Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：周四美股因感恩节休市，周五提前三小时收盘</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582888796077977","uuid":"3582888796077977","gmtCreate":1619796055209,"gmtModify":1630548061864,"name":"masran","pinyin":"masran","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":16,"headSize":276,"tweetSize":98,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":698851498,"gmtCreate":1640347839561,"gmtModify":1640347839791,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698851498","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":2530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698851243,"gmtCreate":1640347676382,"gmtModify":1640347676614,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698851243","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":3148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698965862,"gmtCreate":1640278323261,"gmtModify":1640278323493,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"good to hear","listText":"good to hear","text":"good to hear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698965862","repostId":"1192606453","repostType":2,"isVote":1,"tweetType":1,"viewCount":2421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691250012,"gmtCreate":1640213796164,"gmtModify":1640213796381,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691250012","repostId":"1131862374","repostType":4,"isVote":1,"tweetType":1,"viewCount":2449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693712913,"gmtCreate":1640078865625,"gmtModify":1640078865830,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693712913","repostId":"1149530831","repostType":4,"repost":{"id":"1149530831","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640078220,"share":"https://www.laohu8.com/m/news/1149530831?lang=zh_CN&edition=full","pubTime":"2021-12-21 17:17","market":"us","language":"en","title":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149530831","media":"Tiger Newspress","summary":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Ma","content":"<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会(EC)已批准Veklury的有条件营销授权变更®（瑞德西韦）纳入不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）科学委员会人用药品委员会（CHMP）于12月16日积极建议扩大Veklury的适应症之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着COVID-19发病率再次攀升以及奥密克戎病毒等新变种的出现，我们需要像Veklury这样的有效工具来治疗该疾病的各个阶段，”传染病科主任Roger Paredes医学博士和IrsiCaixa艾滋病研究所表示。“我们现在可以使用Veklury来帮助防止高危患者进展为更严重的疾病，即使他们不需要氧气，以及继续利用Veklury作为治疗严重疾病的关键工具。这一最新批准也将有助于缓解已经因COVID-19负担而承受巨大压力的医疗保健系统的一些压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>EC的决定得到了一项3期随机、双盲、安慰剂对照试验结果的支持，该试验旨在评估静脉（IV）使用Veklury三天疗程治疗疾病进展高风险的非住院患者COVID-19的疗效和安全性。在一项对以1：1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，与安慰剂（5.3%【15/283】）相比，Veklury在第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），具有统计学意义p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗后出现的不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交给科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症增加了Veklury之前的有条件上市许可，使其能够治疗需要补充氧气（治疗开始时的低流量或高流量氧气或其他无创通气）的肺炎成人和青少年（12岁至18岁以下，体重至少40 kg）的COVID-19。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官、医学博士Merdad Parsey说：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些方法可以在疾病过程的早期使用，以帮助欧洲各地的COVID-19患者。”“随着我们对COVID-19疾病如何进展的了解越来越多，很明显，如果在病程早期使用，像Veklury这样的抗病毒药物可以产生重大影响。作为COVID-19住院患者的抗病毒护理标准，我们对Veklury在大流行前线继续发挥的作用感到自豪，我们相信Veklury现在将能够帮助欧洲更多患者缩短从COVID-19中康复的时间。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会(EC)已批准Veklury的有条件营销授权变更®（瑞德西韦）纳入不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）科学委员会人用药品委员会（CHMP）于12月16日积极建议扩大Veklury的适应症之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着COVID-19发病率再次攀升以及奥密克戎病毒等新变种的出现，我们需要像Veklury这样的有效工具来治疗该疾病的各个阶段，”传染病科主任Roger Paredes医学博士和IrsiCaixa艾滋病研究所表示。“我们现在可以使用Veklury来帮助防止高危患者进展为更严重的疾病，即使他们不需要氧气，以及继续利用Veklury作为治疗严重疾病的关键工具。这一最新批准也将有助于缓解已经因COVID-19负担而承受巨大压力的医疗保健系统的一些压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>EC的决定得到了一项3期随机、双盲、安慰剂对照试验结果的支持，该试验旨在评估静脉（IV）使用Veklury三天疗程治疗疾病进展高风险的非住院患者COVID-19的疗效和安全性。在一项对以1：1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，与安慰剂（5.3%【15/283】）相比，Veklury在第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），具有统计学意义p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗后出现的不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交给科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症增加了Veklury之前的有条件上市许可，使其能够治疗需要补充氧气（治疗开始时的低流量或高流量氧气或其他无创通气）的肺炎成人和青少年（12岁至18岁以下，体重至少40 kg）的COVID-19。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官、医学博士Merdad Parsey说：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些方法可以在疾病过程的早期使用，以帮助欧洲各地的COVID-19患者。”“随着我们对COVID-19疾病如何进展的了解越来越多，很明显，如果在病程早期使用，像Veklury这样的抗病毒药物可以产生重大影响。作为COVID-19住院患者的抗病毒护理标准，我们对Veklury在大流行前线继续发挥的作用感到自豪，我们相信Veklury现在将能够帮助欧洲更多患者缩短从COVID-19中康复的时间。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149530831","content_text":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.\n\"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"\nThe EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.\nThis expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).\n\"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":1653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693692245,"gmtCreate":1640011205087,"gmtModify":1640011205299,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"NIO very impressive","listText":"NIO very impressive","text":"NIO very impressive","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693692245","repostId":"1164238522","repostType":2,"isVote":1,"tweetType":1,"viewCount":1918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699829799,"gmtCreate":1639783265714,"gmtModify":1639783265921,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699829799","repostId":"2192497854","repostType":4,"isVote":1,"tweetType":1,"viewCount":1944,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690583165,"gmtCreate":1639691863789,"gmtModify":1639691863955,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"let see","listText":"let see","text":"let see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690583165","repostId":"2191674549","repostType":2,"isVote":1,"tweetType":1,"viewCount":1741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690589177,"gmtCreate":1639691736246,"gmtModify":1639691849682,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"hurray","listText":"hurray","text":"hurray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690589177","repostId":"1117904160","repostType":2,"repost":{"id":"1117904160","kind":"news","pubTimestamp":1639620135,"share":"https://www.laohu8.com/m/news/1117904160?lang=zh_CN&edition=full","pubTime":"2021-12-16 10:02","market":"us","language":"en","title":"Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1117904160","media":"InvestorPlace","summary":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s ","content":"<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（纽约证券交易所股票代码：蔚来）日即将来临，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-16 10:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（纽约证券交易所股票代码：蔚来）日即将来临，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117904160","content_text":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it looks like Nio Day will see the company revealing several new electric vehicles (EVs).\nThat includes a possible two new vehicle models, as well as a new vehicle brand.\nCurrent rumors claim one of the new vehicles in the ET5.\nThis is a mid-size sedan that will likely compete with other EVs on the market at a lower price than the ET7.\nTalk about the ET5 continues to heat up today after the EV company shared an image on its website.\nThis shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.\nThere’s also talk of a potential ET(, which would be a sports coupe.\n\n\nOther rumors claim we might see the company reveal a multipurpose EV as well during the event.\nOf course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.\nLuckily, that’s not too far away.\nNio will hold its special event on December 18, which is this Saturday.\nThe reveal event will take place at the Olympic Sports Center in Suzhou, China.\nNow we just have to wait for Nio Day to get here and confirm or bust all these rumors!","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":1894,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690334260,"gmtCreate":1639632309401,"gmtModify":1639632440388,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690334260","repostId":"2191099021","repostType":2,"isVote":1,"tweetType":1,"viewCount":2423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690334652,"gmtCreate":1639632284485,"gmtModify":1639632416387,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"good thought","listText":"good thought","text":"good thought","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690334652","repostId":"1191022113","repostType":2,"repost":{"id":"1191022113","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639626011,"share":"https://www.laohu8.com/m/news/1191022113?lang=zh_CN&edition=full","pubTime":"2021-12-16 11:40","market":"us","language":"en","title":"Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191022113","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — i","content":"<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了90,455股股票，估计价值8830万美元<b>特斯拉公司</b>，该股在连续几天下跌后上涨时获利了结。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收高1.82%，收于每股975.99美元。埃隆·马斯克(Elon Musk)领导的公司股价今年迄今上涨了约34%，过去一个月下跌了约7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>Ark自主技术与机器人ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易之前，特斯拉在ARKK和ARKW的权重已经跌破10%的门槛，分别为8.14%和9.35%。在ARKQ中，它占投资组合的10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易之前，这三只ETF持有特斯拉199万股股票，价值19.1亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>自9月以来，方舟投资一直在特斯拉寻求盈利——出售价值超过30亿美元的股票——此前，这家电动车公司多年来一直在低得多的水平累积股票。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在ETF中最大的押注——预计该股到2025年底将触及3,000美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他关键交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了104,489股股票，估计价值2,130万美元<b>Roku公司</b>在下降。该股周三收盘下跌7.95%，至每股203.94美元。</li><li>购买了705,660股股票，估计价值1,370万美元<b>罗宾汉市场公司</b>该股收涨1.93%，报每股19.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>凯西·伍德(Cathie Wood)在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了8800万美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-16 11:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了90,455股股票，估计价值8830万美元<b>特斯拉公司</b>，该股在连续几天下跌后上涨时获利了结。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收高1.82%，收于每股975.99美元。埃隆·马斯克(Elon Musk)领导的公司股价今年迄今上涨了约34%，过去一个月下跌了约7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>Ark自主技术与机器人ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易之前，特斯拉在ARKK和ARKW的权重已经跌破10%的门槛，分别为8.14%和9.35%。在ARKQ中，它占投资组合的10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易之前，这三只ETF持有特斯拉199万股股票，价值19.1亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>自9月以来，方舟投资一直在特斯拉寻求盈利——出售价值超过30亿美元的股票——此前，这家电动车公司多年来一直在低得多的水平累积股票。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在ETF中最大的押注——预计该股到2025年底将触及3,000美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他关键交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了104,489股股票，估计价值2,130万美元<b>Roku公司</b>在下降。该股周三收盘下跌7.95%，至每股203.94美元。</li><li>购买了705,660股股票，估计价值1,370万美元<b>罗宾汉市场公司</b>该股收涨1.93%，报每股19.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKQ":"ARK Autonomous Technology & Robotics ETF","ROKU":"Roku Inc","HOOD":"Robinhood","ARKW":"ARK Next Generation Internet ETF","TSLA":"特斯拉","ARKK":"ARK Innovation ETF","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191022113","content_text":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in Tesla Inc, booking profit in the stock as it rose after days of losses.\nThe stock pared earlier losses to close 1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.\nArk Invest sold the shares via the Ark Innovation ETF(BATS:ARKK), the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ) and the Ark Next Generation Internet ETF(BATS:ARKW) on Wednesday.\nTesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.\nThe three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.\nArk Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.\nTesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the $3,000 mark by the end of 2025.\nWood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker Xpeng Inc.\nHere are the other key trades on Wednesday:\n\nBought 104,489 shares — estimated to be worth $21.3 million — in Roku Inc on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.\nBought 705,660 shares — estimated to be worth $13.7 million — in Robinhood Markets Inc. The stock closed 1.93% higher at $19.50 a share.","news_type":1,"symbols_score_info":{"XPEV":0.9,"HOOD":0.9,"ARKK":0.9,"TSLA":0.9,"ROKU":0.9,"ARKQ":0.9,"ARKW":0.9}},"isVote":1,"tweetType":1,"viewCount":754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690335703,"gmtCreate":1639632201836,"gmtModify":1639632202079,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"hurray","listText":"hurray","text":"hurray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690335703","repostId":"1117904160","repostType":2,"repost":{"id":"1117904160","kind":"news","pubTimestamp":1639620135,"share":"https://www.laohu8.com/m/news/1117904160?lang=zh_CN&edition=full","pubTime":"2021-12-16 10:02","market":"us","language":"en","title":"Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1117904160","media":"InvestorPlace","summary":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s ","content":"<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（纽约证券交易所股票代码：蔚来）日即将来临，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022年蔚来日：12月18日蔚来股票投资者值得期待的13件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-16 10:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（纽约证券交易所股票代码：蔚来）日即将来临，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117904160","content_text":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it looks like Nio Day will see the company revealing several new electric vehicles (EVs).\nThat includes a possible two new vehicle models, as well as a new vehicle brand.\nCurrent rumors claim one of the new vehicles in the ET5.\nThis is a mid-size sedan that will likely compete with other EVs on the market at a lower price than the ET7.\nTalk about the ET5 continues to heat up today after the EV company shared an image on its website.\nThis shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.\nThere’s also talk of a potential ET(, which would be a sports coupe.\n\n\nOther rumors claim we might see the company reveal a multipurpose EV as well during the event.\nOf course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.\nLuckily, that’s not too far away.\nNio will hold its special event on December 18, which is this Saturday.\nThe reveal event will take place at the Olympic Sports Center in Suzhou, China.\nNow we just have to wait for Nio Day to get here and confirm or bust all these rumors!","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690018127,"gmtCreate":1639613230300,"gmtModify":1639613230475,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"need booster","listText":"need booster","text":"need booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690018127","repostId":"1194155872","repostType":4,"repost":{"id":"1194155872","kind":"news","pubTimestamp":1639613035,"share":"https://www.laohu8.com/m/news/1194155872?lang=zh_CN&edition=full","pubTime":"2021-12-16 08:03","market":"us","language":"en","title":"Rebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194155872","media":"RTTNews","summary":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day sli","content":"<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.</p><p><blockquote>新加坡股市周三再次下跌，此前一个交易日结束了连续两天下跌超过20点或0.7%的下跌。海峡时报指数目前略低于3,115点的高位，尽管预计周四将再次反弹。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.</p><p><blockquote>在FOMC货币政策会议结果公布后，全球对亚洲市场的预测乐观。欧洲和美国市场稳步走高，亚洲股市预计也将以类似的方式开盘。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.</p><p><blockquote>在房地产和工业股下跌后，海指周三小幅收低，而金融股则涨跌互现。</blockquote></p><p> For the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.</p><p><blockquote>当天，该指数在3,106.63点至3,120.55点之间交易后，下跌6.21点或0.20%，收于3,114.88点。成交量为8.834亿股，价值7.618亿新元。下跌股264家，上涨股180家。</blockquote></p><p> Among the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌0.34%，凯德综合商业信托下跌0.50%，City Developments下跌0.42%，Comfort DelGro上涨1.45%，Dairy Farm International暴跌2.42%，星展集团上涨0.19%，云顶新加坡退保0.64%，吉宝企业下跌0.39%，丰树商业信托下跌0.98%，丰树物流信托下跌0.53%，华侨银行下跌0.27%，胜科工业下跌0.51%，新加坡航空下跌0.20%，新加坡电信下跌0.41%，泰国饮料下跌0.75%，大华银行下跌0.15%，丰益国际下跌0.96%，扬子江造船、新加坡报业控股、新加坡科技工程和新天科技持平。</blockquote></p><p> The lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.</p><p><blockquote>华尔街的领先优势总体上是积极的，主要股指周三开盘小幅走低，但随后下午飙升，收盘大幅走高。</blockquote></p><p> The Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&amp;P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.</p><p><blockquote>道琼斯指数飙升383.25点，涨幅1.08%，收于35,927.43点；纳斯达克指数飙升327.94点，涨幅2.15%，收于15,565.58点；标普500指数上涨75.76点，涨幅1.63%，收于4,709.85点。</blockquote></p><p> The late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.</p><p><blockquote>在美联储宣布了人们普遍预期的加快缩减资产购买计划步伐的决定后，华尔街尾盘上涨。美联储以通胀发展和劳动力市场进一步改善为由表示，已决定将净资产购买速度每月减少300亿美元，是此前宣布的每月150亿美元的两倍。</blockquote></p><p> The Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.</p><p><blockquote>美联储表示，预计每个月净资产购买速度的类似减少可能是适当的，这表明该计划将于明年3月结束。分析师将随后的反弹部分归因于美联储没有更积极地加快停止资产购买的时间表。</blockquote></p><p> Meanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.</p><p><blockquote>与此同时，美联储还宣布了广泛预期的决定，将联邦基金利率目标区间维持在零至0.25%。与9月份的一次加息预测相比，央行的最新预测2022年将加息多达三次。</blockquote></p><p> Despite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.</p><p><blockquote>尽管加息时间可能早于预期，但分析师表示，交易员对美联储最新预测提供的确定性水平提高感到满意。</blockquote></p><p> Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.</p><p><blockquote>美国能源信息署（EIA）表示，上周美国原油库存减少460万桶，原油期货周三收高。西德克萨斯中质原油1月期货收涨0.14美元或0.2%，报每桶70.87美元。</blockquote></p><p></p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">RTTNews</strong><span class=\"h-time small\">2021-12-16 08:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.</p><p><blockquote>新加坡股市周三再次下跌，此前一个交易日结束了连续两天下跌超过20点或0.7%的下跌。海峡时报指数目前略低于3,115点的高位，尽管预计周四将再次反弹。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.</p><p><blockquote>在FOMC货币政策会议结果公布后，全球对亚洲市场的预测乐观。欧洲和美国市场稳步走高，亚洲股市预计也将以类似的方式开盘。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.</p><p><blockquote>在房地产和工业股下跌后，海指周三小幅收低，而金融股则涨跌互现。</blockquote></p><p> For the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.</p><p><blockquote>当天，该指数在3,106.63点至3,120.55点之间交易后，下跌6.21点或0.20%，收于3,114.88点。成交量为8.834亿股，价值7.618亿新元。下跌股264家，上涨股180家。</blockquote></p><p> Among the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌0.34%，凯德综合商业信托下跌0.50%，City Developments下跌0.42%，Comfort DelGro上涨1.45%，Dairy Farm International暴跌2.42%，星展集团上涨0.19%，云顶新加坡退保0.64%，吉宝企业下跌0.39%，丰树商业信托下跌0.98%，丰树物流信托下跌0.53%，华侨银行下跌0.27%，胜科工业下跌0.51%，新加坡航空下跌0.20%，新加坡电信下跌0.41%，泰国饮料下跌0.75%，大华银行下跌0.15%，丰益国际下跌0.96%，扬子江造船、新加坡报业控股、新加坡科技工程和新天科技持平。</blockquote></p><p> The lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.</p><p><blockquote>华尔街的领先优势总体上是积极的，主要股指周三开盘小幅走低，但随后下午飙升，收盘大幅走高。</blockquote></p><p> The Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&amp;P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.</p><p><blockquote>道琼斯指数飙升383.25点，涨幅1.08%，收于35,927.43点；纳斯达克指数飙升327.94点，涨幅2.15%，收于15,565.58点；标普500指数上涨75.76点，涨幅1.63%，收于4,709.85点。</blockquote></p><p> The late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.</p><p><blockquote>在美联储宣布了人们普遍预期的加快缩减资产购买计划步伐的决定后，华尔街尾盘上涨。美联储以通胀发展和劳动力市场进一步改善为由表示，已决定将净资产购买速度每月减少300亿美元，是此前宣布的每月150亿美元的两倍。</blockquote></p><p> The Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.</p><p><blockquote>美联储表示，预计每个月净资产购买速度的类似减少可能是适当的，这表明该计划将于明年3月结束。分析师将随后的反弹部分归因于美联储没有更积极地加快停止资产购买的时间表。</blockquote></p><p> Meanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.</p><p><blockquote>与此同时，美联储还宣布了广泛预期的决定，将联邦基金利率目标区间维持在零至0.25%。与9月份的一次加息预测相比，央行的最新预测2022年将加息多达三次。</blockquote></p><p> Despite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.</p><p><blockquote>尽管加息时间可能早于预期，但分析师表示，交易员对美联储最新预测提供的确定性水平提高感到满意。</blockquote></p><p> Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.</p><p><blockquote>美国能源信息署（EIA）表示，上周美国原油库存减少460万桶，原油期货周三收高。西德克萨斯中质原油1月期货收涨0.14美元或0.2%，报每桶70.87美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx\">RTTNews</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194155872","content_text":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.\nThe global forecast for the Asian markets is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.\nThe STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.\nFor the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.\nAmong the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.\nThe lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.\nThe Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.\nThe late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.\nThe Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.\nMeanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.\nDespite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.\nCrude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.","news_type":1,"symbols_score_info":{"STI.SI":0.9}},"isVote":1,"tweetType":1,"viewCount":773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090796,"gmtCreate":1639090444622,"gmtModify":1639090444779,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605090796","repostId":"1113203379","repostType":4,"repost":{"id":"1113203379","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639061813,"share":"https://www.laohu8.com/m/news/1113203379?lang=zh_CN&edition=full","pubTime":"2021-12-09 22:56","market":"us","language":"en","title":"Crypto stocks dipped in morning trading<blockquote>加密货币股票早盘下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113203379","media":"Tiger Newspress","summary":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining","content":"<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p><p><blockquote>加密货币股票在早盘交易中下跌。Riot Blockchain、Marathon Digital、SoS Ltd、Coinbase、BIT Mining、Canaan、亿邦国际、Square、Bit Digital、第九城市和PayPal跌幅在2%至8%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks dipped in morning trading<blockquote>加密货币股票早盘下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks dipped in morning trading<blockquote>加密货币股票早盘下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-09 22:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p><p><blockquote>加密货币股票在早盘交易中下跌。Riot Blockchain、Marathon Digital、SoS Ltd、Coinbase、BIT Mining、Canaan、亿邦国际、Square、Bit Digital、第九城市和PayPal跌幅在2%至8%之间。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIOT":"Riot Platforms"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113203379","content_text":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.","news_type":1,"symbols_score_info":{"RIOT":0.9}},"isVote":1,"tweetType":1,"viewCount":903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090515,"gmtCreate":1639090391250,"gmtModify":1639090391439,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605090515","repostId":"1165217477","repostType":4,"repost":{"id":"1165217477","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639067136,"share":"https://www.laohu8.com/m/news/1165217477?lang=zh_CN&edition=full","pubTime":"2021-12-10 00:25","market":"us","language":"en","title":"Grab and Lucid stocks plunged more than 10%<blockquote>Grab和Lucid股价暴跌逾10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165217477","media":"Tiger Newspress","summary":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","content":"<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p><p><blockquote>Grab和Lucid股价在周四交易中暴跌超过10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab and Lucid stocks plunged more than 10%<blockquote>Grab和Lucid股价暴跌逾10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab and Lucid stocks plunged more than 10%<blockquote>Grab和Lucid股价暴跌逾10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 00:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p><p><blockquote>Grab和Lucid股价在周四交易中暴跌超过10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165217477","content_text":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","news_type":1,"symbols_score_info":{"GRAB":0.9,"LCID":0.9}},"isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603122557,"gmtCreate":1638376688184,"gmtModify":1638376715328,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"coming up soon","listText":"coming up soon","text":"coming up soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603122557","repostId":"1187123549","repostType":2,"repost":{"id":"1187123549","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638370614,"share":"https://www.laohu8.com/m/news/1187123549?lang=zh_CN&edition=full","pubTime":"2021-12-01 22:56","market":"us","language":"en","title":"Xpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价由涨转跌4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1187123549","media":"Tiger Newspress","summary":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced it","content":"<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p><p><blockquote>小鹏汽车股价早盘由涨转跌4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p><p><blockquote>小鹏汽车今天公布了2021年11月的车辆交付结果。</blockquote></p><p> XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p><p><blockquote>在全球供应链挑战中，小鹏汽车实现了月度交付目标，11月份交付了15,613辆智能电动汽车，同比增长270%。强劲的交付势头证明了小鹏汽车智能电动汽车的竞争力以及在全球供应链各方面持续面临挑战的情况下的稳定执行力。</blockquote></p><p> Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p><p><blockquote>11月份交付量为7,839辆P7智能运动轿车，同比增长187%。2021年9月推出的P5 smart家庭轿车一直在积累稳定的订单积压，11月交付了2,154辆。与此同时，2021年7月推出的G3i智能SUV越来越受到客户的关注，11月份交付了5,546辆（加上交付了74辆G3）。</blockquote></p><p> As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p><p><blockquote>截至2021年11月30日，年初至今的汽车总交付量达到82,155辆，同比增长285%，其中P7交付量为53,110辆。</blockquote></p><p> The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p><p><blockquote>公司截至2021年11月底累计交付量达121,953辆。</blockquote></p><p> In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p><p><blockquote>11月，小鹏汽车推出了全新旗舰智能SUV G9，这是该公司的第四款量产车型，也是首款按照国际安全和环保标准设计的车型。这也是小鹏汽车首款采用一套突破性内部技术的量产车型，包括X-EEA 3.0电子电气架构、最新的XPILOT 4.0高级驾驶辅助系统以及下一代XPower 3.0动力总成和增压系统。该公司计划于2022年第三季度开始交付G9。</blockquote></p><p> XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p><p><blockquote>小鹏汽车一直在扩大其在中国的超级充电网络，截至2021年10月31日，全国已有550个品牌超级充电站在运营。小鹏汽车客户现在可以通过遍布中国的1,734个充电站网络享受免费的超级充电和快速充电服务。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价由涨转跌4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价由涨转跌4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-01 22:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p><p><blockquote>小鹏汽车股价早盘由涨转跌4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p><p><blockquote>小鹏汽车今天公布了2021年11月的车辆交付结果。</blockquote></p><p> XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p><p><blockquote>在全球供应链挑战中，小鹏汽车实现了月度交付目标，11月份交付了15,613辆智能电动汽车，同比增长270%。强劲的交付势头证明了小鹏汽车智能电动汽车的竞争力以及在全球供应链各方面持续面临挑战的情况下的稳定执行力。</blockquote></p><p> Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p><p><blockquote>11月份交付量为7,839辆P7智能运动轿车，同比增长187%。2021年9月推出的P5 smart家庭轿车一直在积累稳定的订单积压，11月交付了2,154辆。与此同时，2021年7月推出的G3i智能SUV越来越受到客户的关注，11月份交付了5,546辆（加上交付了74辆G3）。</blockquote></p><p> As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p><p><blockquote>截至2021年11月30日，年初至今的汽车总交付量达到82,155辆，同比增长285%，其中P7交付量为53,110辆。</blockquote></p><p> The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p><p><blockquote>公司截至2021年11月底累计交付量达121,953辆。</blockquote></p><p> In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p><p><blockquote>11月，小鹏汽车推出了全新旗舰智能SUV G9，这是该公司的第四款量产车型，也是首款按照国际安全和环保标准设计的车型。这也是小鹏汽车首款采用一套突破性内部技术的量产车型，包括X-EEA 3.0电子电气架构、最新的XPILOT 4.0高级驾驶辅助系统以及下一代XPower 3.0动力总成和增压系统。该公司计划于2022年第三季度开始交付G9。</blockquote></p><p> XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p><p><blockquote>小鹏汽车一直在扩大其在中国的超级充电网络，截至2021年10月31日，全国已有550个品牌超级充电站在运营。小鹏汽车客户现在可以通过遍布中国的1,734个充电站网络享受免费的超级充电和快速充电服务。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187123549","content_text":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced its vehicle delivery results for November 2021.\nXPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.\nDeliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).\nAs of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.\nThe Company’s cumulative deliveries reached 121,953 as of the end of November 2021.\nIn November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.\nXPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.","news_type":1,"symbols_score_info":{"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609690307,"gmtCreate":1638274281322,"gmtModify":1638274281408,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609690307","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","kind":"news","pubTimestamp":1638273550,"share":"https://www.laohu8.com/m/news/1192203085?lang=zh_CN&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>新冠抗体药物受奥密克戎挑战初步检测显示</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司的Covid-19抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明，如果新毒株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家表示，对礼来公司(Eli Lilly&amp;Co.)的另一种授权的Covid-19抗体药物混合物进行的单独测试表明，它对奥密克戎病也没有那么有效。礼来公司表示，正在针对其抗体治疗测试新变种，但不愿猜测结果会是什么。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞相评估新的奥密克戎病毒变种对患者、医生和医院一直依赖的Covid-19治疗的影响的早期结果，以及正在开发的有望让人们远离医院的药物。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它含有再生元和礼来药物所针对的刺突蛋白的突变，而其他药物应该表现良好，因为它们攻击的是变种中未改变的病毒元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来自新冠肺炎幸存者或被改造成具有人类免疫系统的小鼠。当感染后不久给药时，这些药物会附着在冠状病毒的表面，阻止它在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权在需要住院治疗患者之前治疗这些患者的药物，这些患者具有发展为严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何防御病毒，包括产生抗体。去年，前总统唐纳德·特朗普将他从Covid-19中迅速康复归功于再生元的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在进行进一步测试后，它将能够在未来几周内量化该变体的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的Paxlovid等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>该公司总裁兼首席科学官George Yancopoulos表示，如果最终测试表明其抗体药物对奥密克戎病毒的效果较差，再生元已经开发出替代抗体，可以将其推向临床测试，并且认为这些抗体将保留对该变种的有效性。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元的一种替代抗体已经处于临床测试阶段，该公司预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎病毒变种，促使药物研究人员争先恐后地看看，如果新冠肺炎病毒最终广泛传播，相对较小的新冠肺炎治疗药箱是否仍能对抗新毒株。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“我们必须承认的是，在过去的六天里，我们的紧迫性有所增加，”扬科普洛斯博士在接受采访时说。“最初的备用计划现在变得更加紧迫。”</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图Fred Hutchinson癌症研究中心的科学家发现，奥密克戎病毒的个体突变降低或消除了再生元和礼来公司的药物附着在病毒上的能力。该中心和西雅图华盛顿大学的候选人。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对针对整个变种的药物进行更全面的测试，以充分了解其影响。“我不确定效果的确切程度，但效果可能会较差，”格雷尼女士说。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问Nicole Kallewaard表示，礼来公司正在针对其药物测试新变种，该药物是两种抗体的组合，称为bamlanivimab和etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变结合在一起时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“我认为我们需要等待整个病毒的确认，”Kallewaard博士说。“希望数据能在未来几周内公布。”</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病毒患病率的上升可能会给那些表示其药物在初步测试中没有出现的竞争对手带来受到该变种影响的机会，其中包括Vir Biotechnology Inc.和葛兰素史克PLC，其药物sotrovimab早些时候被授权紧急使用今年。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc.是一家正在进行临床试验的新冠肺炎抗体药物的生物技术公司，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、葛兰素史克和Adagio表示，他们正在进行进一步测试，以确认他们的药物不受奥密克戎病的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生了突变，已知抗体经常附着在该部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir和Adagio官员表示，两家公司设计抗体的目的是针对病毒上不同冠状病毒中常见的点，这些点即使在多年多次突变后仍保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>Adagio首席执行官蒂尔曼·格恩格罗斯(Tillman Gerngross)在接受采访时表示：“它们与病毒的一个区域结合，该区域经过数十年的进化并没有发生太大变化。”“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，至少需要两周时间才能创建完整的奥密克戎病毒变种版本并测试针对其的抗体药物。尽管如此，科学家们表示，他们对这种变异逃避疫苗、先前感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“奥密克戎还没有成为下一个三角洲，”Vir首席科学官Skip Virgin在接受采访时表示。但“我们认为突变的程度和数量意味着世界需要非常认真地对待奥密克戎。”</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>洛克菲勒大学免疫学家米歇尔·努森茨威格(Michel Nussenzweig)表示，抗病毒药物，包括默克公司(Merck&amp;Co.)和合作伙伴Ridgeback Biotherapeutics LP以及辉瑞公司(Pfizer Inc.)正在接受授权评估的药物，似乎不受该变种的影响，因为它们针对病毒上的不同位点。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直在期待这种药物的批准，在临床试验中，如果尽早服用，这种药物可以降低住院风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“药物的目标似乎压力较小，可能没问题，但这也需要测试，”努森茨威格博士说。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计他们的药物将有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物Veklury将保持对奥密克戎病毒的有效性，就像它对其他令人担忧的变种一样。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>新冠抗体药物受奥密克戎挑战初步检测显示</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>新冠抗体药物受奥密克戎挑战初步检测显示</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-11-30 19:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司的Covid-19抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明，如果新毒株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家表示，对礼来公司(Eli Lilly&amp;Co.)的另一种授权的Covid-19抗体药物混合物进行的单独测试表明，它对奥密克戎病也没有那么有效。礼来公司表示，正在针对其抗体治疗测试新变种，但不愿猜测结果会是什么。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞相评估新的奥密克戎病毒变种对患者、医生和医院一直依赖的Covid-19治疗的影响的早期结果，以及正在开发的有望让人们远离医院的药物。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它含有再生元和礼来药物所针对的刺突蛋白的突变，而其他药物应该表现良好，因为它们攻击的是变种中未改变的病毒元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来自新冠肺炎幸存者或被改造成具有人类免疫系统的小鼠。当感染后不久给药时，这些药物会附着在冠状病毒的表面，阻止它在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权在需要住院治疗患者之前治疗这些患者的药物，这些患者具有发展为严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何防御病毒，包括产生抗体。去年，前总统唐纳德·特朗普将他从Covid-19中迅速康复归功于再生元的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在进行进一步测试后，它将能够在未来几周内量化该变体的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的Paxlovid等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>该公司总裁兼首席科学官George Yancopoulos表示，如果最终测试表明其抗体药物对奥密克戎病毒的效果较差，再生元已经开发出替代抗体，可以将其推向临床测试，并且认为这些抗体将保留对该变种的有效性。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元的一种替代抗体已经处于临床测试阶段，该公司预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎病毒变种，促使药物研究人员争先恐后地看看，如果新冠肺炎病毒最终广泛传播，相对较小的新冠肺炎治疗药箱是否仍能对抗新毒株。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“我们必须承认的是，在过去的六天里，我们的紧迫性有所增加，”扬科普洛斯博士在接受采访时说。“最初的备用计划现在变得更加紧迫。”</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图Fred Hutchinson癌症研究中心的科学家发现，奥密克戎病毒的个体突变降低或消除了再生元和礼来公司的药物附着在病毒上的能力。该中心和西雅图华盛顿大学的候选人。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对针对整个变种的药物进行更全面的测试，以充分了解其影响。“我不确定效果的确切程度，但效果可能会较差，”格雷尼女士说。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问Nicole Kallewaard表示，礼来公司正在针对其药物测试新变种，该药物是两种抗体的组合，称为bamlanivimab和etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变结合在一起时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“我认为我们需要等待整个病毒的确认，”Kallewaard博士说。“希望数据能在未来几周内公布。”</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病毒患病率的上升可能会给那些表示其药物在初步测试中没有出现的竞争对手带来受到该变种影响的机会，其中包括Vir Biotechnology Inc.和葛兰素史克PLC，其药物sotrovimab早些时候被授权紧急使用今年。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc.是一家正在进行临床试验的新冠肺炎抗体药物的生物技术公司，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、葛兰素史克和Adagio表示，他们正在进行进一步测试，以确认他们的药物不受奥密克戎病的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生了突变，已知抗体经常附着在该部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir和Adagio官员表示，两家公司设计抗体的目的是针对病毒上不同冠状病毒中常见的点，这些点即使在多年多次突变后仍保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>Adagio首席执行官蒂尔曼·格恩格罗斯(Tillman Gerngross)在接受采访时表示：“它们与病毒的一个区域结合，该区域经过数十年的进化并没有发生太大变化。”“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，至少需要两周时间才能创建完整的奥密克戎病毒变种版本并测试针对其的抗体药物。尽管如此，科学家们表示，他们对这种变异逃避疫苗、先前感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“奥密克戎还没有成为下一个三角洲，”Vir首席科学官Skip Virgin在接受采访时表示。但“我们认为突变的程度和数量意味着世界需要非常认真地对待奥密克戎。”</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>洛克菲勒大学免疫学家米歇尔·努森茨威格(Michel Nussenzweig)表示，抗病毒药物，包括默克公司(Merck&amp;Co.)和合作伙伴Ridgeback Biotherapeutics LP以及辉瑞公司(Pfizer Inc.)正在接受授权评估的药物，似乎不受该变种的影响，因为它们针对病毒上的不同位点。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直在期待这种药物的批准，在临床试验中，如果尽早服用，这种药物可以降低住院风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“药物的目标似乎压力较小，可能没问题，但这也需要测试，”努森茨威格博士说。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计他们的药物将有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物Veklury将保持对奥密克戎病毒的有效性，就像它对其他令人担忧的变种一样。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1,"symbols_score_info":{"LLY":0.9,"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609604793,"gmtCreate":1638274097547,"gmtModify":1638274097637,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"think again","listText":"think again","text":"think again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609604793","repostId":"2187947581","repostType":4,"isVote":1,"tweetType":1,"viewCount":782,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609605147,"gmtCreate":1638273926952,"gmtModify":1638273927084,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"enjoy wen it go up","listText":"enjoy wen it go up","text":"enjoy wen it go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609605147","repostId":"1164097100","repostType":2,"repost":{"id":"1164097100","kind":"news","pubTimestamp":1638237374,"share":"https://www.laohu8.com/m/news/1164097100?lang=zh_CN&edition=full","pubTime":"2021-11-30 09:56","market":"us","language":"en","title":"AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票NFT赠品的AMC股票趋势</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164097100","media":"InvestorPlace","summary":"AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is","content":"<p><div> AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible ...</p><p><blockquote><div>AMC院线（纽约证券交易所股票代码：AMC）将赌注押在一位超级英雄蜘蛛侠身上。事实上，在这家连锁影院宣布将发行86,000部不可替代电影后，AMC股票再次成为焦点...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票NFT赠品的AMC股票趋势</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票NFT赠品的AMC股票趋势</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-11-30 09:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible ...</p><p><blockquote><div>AMC院线（纽约证券交易所股票代码：AMC）将赌注押在一位超级英雄蜘蛛侠身上。事实上，在这家连锁影院宣布将发行86,000部不可替代电影后，AMC股票再次成为焦点...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164097100","content_text":"AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible tokenswith Marvel Spider-Man: No Way Hometickets. The combo of meme stock and NFTs certainly has investors watching!\nSo what do you need to know?\nAMC is truly breaking new ground with its first-ever NFT promotion. A joint effort between Sony Pictures and AMC, the collaboration will yield roughly 90,000 NFTs. The NFTs will go to a limited number of ticket buyers for the Dec. 16 premier.\nNow, there are some other conditions investors should note. To qualify for the NFTs, buyers must be members of AMC Stubs A-list, Stubs Premiere or AMC Investor Connect on the AMC website. Buyers must have their Stubs account number associated with the purchase, and their ticket must be scanned upon entrance to the movie. In addition, the NFTs must be redeemed by March 1.\nDespite the enticing offer, AMC stock was fairly unresponsive to the news, down 2% on the day.\nCan AMC Stock Overcome Its Meme-ified Past?\nAMC remains hopeful that it can entice the NFT bulls, and Spider-Man may be just the person it needs. Adam Aron, CEO of AMC,commented onthe giveaway and said this:\n\n “… the incredibly talented artists at Cub Studios are creating more than 100 unique NFTs giving appropriate respect to this most recent incarnation of the timeless and ever so popular Spider-Man franchise. For those members of our AMC Stubs A-List, AMC Stubs Premiere and AMC Investor Connect program who are among the first to purchase or reserve their ticket to opening day at AMC, this unprecedented Spider-Man NFT is truly a ticket-purchase gift like nothing we’ve ever offered before. … So, my advice is to get your Spider-Man tickets as quickly as you can.”\n\nAMC believes it can turn around its tumultuous past by calling in a crypto lifeline. If the moves catch the gaze of the Reddit bulls, it certainly remains a possibility.\nWith AMC currently at $36.84, it remains to be seen how much movement the NFT offer will grant it. One thing for sure is that all eyes are on AMC stock prices heading into the December premier.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":839,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126513,"gmtCreate":1637746134207,"gmtModify":1637746138028,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"enjoy the holiday","listText":"enjoy the holiday","text":"enjoy the holiday","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126513","repostId":"1151702113","repostType":4,"repost":{"id":"1151702113","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637559387,"share":"https://www.laohu8.com/m/news/1151702113?lang=zh_CN&edition=full","pubTime":"2021-11-22 13:36","market":"us","language":"en","title":"Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：周四美股因感恩节休市，周五提前三小时收盘</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1151702113","media":"Tiger Newspress","summary":"November 25th (this Thursday) is Thanksgiving Day.All financial markets in the United States, includ","content":"<p>November 25th&nbsp;(this&nbsp;Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.</p><p><blockquote>11月25日（本周四）是感恩节。包括美股在内的美国所有金融市场将休市一天。</blockquote></p><p> On November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at&nbsp;U.S.&nbsp;Eastern Time&nbsp;1 p.m.(Beijing time/SGT&nbsp;2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.</p><p><blockquote>11月26日（本周五），纳斯达克和纽约证券交易所于美国东部时间下午1点（北京时间/SGT周六凌晨2点）结束交易，交易时间为北京时间22:30-次日2:00。所以会比正常关门时间提前3个小时。</blockquote></p><p> Stocks&nbsp;in&nbsp;China,Britain, Australia&nbsp;and Singapore&nbsp;will&nbsp;trade as usual.</p><p><blockquote>中国、英国、澳大利亚和新加坡的股票将照常交易。</blockquote></p><p> <b>Background</b></p><p><blockquote><b>背景</b></blockquote></p><p> Thanksgiving&nbsp;Day&nbsp;is a national&nbsp;holiday&nbsp;celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the&nbsp;harvest&nbsp;and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving&nbsp;Day&nbsp;is celebrated on the&nbsp;second Monday of October&nbsp;in Canada and on the&nbsp;fourth Thursday of November&nbsp;in the United States and around the same part of the year in other places.&nbsp;</p><p><blockquote>感恩节是一个全国性的节日，在美国、加拿大、格林纳达、圣卢西亚和利比里亚的不同日期庆祝。它开始是一个感谢和牺牲丰收和前一年祝福的日子。德国和日本也有类似的节日假期。加拿大在十月的第二个星期一庆祝感恩节，美国在十一月的第四个星期四庆祝感恩节，其他地方在一年中的同一时间庆祝感恩节。</blockquote></p><p> Black Friday&nbsp;is a colloquial term for the Friday following&nbsp;Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight&nbsp;or even on Thanksgiving Day.</p><p><blockquote>黑色星期五是美国感恩节后星期五的通俗说法。许多商店以折扣价提供高度促销的销售，并且通常很早就开门，有时早到午夜，甚至在感恩节。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/af950d731994581f416aa413e17585d3\" tg-width=\"450\" tg-height=\"281\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：周四美股因感恩节休市，周五提前三小时收盘</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：周四美股因感恩节休市，周五提前三小时收盘</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-22 13:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>November 25th&nbsp;(this&nbsp;Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.</p><p><blockquote>11月25日（本周四）是感恩节。包括美股在内的美国所有金融市场将休市一天。</blockquote></p><p> On November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at&nbsp;U.S.&nbsp;Eastern Time&nbsp;1 p.m.(Beijing time/SGT&nbsp;2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.</p><p><blockquote>11月26日（本周五），纳斯达克和纽约证券交易所于美国东部时间下午1点（北京时间/SGT周六凌晨2点）结束交易，交易时间为北京时间22:30-次日2:00。所以会比正常关门时间提前3个小时。</blockquote></p><p> Stocks&nbsp;in&nbsp;China,Britain, Australia&nbsp;and Singapore&nbsp;will&nbsp;trade as usual.</p><p><blockquote>中国、英国、澳大利亚和新加坡的股票将照常交易。</blockquote></p><p> <b>Background</b></p><p><blockquote><b>背景</b></blockquote></p><p> Thanksgiving&nbsp;Day&nbsp;is a national&nbsp;holiday&nbsp;celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the&nbsp;harvest&nbsp;and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving&nbsp;Day&nbsp;is celebrated on the&nbsp;second Monday of October&nbsp;in Canada and on the&nbsp;fourth Thursday of November&nbsp;in the United States and around the same part of the year in other places.&nbsp;</p><p><blockquote>感恩节是一个全国性的节日，在美国、加拿大、格林纳达、圣卢西亚和利比里亚的不同日期庆祝。它开始是一个感谢和牺牲丰收和前一年祝福的日子。德国和日本也有类似的节日假期。加拿大在十月的第二个星期一庆祝感恩节，美国在十一月的第四个星期四庆祝感恩节，其他地方在一年中的同一时间庆祝感恩节。</blockquote></p><p> Black Friday&nbsp;is a colloquial term for the Friday following&nbsp;Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight&nbsp;or even on Thanksgiving Day.</p><p><blockquote>黑色星期五是美国感恩节后星期五的通俗说法。许多商店以折扣价提供高度促销的销售，并且通常很早就开门，有时早到午夜，甚至在感恩节。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/af950d731994581f416aa413e17585d3\" tg-width=\"450\" tg-height=\"281\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151702113","content_text":"November 25th (this Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.\nOn November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at U.S. Eastern Time 1 p.m.(Beijing time/SGT 2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.\nStocks in China,Britain, Australia and Singapore will trade as usual.\nBackground\nThanksgiving Day is a national holiday celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the harvest and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving Day is celebrated on the second Monday of October in Canada and on the fourth Thursday of November in the United States and around the same part of the year in other places. \nBlack Friday is a colloquial term for the Friday following Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight or even on Thanksgiving Day.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":650,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698851243,"gmtCreate":1640347676382,"gmtModify":1640347676614,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698851243","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":3148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886431093,"gmtCreate":1631613822012,"gmtModify":1631890295712,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/886431093","repostId":"1160275332","repostType":4,"repost":{"id":"1160275332","kind":"news","pubTimestamp":1631604098,"share":"https://www.laohu8.com/m/news/1160275332?lang=zh_CN&edition=full","pubTime":"2021-09-14 15:21","market":"us","language":"en","title":"Busy IPO market this week poised to make 2021 the biggest year ever by proceeds<blockquote>本周繁忙的IPO市场有望使2021年成为有史以来收益最大的一年</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160275332","media":"MarketWatch","summary":"Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit th","content":"<p>Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit the market this week </p><p><blockquote>罗杰·费德勒支持的瑞士跑鞋公司和得来速咖啡连锁店预计将于本周上市</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18111af5f5bda21b3128860fe616c5ca\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Swiss tennis giant Roger Federer is a backer of one of this week's bigger IPOs.</span></p><p><blockquote><p class=\"t-img-caption\"><span>瑞士网球巨头罗杰·费德勒是本周最大IPO之一的支持者。</span></p></blockquote></p><p> After a flurry of initial-public-offering launches last week&nbsp;set the market up for a busy fall for deals, 11 are expected to price this week and raise more than $3 billion in proceeds. </p><p><blockquote>上周一系列首次公开募股引发市场交易繁忙，预计本周将有11家公司定价，筹集超过30亿美元的资金。</blockquote></p><p> If all deals materialize, it will make 2021 the biggest year for IPO proceeds ever, and shatter the previous record by about 30%, according to Bill Smith, founder and chief executive of Renaissance Capital, a provider of institutional research and exchange-traded funds oriented around IPOs. The market is expected to see some 375 deals for the year, raising $125 billion, according to Renaissance, beating the $97 billion raised in 2000 during the dot-com boom. </p><p><blockquote>机构研究和交易所交易基金提供商Renaissance Capital创始人兼首席执行官比尔·史密斯(Bill Smith)表示，如果所有交易都实现，2021年将成为有史以来IPO收益最大的一年，并将之前的记录打破约30%。以IPO为导向的基金。据Renaissance称，预计今年市场将出现约375笔交易，筹集1250亿美元，超过2000年互联网繁荣期间筹集的970亿美元。</blockquote></p><p> “After the long summer break, this week is a litmus test for upcoming tech, biotech, and consumer IPOs,” Smith wrote in a market commentary. The list includes a Swiss running-shoe company backed by tennis giant Roger Federer, a drive-through coffee kiosk operator and a mortgage insurer that was spun out of insurer Genworth Financial. </p><p><blockquote>史密斯在市场评论中写道：“在漫长的暑假之后，本周是即将到来的科技、生物技术和消费者IPO的试金石。”该名单包括一家由网球巨头罗杰·费德勒支持的瑞士跑鞋公司、一家得来速咖啡亭运营商以及一家从保险公司Genworth Financial分拆出来的抵押贷款保险公司。</blockquote></p><p> The biggest deal of the week is expected to come from Thoughtworks,a Chicago-based technology consultancy that will go public at a valuation of up to $6.1 billion.</p><p><blockquote>本周最大的交易预计将来自总部位于芝加哥的技术咨询公司Thoughtworks，该公司将以高达61亿美元的估值上市。</blockquote></p><p> The company, which expects to change its name from Turing Holding Corp. to Thoughtworks with completion of the IPO, said a total of 36.84 million shares will be offered, split between the company and selling shareholders.</p><p><blockquote>该公司预计在IPO完成后将更名从Turing Holding Corp.更名为Thoughtworks，并表示将发行总计3684万股股票，由公司和出售股东分配。</blockquote></p><p> The deal is expected to price at between $18 and $20 a share, and the stock will trade on the Nasdaq under the ticker symbol “TWKS.” Goldman Sachs and JPMorgan are the lead underwriters. The company recorded net income of $79.3 million on revenue of $803.4 million in 2020, after income of $28.4 million on revenue of $772.2 million in 2019.</p><p><blockquote>这笔交易预计价格为每股18美元至20美元，股票将在纳斯达克交易，股票代码为“TWKS”。高盛和摩根大通是主承销商。本公司于2020年录得净收入79.3百万美元，收入为8.03.4百万美元，二零一九年录得7.72.2百万美元后，收入净额为2840万美元。</blockquote></p><p> The Swiss athletic-footwear maker On Holding&nbsp;is expected to raise up to $622 million at a valuation of almost $6 billion. On has applied to list 31.1 million shares priced at $18 to $20 each on the New York Stock Exchange, under the ticker symbol “ONON.”</p><p><blockquote>这家持有股份的瑞士运动鞋制造商预计将以近60亿美元的估值筹集至多6.22亿美元。On已申请在纽约证券交易所上市3110万股，每股价格为18至20美元，股票代码为“ONON”。</blockquote></p><p> Goldman Sachs, Morgan Stanley and Morgan Stanley are lead underwriters in a syndicate of nine banks on the On deal. Proceeds are to be used for general corporate purposes. The company has a line that it co-developed with Federer.</p><p><blockquote>高盛、摩根士丹利和摩根士丹利是此次交易的九家银行组成的银团的主承销商。收益将用于一般公司用途。该公司有一条与费德勒共同开发的生产线。</blockquote></p><p> The company had net income of 3.8 million Swiss francs ($4.1 million) in the six months through June 30, after a loss of 33.1 million francs in the year-earlier period,&nbsp;according to its IPO documents.&nbsp;Sales came to 315.5 million francs, up from 170.9 million francs.</p><p><blockquote>根据其IPO文件，在截至6月30日的六个月中，该公司的净利润为380万瑞士法郎（合410万美元），而上年同期为亏损3310万瑞士法郎，而去年同期的销售额为3.155亿瑞士法郎，高于1.709亿瑞士法郎。</blockquote></p><p> Also from Switzerland, sports betting site Sportrader Group AG&nbsp;plans to offer 19 million shares priced at $25 to $28 each, for a valuation of up to $31 billion. The company has applied to list on Nasdaq under the ticker symbol “SRAD.” JPMorgan, Morgan Stanley, Citigroup and UBS are lead underwriters in a syndicate of 13 banks working on the deal.</p><p><blockquote>同样来自瑞士的体育博彩网站Sportrader Group AG计划以每股25至28美元的价格发行1900万股股票，估值高达310亿美元。该公司已申请在纳斯达克上市，股票代码为“SRAD”。摩根大通、摩根士丹利、花旗集团和瑞银是参与该交易的13家银行组成的银团的主承销商。</blockquote></p><p> Proceeds are to be used for working capital and to spur growth. The company had a net profit of $29.9 million in the first six months of the year, on revenue of $321 million,&nbsp;according to its filing documents.</p><p><blockquote>收益将用于营运资金和刺激增长。根据其备案文件，该公司今年前六个月净利润为2990万美元，营收为3.21亿美元。</blockquote></p><p> Dutch Bros Inc.,an operator of drive-through shops that serve hot and cold drinks mostly in western U.S. states, is planning to offer 21.1 million shares priced at $18 to $20 each in its IPO, valuing the company at up to $3.3 billion.</p><p><blockquote>Dutch Bros Inc.是一家主要在美国西部各州提供冷热饮料的免下车商店运营商，计划在IPO中发行2110万股股票，每股价格为18至20美元，公司估值高达33亿美元。</blockquote></p><p> BofA Securities, JPMorgan and Jefferies are lead underwriters in a syndicate of 13 banks working on the deal. The company has applied to list on the New York Stock Exchange under the ticker symbol “BROS.”</p><p><blockquote>美国银行证券、摩根大通和杰富瑞是参与该交易的13家银行组成的财团的主承销商。该公司已申请在纽约证券交易所上市，股票代码为“BROS”。</blockquote></p><p> Proceeds are to be used to purchase additional Class A shares — the company is planning to have four classes of stock with differing voting rights. The company had a net loss of $13.6 million, or 32 cents a share, in the first six months of the year, narrower than the loss of $16.5 million, or 38 cents a share, posted in the year-earlier period. Revenue fell to $227.9 million from $327.4 million.</p><p><blockquote>所得款项将用于购买额外的A类股票——该公司计划拥有四类具有不同投票权的股票。该公司今年前六个月的净亏损为1,360万美元，即每股亏损32美分，低于去年同期的1,650万美元，即每股亏损38美分。收入从3.274亿美元降至2.279亿美元。</blockquote></p><p> <b>Rounding out the list are:</b></p><p><blockquote><b>名单上还有：</b></blockquote></p><p> •&nbsp;Definitive Healthcare Corp.,&nbsp;a Massachusetts-based provider of healthcare commercial intelligence, is planning to offer 15.56 million shares in its PO, which is expected to price between $21 and $24 a share. At that pricing, the company could be valued at up to $3.55 billion.</p><p><blockquote>•总部位于马萨诸塞州的医疗保健商业情报提供商Definitive Healthcare Corp.计划在其PO中发行1556万股股票，预计定价在每股21美元至24美元之间。按照这个定价，该公司的估值可能高达35.5亿美元。</blockquote></p><p></p><p> •&nbsp;Enact Holdings Inc., a mortgage insurer owned by Genworth, is planning to offer 13.3 million shares priced at $19 to $20 each. The company would be valued at $3.3 billion at the top of that range. The company said all shares will be sold by Genworth and it will not receive any proceeds. It has applied to list on Nasdaq under the ticker “ACT.” Goldman Sachs and JPMorgan are lead underwriters in a team of nine banks working on the deal.</p><p><blockquote>Genworth旗下的抵押贷款保险公司Enact Holdings Inc.计划发行1330万股股票，每股价格为19至20美元。该公司的估值为33亿美元，处于该范围的顶部。该公司表示，Genworth将出售所有股份，不会获得任何收益。它已申请在纳斯达克上市，股票代码为“ACT”。高盛和摩根大通是参与该交易的九家银行团队的主承销商。</blockquote></p><p> •&nbsp;ForgeRock<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>&nbsp;a California-based identity security platform, is looking to raise up to $264 million with an offering of 11 million shares priced between $21 and $24 a share. That pricing would value the company a valuation of up to $1.91 billion.</p><p><blockquote>•锻造岩石<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>一家总部位于加州的身份安全平台希望通过发行1100万股股票，每股价格在21美元至24美元之间，筹集至多2.64亿美元。该定价将使该公司估值高达19.1亿美元。</blockquote></p><p> The stock is expected to list on the NYSE under the ticker symbol “FORG.” Morgan Stanley and JPMorgan are the lead underwriters. The company recorded a net loss of $41.8 million on revenue of $127.6 million in 2020, after a loss of $36.9 million on revenue of $104.5 million in 2019.</p><p><blockquote>该股预计将在纽约证券交易所上市，股票代码为“FORG”。摩根士丹利和摩根大通是主承销商。该公司在2020年录得净亏损4180万美元，营收为1.276亿美元，而2019年营收为1.045亿美元，亏损3690万美元。</blockquote></p><p> <b>•</b>Dice Therapeutics&nbsp;is expected to raise up to $170 million at a valuation of up to $583 million and list on Nasdaq under the ticker symbol “DICE.” The biotech is developing therapies to treat chronic diseases in the field of immunology.</p><p><blockquote><b>•</b>Dice Therapeutics预计将以高达5.83亿美元的估值筹集至多1.7亿美元，并在纳斯达克上市，股票代码为“DICE”。该生物技术公司正在免疫学领域开发治疗慢性疾病的疗法。</blockquote></p><p> <b>•</b>Surgical robotics developer Procept BioRobotics,is aiming to raise up to $132 million at a valuation of about $1 billion with plans to list on Nasdaq under the ticker symbol “PRCT.” BofA Securities and Goldman Sachs are lead underwriters.</p><p><blockquote><b>•</b>手术机器人开发商Procept BioRobotics计划以约10亿美元的估值筹集至多1.32亿美元，并计划在纳斯达克上市，股票代码为“PRCT”。美银证券和高盛是主承销商。</blockquote></p><p> “We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH,” the company says in its IPO documents.</p><p><blockquote>该公司在其IPO文件中表示：“我们开发、制造和销售AquaBeam机器人系统，这是一种先进的图像引导手术机器人系统，用于微创泌尿外科手术，最初重点是治疗良性前列腺增生（BPH）。”</blockquote></p><p> <b>•</b>Tyra Biosciences is aiming to raise $107.2 million in IPO proceeds at a valuation of $589 million. The biotech’s leading product candidate is a treatment for bladder cancer. It has applied to list on Nasdaq under the symbol “TYRA.”</p><p><blockquote><b>•</b>Tyra Biosciences的目标是通过IPO筹集1.072亿美元，估值为5.89亿美元。该生物技术公司的领先候选产品是膀胱癌的治疗方法。它已申请在纳斯达克上市，股票代码为“TYRA”。</blockquote></p><p> <b>•</b>EzFill Holdings, an app-based mobile fueling company in South Florida, is planning to raise $25 million at a valuation of $100 million. The company has applied to list on Nasdaq under the ticker symbol “EZFL.” ThinkEquity is sole underwriter.</p><p><blockquote><b>•</b>EzFill Holdings是一家位于南佛罗里达州的基于应用程序的移动加油公司，计划以1亿美元的估值筹集2500万美元。该公司已申请在纳斯达克上市，股票代码为“EZFL”。ThinkEquity是独家承销商。</blockquote></p><p> The Renaissance IPO ETF&nbsp;has gained 6% to date in 2021, while the S&amp;P 500&nbsp;has advanced 19%.</p><p><blockquote>2021年迄今为止，Renaissance IPO ETF已上涨6%，而标普500则上涨19%。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Busy IPO market this week poised to make 2021 the biggest year ever by proceeds<blockquote>本周繁忙的IPO市场有望使2021年成为有史以来收益最大的一年</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBusy IPO market this week poised to make 2021 the biggest year ever by proceeds<blockquote>本周繁忙的IPO市场有望使2021年成为有史以来收益最大的一年</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-09-14 15:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit the market this week </p><p><blockquote>罗杰·费德勒支持的瑞士跑鞋公司和得来速咖啡连锁店预计将于本周上市</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18111af5f5bda21b3128860fe616c5ca\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Swiss tennis giant Roger Federer is a backer of one of this week's bigger IPOs.</span></p><p><blockquote><p class=\"t-img-caption\"><span>瑞士网球巨头罗杰·费德勒是本周最大IPO之一的支持者。</span></p></blockquote></p><p> After a flurry of initial-public-offering launches last week&nbsp;set the market up for a busy fall for deals, 11 are expected to price this week and raise more than $3 billion in proceeds. </p><p><blockquote>上周一系列首次公开募股引发市场交易繁忙，预计本周将有11家公司定价，筹集超过30亿美元的资金。</blockquote></p><p> If all deals materialize, it will make 2021 the biggest year for IPO proceeds ever, and shatter the previous record by about 30%, according to Bill Smith, founder and chief executive of Renaissance Capital, a provider of institutional research and exchange-traded funds oriented around IPOs. The market is expected to see some 375 deals for the year, raising $125 billion, according to Renaissance, beating the $97 billion raised in 2000 during the dot-com boom. </p><p><blockquote>机构研究和交易所交易基金提供商Renaissance Capital创始人兼首席执行官比尔·史密斯(Bill Smith)表示，如果所有交易都实现，2021年将成为有史以来IPO收益最大的一年，并将之前的记录打破约30%。以IPO为导向的基金。据Renaissance称，预计今年市场将出现约375笔交易，筹集1250亿美元，超过2000年互联网繁荣期间筹集的970亿美元。</blockquote></p><p> “After the long summer break, this week is a litmus test for upcoming tech, biotech, and consumer IPOs,” Smith wrote in a market commentary. The list includes a Swiss running-shoe company backed by tennis giant Roger Federer, a drive-through coffee kiosk operator and a mortgage insurer that was spun out of insurer Genworth Financial. </p><p><blockquote>史密斯在市场评论中写道：“在漫长的暑假之后，本周是即将到来的科技、生物技术和消费者IPO的试金石。”该名单包括一家由网球巨头罗杰·费德勒支持的瑞士跑鞋公司、一家得来速咖啡亭运营商以及一家从保险公司Genworth Financial分拆出来的抵押贷款保险公司。</blockquote></p><p> The biggest deal of the week is expected to come from Thoughtworks,a Chicago-based technology consultancy that will go public at a valuation of up to $6.1 billion.</p><p><blockquote>本周最大的交易预计将来自总部位于芝加哥的技术咨询公司Thoughtworks，该公司将以高达61亿美元的估值上市。</blockquote></p><p> The company, which expects to change its name from Turing Holding Corp. to Thoughtworks with completion of the IPO, said a total of 36.84 million shares will be offered, split between the company and selling shareholders.</p><p><blockquote>该公司预计在IPO完成后将更名从Turing Holding Corp.更名为Thoughtworks，并表示将发行总计3684万股股票，由公司和出售股东分配。</blockquote></p><p> The deal is expected to price at between $18 and $20 a share, and the stock will trade on the Nasdaq under the ticker symbol “TWKS.” Goldman Sachs and JPMorgan are the lead underwriters. The company recorded net income of $79.3 million on revenue of $803.4 million in 2020, after income of $28.4 million on revenue of $772.2 million in 2019.</p><p><blockquote>这笔交易预计价格为每股18美元至20美元，股票将在纳斯达克交易，股票代码为“TWKS”。高盛和摩根大通是主承销商。本公司于2020年录得净收入79.3百万美元，收入为8.03.4百万美元，二零一九年录得7.72.2百万美元后，收入净额为2840万美元。</blockquote></p><p> The Swiss athletic-footwear maker On Holding&nbsp;is expected to raise up to $622 million at a valuation of almost $6 billion. On has applied to list 31.1 million shares priced at $18 to $20 each on the New York Stock Exchange, under the ticker symbol “ONON.”</p><p><blockquote>这家持有股份的瑞士运动鞋制造商预计将以近60亿美元的估值筹集至多6.22亿美元。On已申请在纽约证券交易所上市3110万股，每股价格为18至20美元，股票代码为“ONON”。</blockquote></p><p> Goldman Sachs, Morgan Stanley and Morgan Stanley are lead underwriters in a syndicate of nine banks on the On deal. Proceeds are to be used for general corporate purposes. The company has a line that it co-developed with Federer.</p><p><blockquote>高盛、摩根士丹利和摩根士丹利是此次交易的九家银行组成的银团的主承销商。收益将用于一般公司用途。该公司有一条与费德勒共同开发的生产线。</blockquote></p><p> The company had net income of 3.8 million Swiss francs ($4.1 million) in the six months through June 30, after a loss of 33.1 million francs in the year-earlier period,&nbsp;according to its IPO documents.&nbsp;Sales came to 315.5 million francs, up from 170.9 million francs.</p><p><blockquote>根据其IPO文件，在截至6月30日的六个月中，该公司的净利润为380万瑞士法郎（合410万美元），而上年同期为亏损3310万瑞士法郎，而去年同期的销售额为3.155亿瑞士法郎，高于1.709亿瑞士法郎。</blockquote></p><p> Also from Switzerland, sports betting site Sportrader Group AG&nbsp;plans to offer 19 million shares priced at $25 to $28 each, for a valuation of up to $31 billion. The company has applied to list on Nasdaq under the ticker symbol “SRAD.” JPMorgan, Morgan Stanley, Citigroup and UBS are lead underwriters in a syndicate of 13 banks working on the deal.</p><p><blockquote>同样来自瑞士的体育博彩网站Sportrader Group AG计划以每股25至28美元的价格发行1900万股股票，估值高达310亿美元。该公司已申请在纳斯达克上市，股票代码为“SRAD”。摩根大通、摩根士丹利、花旗集团和瑞银是参与该交易的13家银行组成的银团的主承销商。</blockquote></p><p> Proceeds are to be used for working capital and to spur growth. The company had a net profit of $29.9 million in the first six months of the year, on revenue of $321 million,&nbsp;according to its filing documents.</p><p><blockquote>收益将用于营运资金和刺激增长。根据其备案文件，该公司今年前六个月净利润为2990万美元，营收为3.21亿美元。</blockquote></p><p> Dutch Bros Inc.,an operator of drive-through shops that serve hot and cold drinks mostly in western U.S. states, is planning to offer 21.1 million shares priced at $18 to $20 each in its IPO, valuing the company at up to $3.3 billion.</p><p><blockquote>Dutch Bros Inc.是一家主要在美国西部各州提供冷热饮料的免下车商店运营商，计划在IPO中发行2110万股股票，每股价格为18至20美元，公司估值高达33亿美元。</blockquote></p><p> BofA Securities, JPMorgan and Jefferies are lead underwriters in a syndicate of 13 banks working on the deal. The company has applied to list on the New York Stock Exchange under the ticker symbol “BROS.”</p><p><blockquote>美国银行证券、摩根大通和杰富瑞是参与该交易的13家银行组成的财团的主承销商。该公司已申请在纽约证券交易所上市，股票代码为“BROS”。</blockquote></p><p> Proceeds are to be used to purchase additional Class A shares — the company is planning to have four classes of stock with differing voting rights. The company had a net loss of $13.6 million, or 32 cents a share, in the first six months of the year, narrower than the loss of $16.5 million, or 38 cents a share, posted in the year-earlier period. Revenue fell to $227.9 million from $327.4 million.</p><p><blockquote>所得款项将用于购买额外的A类股票——该公司计划拥有四类具有不同投票权的股票。该公司今年前六个月的净亏损为1,360万美元，即每股亏损32美分，低于去年同期的1,650万美元，即每股亏损38美分。收入从3.274亿美元降至2.279亿美元。</blockquote></p><p> <b>Rounding out the list are:</b></p><p><blockquote><b>名单上还有：</b></blockquote></p><p> •&nbsp;Definitive Healthcare Corp.,&nbsp;a Massachusetts-based provider of healthcare commercial intelligence, is planning to offer 15.56 million shares in its PO, which is expected to price between $21 and $24 a share. At that pricing, the company could be valued at up to $3.55 billion.</p><p><blockquote>•总部位于马萨诸塞州的医疗保健商业情报提供商Definitive Healthcare Corp.计划在其PO中发行1556万股股票，预计定价在每股21美元至24美元之间。按照这个定价，该公司的估值可能高达35.5亿美元。</blockquote></p><p></p><p> •&nbsp;Enact Holdings Inc., a mortgage insurer owned by Genworth, is planning to offer 13.3 million shares priced at $19 to $20 each. The company would be valued at $3.3 billion at the top of that range. The company said all shares will be sold by Genworth and it will not receive any proceeds. It has applied to list on Nasdaq under the ticker “ACT.” Goldman Sachs and JPMorgan are lead underwriters in a team of nine banks working on the deal.</p><p><blockquote>Genworth旗下的抵押贷款保险公司Enact Holdings Inc.计划发行1330万股股票，每股价格为19至20美元。该公司的估值为33亿美元，处于该范围的顶部。该公司表示，Genworth将出售所有股份，不会获得任何收益。它已申请在纳斯达克上市，股票代码为“ACT”。高盛和摩根大通是参与该交易的九家银行团队的主承销商。</blockquote></p><p> •&nbsp;ForgeRock<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>&nbsp;a California-based identity security platform, is looking to raise up to $264 million with an offering of 11 million shares priced between $21 and $24 a share. That pricing would value the company a valuation of up to $1.91 billion.</p><p><blockquote>•锻造岩石<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>一家总部位于加州的身份安全平台希望通过发行1100万股股票，每股价格在21美元至24美元之间，筹集至多2.64亿美元。该定价将使该公司估值高达19.1亿美元。</blockquote></p><p> The stock is expected to list on the NYSE under the ticker symbol “FORG.” Morgan Stanley and JPMorgan are the lead underwriters. The company recorded a net loss of $41.8 million on revenue of $127.6 million in 2020, after a loss of $36.9 million on revenue of $104.5 million in 2019.</p><p><blockquote>该股预计将在纽约证券交易所上市，股票代码为“FORG”。摩根士丹利和摩根大通是主承销商。该公司在2020年录得净亏损4180万美元，营收为1.276亿美元，而2019年营收为1.045亿美元，亏损3690万美元。</blockquote></p><p> <b>•</b>Dice Therapeutics&nbsp;is expected to raise up to $170 million at a valuation of up to $583 million and list on Nasdaq under the ticker symbol “DICE.” The biotech is developing therapies to treat chronic diseases in the field of immunology.</p><p><blockquote><b>•</b>Dice Therapeutics预计将以高达5.83亿美元的估值筹集至多1.7亿美元，并在纳斯达克上市，股票代码为“DICE”。该生物技术公司正在免疫学领域开发治疗慢性疾病的疗法。</blockquote></p><p> <b>•</b>Surgical robotics developer Procept BioRobotics,is aiming to raise up to $132 million at a valuation of about $1 billion with plans to list on Nasdaq under the ticker symbol “PRCT.” BofA Securities and Goldman Sachs are lead underwriters.</p><p><blockquote><b>•</b>手术机器人开发商Procept BioRobotics计划以约10亿美元的估值筹集至多1.32亿美元，并计划在纳斯达克上市，股票代码为“PRCT”。美银证券和高盛是主承销商。</blockquote></p><p> “We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH,” the company says in its IPO documents.</p><p><blockquote>该公司在其IPO文件中表示：“我们开发、制造和销售AquaBeam机器人系统，这是一种先进的图像引导手术机器人系统，用于微创泌尿外科手术，最初重点是治疗良性前列腺增生（BPH）。”</blockquote></p><p> <b>•</b>Tyra Biosciences is aiming to raise $107.2 million in IPO proceeds at a valuation of $589 million. The biotech’s leading product candidate is a treatment for bladder cancer. It has applied to list on Nasdaq under the symbol “TYRA.”</p><p><blockquote><b>•</b>Tyra Biosciences的目标是通过IPO筹集1.072亿美元，估值为5.89亿美元。该生物技术公司的领先候选产品是膀胱癌的治疗方法。它已申请在纳斯达克上市，股票代码为“TYRA”。</blockquote></p><p> <b>•</b>EzFill Holdings, an app-based mobile fueling company in South Florida, is planning to raise $25 million at a valuation of $100 million. The company has applied to list on Nasdaq under the ticker symbol “EZFL.” ThinkEquity is sole underwriter.</p><p><blockquote><b>•</b>EzFill Holdings是一家位于南佛罗里达州的基于应用程序的移动加油公司，计划以1亿美元的估值筹集2500万美元。该公司已申请在纳斯达克上市，股票代码为“EZFL”。ThinkEquity是独家承销商。</blockquote></p><p> The Renaissance IPO ETF&nbsp;has gained 6% to date in 2021, while the S&amp;P 500&nbsp;has advanced 19%.</p><p><blockquote>2021年迄今为止，Renaissance IPO ETF已上涨6%，而标普500则上涨19%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/busy-ipo-market-this-week-may-make-2021-the-biggest-year-for-proceeds-and-break-previous-record-by-30-11631554372?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWKS":"Thoughtworks Holding Inc.","FORG":"ForgeRock, Inc.",".DJI":"道琼斯","ONON":"On Holding AG","BROS":"Dutch Bros Inc.","DRNA":"Dicerna Pharmaceuticals, Inc.","TYRA":"Tyra Biosciences, Inc.",".IXIC":"NASDAQ Composite","SRAD":"Sportradar Group AG","PRCT":"PROCEPT BioRobotics",".SPX":"S&P 500 Index","DH":"Definitive Healthcare Corp."},"source_url":"https://www.marketwatch.com/story/busy-ipo-market-this-week-may-make-2021-the-biggest-year-for-proceeds-and-break-previous-record-by-30-11631554372?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160275332","content_text":"Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit the market this week \nSwiss tennis giant Roger Federer is a backer of one of this week's bigger IPOs.\n\n\nAfter a flurry of initial-public-offering launches last week set the market up for a busy fall for deals, 11 are expected to price this week and raise more than $3 billion in proceeds. \n\nIf all deals materialize, it will make 2021 the biggest year for IPO proceeds ever, and shatter the previous record by about 30%, according to Bill Smith, founder and chief executive of Renaissance Capital, a provider of institutional research and exchange-traded funds oriented around IPOs. The market is expected to see some 375 deals for the year, raising $125 billion, according to Renaissance, beating the $97 billion raised in 2000 during the dot-com boom. \n\n“After the long summer break, this week is a litmus test for upcoming tech, biotech, and consumer IPOs,” Smith wrote in a market commentary. The list includes a Swiss running-shoe company backed by tennis giant Roger Federer, a drive-through coffee kiosk operator and a mortgage insurer that was spun out of insurer Genworth Financial. \n\nThe biggest deal of the week is expected to come from Thoughtworks,a Chicago-based technology consultancy that will go public at a valuation of up to $6.1 billion.\nThe company, which expects to change its name from Turing Holding Corp. to Thoughtworks with completion of the IPO, said a total of 36.84 million shares will be offered, split between the company and selling shareholders.\n\nThe deal is expected to price at between $18 and $20 a share, and the stock will trade on the Nasdaq under the ticker symbol “TWKS.” Goldman Sachs and JPMorgan are the lead underwriters. The company recorded net income of $79.3 million on revenue of $803.4 million in 2020, after income of $28.4 million on revenue of $772.2 million in 2019.\nThe Swiss athletic-footwear maker On Holding is expected to raise up to $622 million at a valuation of almost $6 billion. On has applied to list 31.1 million shares priced at $18 to $20 each on the New York Stock Exchange, under the ticker symbol “ONON.”\n\nGoldman Sachs, Morgan Stanley and Morgan Stanley are lead underwriters in a syndicate of nine banks on the On deal. Proceeds are to be used for general corporate purposes. The company has a line that it co-developed with Federer.\n\nThe company had net income of 3.8 million Swiss francs ($4.1 million) in the six months through June 30, after a loss of 33.1 million francs in the year-earlier period, according to its IPO documents. Sales came to 315.5 million francs, up from 170.9 million francs.\n\nAlso from Switzerland, sports betting site Sportrader Group AG plans to offer 19 million shares priced at $25 to $28 each, for a valuation of up to $31 billion. The company has applied to list on Nasdaq under the ticker symbol “SRAD.” JPMorgan, Morgan Stanley, Citigroup and UBS are lead underwriters in a syndicate of 13 banks working on the deal.\n\nProceeds are to be used for working capital and to spur growth. The company had a net profit of $29.9 million in the first six months of the year, on revenue of $321 million, according to its filing documents.\n\nDutch Bros Inc.,an operator of drive-through shops that serve hot and cold drinks mostly in western U.S. states, is planning to offer 21.1 million shares priced at $18 to $20 each in its IPO, valuing the company at up to $3.3 billion.\n\nBofA Securities, JPMorgan and Jefferies are lead underwriters in a syndicate of 13 banks working on the deal. The company has applied to list on the New York Stock Exchange under the ticker symbol “BROS.”\nProceeds are to be used to purchase additional Class A shares — the company is planning to have four classes of stock with differing voting rights. The company had a net loss of $13.6 million, or 32 cents a share, in the first six months of the year, narrower than the loss of $16.5 million, or 38 cents a share, posted in the year-earlier period. Revenue fell to $227.9 million from $327.4 million.\n\nRounding out the list are:\n• Definitive Healthcare Corp., a Massachusetts-based provider of healthcare commercial intelligence, is planning to offer 15.56 million shares in its PO, which is expected to price between $21 and $24 a share. At that pricing, the company could be valued at up to $3.55 billion.\n• Enact Holdings Inc., a mortgage insurer owned by Genworth, is planning to offer 13.3 million shares priced at $19 to $20 each. The company would be valued at $3.3 billion at the top of that range. The company said all shares will be sold by Genworth and it will not receive any proceeds. It has applied to list on Nasdaq under the ticker “ACT.” Goldman Sachs and JPMorgan are lead underwriters in a team of nine banks working on the deal.\n• ForgeRock, a California-based identity security platform, is looking to raise up to $264 million with an offering of 11 million shares priced between $21 and $24 a share. That pricing would value the company a valuation of up to $1.91 billion.\nThe stock is expected to list on the NYSE under the ticker symbol “FORG.” Morgan Stanley and JPMorgan are the lead underwriters. The company recorded a net loss of $41.8 million on revenue of $127.6 million in 2020, after a loss of $36.9 million on revenue of $104.5 million in 2019.\n•Dice Therapeutics is expected to raise up to $170 million at a valuation of up to $583 million and list on Nasdaq under the ticker symbol “DICE.” The biotech is developing therapies to treat chronic diseases in the field of immunology.\n•Surgical robotics developer Procept BioRobotics,is aiming to raise up to $132 million at a valuation of about $1 billion with plans to list on Nasdaq under the ticker symbol “PRCT.” BofA Securities and Goldman Sachs are lead underwriters.\n“We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH,” the company says in its IPO documents.\n•Tyra Biosciences is aiming to raise $107.2 million in IPO proceeds at a valuation of $589 million. The biotech’s leading product candidate is a treatment for bladder cancer. It has applied to list on Nasdaq under the symbol “TYRA.”\n•EzFill Holdings, an app-based mobile fueling company in South Florida, is planning to raise $25 million at a valuation of $100 million. The company has applied to list on Nasdaq under the ticker symbol “EZFL.” ThinkEquity is sole underwriter.\nThe Renaissance IPO ETF has gained 6% to date in 2021, while the S&P 500 has advanced 19%.","news_type":1,"symbols_score_info":{".IXIC":0.9,"DRNA":0.9,"ONON":0.9,"TYRA":0.9,"BROS":0.9,"TWKS":0.9,"SRAD":0.9,"DH":0.9,"FORG":0.9,".DJI":0.9,".SPX":0.9,"PRCT":0.9,"ACT.UK":0.9}},"isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":868026688,"gmtCreate":1632556527144,"gmtModify":1632657795625,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"hope to success","listText":"hope to success","text":"hope to success","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/868026688","repostId":"1117076176","repostType":4,"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":148332278,"gmtCreate":1625928474894,"gmtModify":1633931523624,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like&nbsp;","listText":"like&nbsp;","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/148332278","repostId":"2150053623","repostType":4,"repost":{"id":"2150053623","kind":"highlight","pubTimestamp":1625883910,"share":"https://www.laohu8.com/m/news/2150053623?lang=zh_CN&edition=full","pubTime":"2021-07-10 10:25","market":"us","language":"en","title":"A crazy week for U.S. stocks came with a change in the market narrative -- should investors believe it?<blockquote>美股疯狂的一周伴随着市场叙事的变化——投资者应该相信吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2150053623","media":"MarketWatch","summary":"Investors must decide whether they believe stalling economic growth is a bigger threat than an infla","content":"<p>Investors must decide whether they believe stalling economic growth is a bigger threat than an inflation surge</p><p><blockquote>投资者必须决定他们是否认为经济增长停滞是比通胀飙升更大的威胁</blockquote></p><p> <img src=\"https://static.tigerbbs.com/32ec205cf1616aaba5573cc40240a899\" tg-width=\"1260\" tg-height=\"876\"></p><p><blockquote></blockquote></p><p> Fears of runaway inflation have been swapped for worries about a rapid slowdown in global economic growth -- and that made for one very long, holiday-shortened week for U.S. investors -- but is this new narrative the right <a href=\"https://laohu8.com/S/AONE.U\">one</a> ?</p><p><blockquote>对通货膨胀失控的担忧已经被对全球经济增长迅速放缓的担忧所取代——这使得美国投资者度过了一个漫长的假期——但这种新的说法正确吗<a href=\"https://laohu8.com/S/AONE.U\">一</a>？</blockquote></p><p> A Treasury debt rally became a buying frenzy , sending long-term yields sharply lower. That took any remaining wind out of the sails of the so-called reflation trade, which had favored shares of more cyclically sensitive companies expected to benefit the most from rising prices and accelerating economic growth.</p><p><blockquote>国债反弹变成了买盘狂潮，导致长期收益率大幅走低。这使得所谓的通货再膨胀交易失去了任何剩余的动力，该交易青睐对周期性更敏感的公司的股票，预计这些公司将从价格上涨和经济增长加速中受益最多。</blockquote></p><p> What changed? There are three important elements to the shift in the market narrative, said Lauren Goodwin, economist and portfolio strategist at New York Life Investments, which has $605 billion in assets under management.</p><p><blockquote>什么变了？管理着6050亿美元资产的纽约人寿投资公司(New York Life Investments)经济学家兼投资组合策略师劳伦·古德温(Lauren Goodwin)表示，市场叙事的转变有三个重要因素。</blockquote></p><p> The first is a perceived change in the way the Federal Reserve reacts to data, with investors no longer looking for policy makers to be as tolerant of economic overheating and rising inflation as previously thought, she said. The second is that while economic growth is expected to remain strong, the pace of growth is expected to have peaked . Third, there are worries the spread of the delta and other variants of the coronavirus that causes COVID-19 could force a renewed round of restrictions that will weigh on global economic activity.</p><p><blockquote>她表示，首先是美联储对数据的反应方式发生了明显的变化，投资者不再希望政策制定者像之前认为的那样容忍经济过热和通胀上升。二是虽然经济增长预计将保持强劲，但增长速度预计已经见顶。第三，人们担心导致新冠肺炎的三角洲和其他冠状病毒变种的传播可能会迫使新一轮限制，这将给全球经济活动带来压力。</blockquote></p><p> \"Together, that's a very different consensus market narrative than we had a few weeks ago, when the focus was all about stimulus and overheating,\" Goodwin said, in a phone interview, noting that investors must now ask: \"Is this new narrative the right one?\"</p><p><blockquote>古德温在接受电话采访时表示：“总的来说，这与几周前的市场共识叙事截然不同，当时的焦点都是刺激和过热。”他指出，投资者现在必须问：“这种新的叙事是正确的吗？”一个？”</blockquote></p><p> The real pain in the past week was in the Treasury market, where a rally drove long-term yields sharply lower and prices higher. Much of that rally was attributed to forced short covering by Treasury bears, who had feared inflation, creating something of a feeding frenzy, driving the 10-year yield to a five-month low below 1.25% on Thursday before finally relenting.</p><p><blockquote>过去一周真正的痛苦在于美国国债市场，该市场的反弹导致长期收益率大幅下跌，价格上涨。此次上涨很大程度上归因于美国国债空头被迫进行空头回补，他们担心通胀，造成了某种程度的买入狂潮，周四将10年期国债收益率推至1.25%以下的五个月低点，然后最终回落。</blockquote></p><p> But analysts said the move, at least in part, also reflected legitimate concerns over the global economic growth outlook .</p><p><blockquote>但分析师表示，此举至少在一定程度上也反映了对全球经济增长前景的合理担忧。</blockquote></p><p> That Thursday dive in yields, and accompanying growth fears, triggered a broad stock-market selloff that saw the S&amp;P 500 and Nasdaq Composite retreat from all-time highs, while the Dow Jones Industrial Average shed more than 500 points at its session low. Stocks trimmed losses by the close and then pushed higher Friday, with all three major indexes finishing at records .</p><p><blockquote>周四收益率暴跌以及随之而来的增长担忧引发了股市大范围抛售，标普500和纳斯达克综合指数从历史高点回落，而道琼斯工业平均指数则在盘中低点下跌了500多点。周五股市收盘时收复跌幅，然后走高，三大股指均创历史新高。</blockquote></p><p> One casualty was the stock market reflation trade. The small-cap Russell 2000 index RUT (#phrase-company?ref=COMPANY%7CRUT;onlineSignificance=passing-mention) fell 1.1% for a second straight week of losses, while the tech-heavy Nasdaq-100 saw a 0.4% weekly rise. Value stocks underperformed, with the Russell 1000 Value Index falling 0.3%, while the Russell 1000 Growth Index rose 1%.</p><p><blockquote>其中一个受害者是股市通货再膨胀交易。小盘股罗素2000指数RUT（#phrase-company？ref=company%7CRUT；onlineSignificance=passing-mention）连续第二周下跌1.1%，而以科技股为主的纳斯达克100指数周上涨0.4%。价值股表现不佳，罗素1000价值指数下跌0.3%，罗素1000成长指数上涨1%。</blockquote></p><p> \"The 'reflation' and 'rotation' trades -- associated with optimism about rapid, broad-based economic recovery from the pandemic and higher inflation -- has arguably been flagging since as long ago as the end of the first quarter, but clearly took another hit this week,\" said Oliver Jones, senior markets economist at research firm Capital Economics, in a Friday note.</p><p><blockquote>研究公司凯投宏观(Capital Economics)高级市场经济学家奥利弗·琼斯(Oliver Jones)在周五的一份报告中表示：“‘通货再膨胀’和‘轮换’交易——与对经济从大流行和通胀上升中快速、广泛复苏的乐观情绪相关——可以说早在第一季度末就一直在萎靡不振，但显然受到了打击。”</blockquote></p><p> Sectors, like energy and financials, and factors, such as value, that benefited most from the reflation/rotation narrative have underperformed, he noted.</p><p><blockquote>他指出，从通货再膨胀/轮动叙事中受益最多的能源和金融等行业以及价值等因素表现不佳。</blockquote></p><p> Jones argued that it makes sense for optimism about the U.S. economic recovery to top out as supply constraints bite into activity. And global growth expectations may also see pressure, with China's economy likely to continue to disappoint.</p><p><blockquote>琼斯认为，随着供应限制影响经济活动，对美国经济复苏的乐观情绪达到顶峰是有道理的。全球增长预期也可能面临压力，中国经济可能继续令人失望。</blockquote></p><p> At the same time, the U.S. economy remains on track for a very strong recovery in absolute terms, far exceeding the one that followed the global financial crisis of 2008. And core inflation in the U.S. may prove somewhat more persistent than anticipated, he argued.</p><p><blockquote>与此同时，从绝对值来看，美国经济仍有望实现非常强劲的复苏，远远超过2008年全球金融危机后的复苏。他认为，美国的核心通胀可能比预期更加持久。</blockquote></p><p> That sets the stage for a scenario in which \"the rotation/reflation trade label may become progressively less useful in the coming quarters,\" he said.</p><p><blockquote>他表示，这为“轮换/通货再膨胀贸易标签在未来几个季度可能会逐渐变得不那么有用”的情况奠定了基础。</blockquote></p><p> In particular, parts of the trade, including rapid gains in most stock markets and outperformance by energy companies is likely over for now, he said, while the drop in Treasury yields is probably an \"overreaction\" given the path of growth and inflation in the U.S.</p><p><blockquote>他表示，特别是部分交易，包括大多数股市的快速上涨和能源公司的优异表现，目前可能已经结束，而考虑到美国的增长和通胀路径，美国国债收益率的下降可能是“过度反应”。</blockquote></p><p> Investors will get a look at evidence on both the inflation and growth front in the coming week. The June consumer-price index is set for release Tuesday, while a producer-price reading is set for Wednesday. A raft of other economic data is due over the course of the week, including June retail sales figures on Friday.</p><p><blockquote>投资者将在未来一周看到通胀和增长方面的证据。6月份消费者价格指数定于周二发布，生产者价格指数定于周三发布。本周将公布大量其他经济数据，包括周五公布的6月份零售销售数据。</blockquote></p><p></p><p> And then there's the start of the corporate earnings reporting season, which is expected to offer another peak as profits roared in the second quarter relative to the early days of the pandemic last year.</p><p><blockquote>然后是企业财报季的开始，预计将迎来另一个高峰，因为与去年大流行初期相比，第二季度的利润大幅增长。</blockquote></p><p> \"With earnings season kicking off next week, the bar is set quite high and corporate America better produce another stellar quarter or there could be some disappointed bulls,\" said Ryan Detrick, chief market strategist at LPL Financial, after Friday's record close.</p><p><blockquote>LPL Financial首席市场策略师瑞安·德特里克(Ryan Detrick)在周五创纪录的收盘价后表示：“随着下周财报季的开始，标准设定得相当高，美国企业界最好再创辉煌的季度，否则可能会出现一些失望的多头。”</blockquote></p><p> Goodwin said the choice for investors boils down to either leaning into the old narrative that benefits cyclical stocks and shorter duration assets or the new one that expects economic growth to prove more sluggish and anemic, much as it was before the pandemic, favoring growth stocks and defensive sectors.</p><p><blockquote>古德温表示，投资者的选择可以归结为要么倾向于有利于周期性股票和短期资产的旧说法，要么倾向于预计经济增长将更加低迷和乏力的新说法，就像大流行之前一样，有利于成长型股票和防御性股票部门。</blockquote></p><p> The best response, however, may be a little bit of both, Goodwin said.</p><p><blockquote>然而，古德温说，最好的反应可能是两者兼而有之。</blockquote></p><p> Reflation likely still has some room to run in the near term. Distribution of child tax credit payments will begin later this month, while labor shortages may be alleviated in coming months as children return to school and additional unemployment benefits expire, she said, while consumers are sitting on sizable savings.</p><p><blockquote>通货再膨胀在短期内可能仍有一定的运行空间。她表示，儿童税收抵免付款的分配将于本月晚些时候开始，而随着儿童重返校园和额外失业救济金到期，劳动力短缺可能会在未来几个月得到缓解，而消费者则坐拥可观的储蓄。</blockquote></p><p> At the same time, growth and inflation are peaking, she said, and valuations are stretched across asset classes. While still maintaining a cyclical tilt, the changing backdrop calls for a more balanced approach to portfolios, she said.</p><p><blockquote>她表示，与此同时，增长和通胀正在见顶，各资产类别的估值都在扩大。她表示，虽然仍保持周期性倾斜，但不断变化的背景为采取更平衡的投资组合方法提供了评级。</blockquote></p><p> Investors need to look closely at sectors and individual companies that can leverage changing trends and pass rising prices on to consumers, she said, in a more selective environment rather than one in which a rising tide raises all boats.</p><p><blockquote>她表示，投资者需要在更具选择性的环境中，而不是水涨船高的环境中，密切关注能够利用不断变化的趋势并将价格上涨转嫁给消费者的行业和个别公司。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A crazy week for U.S. stocks came with a change in the market narrative -- should investors believe it?<blockquote>美股疯狂的一周伴随着市场叙事的变化——投资者应该相信吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA crazy week for U.S. stocks came with a change in the market narrative -- should investors believe it?<blockquote>美股疯狂的一周伴随着市场叙事的变化——投资者应该相信吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-07-10 10:25</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investors must decide whether they believe stalling economic growth is a bigger threat than an inflation surge</p><p><blockquote>投资者必须决定他们是否认为经济增长停滞是比通胀飙升更大的威胁</blockquote></p><p> <img src=\"https://static.tigerbbs.com/32ec205cf1616aaba5573cc40240a899\" tg-width=\"1260\" tg-height=\"876\"></p><p><blockquote></blockquote></p><p> Fears of runaway inflation have been swapped for worries about a rapid slowdown in global economic growth -- and that made for one very long, holiday-shortened week for U.S. investors -- but is this new narrative the right <a href=\"https://laohu8.com/S/AONE.U\">one</a> ?</p><p><blockquote>对通货膨胀失控的担忧已经被对全球经济增长迅速放缓的担忧所取代——这使得美国投资者度过了一个漫长的假期——但这种新的说法正确吗<a href=\"https://laohu8.com/S/AONE.U\">一</a>？</blockquote></p><p> A Treasury debt rally became a buying frenzy , sending long-term yields sharply lower. That took any remaining wind out of the sails of the so-called reflation trade, which had favored shares of more cyclically sensitive companies expected to benefit the most from rising prices and accelerating economic growth.</p><p><blockquote>国债反弹变成了买盘狂潮，导致长期收益率大幅走低。这使得所谓的通货再膨胀交易失去了任何剩余的动力，该交易青睐对周期性更敏感的公司的股票，预计这些公司将从价格上涨和经济增长加速中受益最多。</blockquote></p><p> What changed? There are three important elements to the shift in the market narrative, said Lauren Goodwin, economist and portfolio strategist at New York Life Investments, which has $605 billion in assets under management.</p><p><blockquote>什么变了？管理着6050亿美元资产的纽约人寿投资公司(New York Life Investments)经济学家兼投资组合策略师劳伦·古德温(Lauren Goodwin)表示，市场叙事的转变有三个重要因素。</blockquote></p><p> The first is a perceived change in the way the Federal Reserve reacts to data, with investors no longer looking for policy makers to be as tolerant of economic overheating and rising inflation as previously thought, she said. The second is that while economic growth is expected to remain strong, the pace of growth is expected to have peaked . Third, there are worries the spread of the delta and other variants of the coronavirus that causes COVID-19 could force a renewed round of restrictions that will weigh on global economic activity.</p><p><blockquote>她表示，首先是美联储对数据的反应方式发生了明显的变化，投资者不再希望政策制定者像之前认为的那样容忍经济过热和通胀上升。二是虽然经济增长预计将保持强劲，但增长速度预计已经见顶。第三，人们担心导致新冠肺炎的三角洲和其他冠状病毒变种的传播可能会迫使新一轮限制，这将给全球经济活动带来压力。</blockquote></p><p> \"Together, that's a very different consensus market narrative than we had a few weeks ago, when the focus was all about stimulus and overheating,\" Goodwin said, in a phone interview, noting that investors must now ask: \"Is this new narrative the right one?\"</p><p><blockquote>古德温在接受电话采访时表示：“总的来说，这与几周前的市场共识叙事截然不同，当时的焦点都是刺激和过热。”他指出，投资者现在必须问：“这种新的叙事是正确的吗？”一个？”</blockquote></p><p> The real pain in the past week was in the Treasury market, where a rally drove long-term yields sharply lower and prices higher. Much of that rally was attributed to forced short covering by Treasury bears, who had feared inflation, creating something of a feeding frenzy, driving the 10-year yield to a five-month low below 1.25% on Thursday before finally relenting.</p><p><blockquote>过去一周真正的痛苦在于美国国债市场，该市场的反弹导致长期收益率大幅下跌，价格上涨。此次上涨很大程度上归因于美国国债空头被迫进行空头回补，他们担心通胀，造成了某种程度的买入狂潮，周四将10年期国债收益率推至1.25%以下的五个月低点，然后最终回落。</blockquote></p><p> But analysts said the move, at least in part, also reflected legitimate concerns over the global economic growth outlook .</p><p><blockquote>但分析师表示，此举至少在一定程度上也反映了对全球经济增长前景的合理担忧。</blockquote></p><p> That Thursday dive in yields, and accompanying growth fears, triggered a broad stock-market selloff that saw the S&amp;P 500 and Nasdaq Composite retreat from all-time highs, while the Dow Jones Industrial Average shed more than 500 points at its session low. Stocks trimmed losses by the close and then pushed higher Friday, with all three major indexes finishing at records .</p><p><blockquote>周四收益率暴跌以及随之而来的增长担忧引发了股市大范围抛售，标普500和纳斯达克综合指数从历史高点回落，而道琼斯工业平均指数则在盘中低点下跌了500多点。周五股市收盘时收复跌幅，然后走高，三大股指均创历史新高。</blockquote></p><p> One casualty was the stock market reflation trade. The small-cap Russell 2000 index RUT (#phrase-company?ref=COMPANY%7CRUT;onlineSignificance=passing-mention) fell 1.1% for a second straight week of losses, while the tech-heavy Nasdaq-100 saw a 0.4% weekly rise. Value stocks underperformed, with the Russell 1000 Value Index falling 0.3%, while the Russell 1000 Growth Index rose 1%.</p><p><blockquote>其中一个受害者是股市通货再膨胀交易。小盘股罗素2000指数RUT（#phrase-company？ref=company%7CRUT；onlineSignificance=passing-mention）连续第二周下跌1.1%，而以科技股为主的纳斯达克100指数周上涨0.4%。价值股表现不佳，罗素1000价值指数下跌0.3%，罗素1000成长指数上涨1%。</blockquote></p><p> \"The 'reflation' and 'rotation' trades -- associated with optimism about rapid, broad-based economic recovery from the pandemic and higher inflation -- has arguably been flagging since as long ago as the end of the first quarter, but clearly took another hit this week,\" said Oliver Jones, senior markets economist at research firm Capital Economics, in a Friday note.</p><p><blockquote>研究公司凯投宏观(Capital Economics)高级市场经济学家奥利弗·琼斯(Oliver Jones)在周五的一份报告中表示：“‘通货再膨胀’和‘轮换’交易——与对经济从大流行和通胀上升中快速、广泛复苏的乐观情绪相关——可以说早在第一季度末就一直在萎靡不振，但显然受到了打击。”</blockquote></p><p> Sectors, like energy and financials, and factors, such as value, that benefited most from the reflation/rotation narrative have underperformed, he noted.</p><p><blockquote>他指出，从通货再膨胀/轮动叙事中受益最多的能源和金融等行业以及价值等因素表现不佳。</blockquote></p><p> Jones argued that it makes sense for optimism about the U.S. economic recovery to top out as supply constraints bite into activity. And global growth expectations may also see pressure, with China's economy likely to continue to disappoint.</p><p><blockquote>琼斯认为，随着供应限制影响经济活动，对美国经济复苏的乐观情绪达到顶峰是有道理的。全球增长预期也可能面临压力，中国经济可能继续令人失望。</blockquote></p><p> At the same time, the U.S. economy remains on track for a very strong recovery in absolute terms, far exceeding the one that followed the global financial crisis of 2008. And core inflation in the U.S. may prove somewhat more persistent than anticipated, he argued.</p><p><blockquote>与此同时，从绝对值来看，美国经济仍有望实现非常强劲的复苏，远远超过2008年全球金融危机后的复苏。他认为，美国的核心通胀可能比预期更加持久。</blockquote></p><p> That sets the stage for a scenario in which \"the rotation/reflation trade label may become progressively less useful in the coming quarters,\" he said.</p><p><blockquote>他表示，这为“轮换/通货再膨胀贸易标签在未来几个季度可能会逐渐变得不那么有用”的情况奠定了基础。</blockquote></p><p> In particular, parts of the trade, including rapid gains in most stock markets and outperformance by energy companies is likely over for now, he said, while the drop in Treasury yields is probably an \"overreaction\" given the path of growth and inflation in the U.S.</p><p><blockquote>他表示，特别是部分交易，包括大多数股市的快速上涨和能源公司的优异表现，目前可能已经结束，而考虑到美国的增长和通胀路径，美国国债收益率的下降可能是“过度反应”。</blockquote></p><p> Investors will get a look at evidence on both the inflation and growth front in the coming week. The June consumer-price index is set for release Tuesday, while a producer-price reading is set for Wednesday. A raft of other economic data is due over the course of the week, including June retail sales figures on Friday.</p><p><blockquote>投资者将在未来一周看到通胀和增长方面的证据。6月份消费者价格指数定于周二发布，生产者价格指数定于周三发布。本周将公布大量其他经济数据，包括周五公布的6月份零售销售数据。</blockquote></p><p></p><p> And then there's the start of the corporate earnings reporting season, which is expected to offer another peak as profits roared in the second quarter relative to the early days of the pandemic last year.</p><p><blockquote>然后是企业财报季的开始，预计将迎来另一个高峰，因为与去年大流行初期相比，第二季度的利润大幅增长。</blockquote></p><p> \"With earnings season kicking off next week, the bar is set quite high and corporate America better produce another stellar quarter or there could be some disappointed bulls,\" said Ryan Detrick, chief market strategist at LPL Financial, after Friday's record close.</p><p><blockquote>LPL Financial首席市场策略师瑞安·德特里克(Ryan Detrick)在周五创纪录的收盘价后表示：“随着下周财报季的开始，标准设定得相当高，美国企业界最好再创辉煌的季度，否则可能会出现一些失望的多头。”</blockquote></p><p> Goodwin said the choice for investors boils down to either leaning into the old narrative that benefits cyclical stocks and shorter duration assets or the new one that expects economic growth to prove more sluggish and anemic, much as it was before the pandemic, favoring growth stocks and defensive sectors.</p><p><blockquote>古德温表示，投资者的选择可以归结为要么倾向于有利于周期性股票和短期资产的旧说法，要么倾向于预计经济增长将更加低迷和乏力的新说法，就像大流行之前一样，有利于成长型股票和防御性股票部门。</blockquote></p><p> The best response, however, may be a little bit of both, Goodwin said.</p><p><blockquote>然而，古德温说，最好的反应可能是两者兼而有之。</blockquote></p><p> Reflation likely still has some room to run in the near term. Distribution of child tax credit payments will begin later this month, while labor shortages may be alleviated in coming months as children return to school and additional unemployment benefits expire, she said, while consumers are sitting on sizable savings.</p><p><blockquote>通货再膨胀在短期内可能仍有一定的运行空间。她表示，儿童税收抵免付款的分配将于本月晚些时候开始，而随着儿童重返校园和额外失业救济金到期，劳动力短缺可能会在未来几个月得到缓解，而消费者则坐拥可观的储蓄。</blockquote></p><p> At the same time, growth and inflation are peaking, she said, and valuations are stretched across asset classes. While still maintaining a cyclical tilt, the changing backdrop calls for a more balanced approach to portfolios, she said.</p><p><blockquote>她表示，与此同时，增长和通胀正在见顶，各资产类别的估值都在扩大。她表示，虽然仍保持周期性倾斜，但不断变化的背景为采取更平衡的投资组合方法提供了评级。</blockquote></p><p> Investors need to look closely at sectors and individual companies that can leverage changing trends and pass rising prices on to consumers, she said, in a more selective environment rather than one in which a rising tide raises all boats.</p><p><blockquote>她表示，投资者需要在更具选择性的环境中，而不是水涨船高的环境中，密切关注能够利用不断变化的趋势并将价格上涨转嫁给消费者的行业和个别公司。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/a-crazy-week-for-u-s-stocks-came-with-a-change-in-the-market-narrative-should-investors-believe-it-11625865324?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/a-crazy-week-for-u-s-stocks-came-with-a-change-in-the-market-narrative-should-investors-believe-it-11625865324?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150053623","content_text":"Investors must decide whether they believe stalling economic growth is a bigger threat than an inflation surge\n\nFears of runaway inflation have been swapped for worries about a rapid slowdown in global economic growth -- and that made for one very long, holiday-shortened week for U.S. investors -- but is this new narrative the right one ?\nA Treasury debt rally became a buying frenzy , sending long-term yields sharply lower. That took any remaining wind out of the sails of the so-called reflation trade, which had favored shares of more cyclically sensitive companies expected to benefit the most from rising prices and accelerating economic growth.\nWhat changed? There are three important elements to the shift in the market narrative, said Lauren Goodwin, economist and portfolio strategist at New York Life Investments, which has $605 billion in assets under management.\nThe first is a perceived change in the way the Federal Reserve reacts to data, with investors no longer looking for policy makers to be as tolerant of economic overheating and rising inflation as previously thought, she said. The second is that while economic growth is expected to remain strong, the pace of growth is expected to have peaked . Third, there are worries the spread of the delta and other variants of the coronavirus that causes COVID-19 could force a renewed round of restrictions that will weigh on global economic activity.\n\"Together, that's a very different consensus market narrative than we had a few weeks ago, when the focus was all about stimulus and overheating,\" Goodwin said, in a phone interview, noting that investors must now ask: \"Is this new narrative the right one?\"\nThe real pain in the past week was in the Treasury market, where a rally drove long-term yields sharply lower and prices higher. Much of that rally was attributed to forced short covering by Treasury bears, who had feared inflation, creating something of a feeding frenzy, driving the 10-year yield to a five-month low below 1.25% on Thursday before finally relenting.\nBut analysts said the move, at least in part, also reflected legitimate concerns over the global economic growth outlook .\nThat Thursday dive in yields, and accompanying growth fears, triggered a broad stock-market selloff that saw the S&P 500 and Nasdaq Composite retreat from all-time highs, while the Dow Jones Industrial Average shed more than 500 points at its session low. Stocks trimmed losses by the close and then pushed higher Friday, with all three major indexes finishing at records .\nOne casualty was the stock market reflation trade. The small-cap Russell 2000 index RUT (#phrase-company?ref=COMPANY%7CRUT;onlineSignificance=passing-mention) fell 1.1% for a second straight week of losses, while the tech-heavy Nasdaq-100 saw a 0.4% weekly rise. Value stocks underperformed, with the Russell 1000 Value Index falling 0.3%, while the Russell 1000 Growth Index rose 1%.\n\"The 'reflation' and 'rotation' trades -- associated with optimism about rapid, broad-based economic recovery from the pandemic and higher inflation -- has arguably been flagging since as long ago as the end of the first quarter, but clearly took another hit this week,\" said Oliver Jones, senior markets economist at research firm Capital Economics, in a Friday note.\nSectors, like energy and financials, and factors, such as value, that benefited most from the reflation/rotation narrative have underperformed, he noted.\nJones argued that it makes sense for optimism about the U.S. economic recovery to top out as supply constraints bite into activity. And global growth expectations may also see pressure, with China's economy likely to continue to disappoint.\nAt the same time, the U.S. economy remains on track for a very strong recovery in absolute terms, far exceeding the one that followed the global financial crisis of 2008. And core inflation in the U.S. may prove somewhat more persistent than anticipated, he argued.\nThat sets the stage for a scenario in which \"the rotation/reflation trade label may become progressively less useful in the coming quarters,\" he said.\nIn particular, parts of the trade, including rapid gains in most stock markets and outperformance by energy companies is likely over for now, he said, while the drop in Treasury yields is probably an \"overreaction\" given the path of growth and inflation in the U.S.\nInvestors will get a look at evidence on both the inflation and growth front in the coming week. The June consumer-price index is set for release Tuesday, while a producer-price reading is set for Wednesday. A raft of other economic data is due over the course of the week, including June retail sales figures on Friday.\nAnd then there's the start of the corporate earnings reporting season, which is expected to offer another peak as profits roared in the second quarter relative to the early days of the pandemic last year.\n\"With earnings season kicking off next week, the bar is set quite high and corporate America better produce another stellar quarter or there could be some disappointed bulls,\" said Ryan Detrick, chief market strategist at LPL Financial, after Friday's record close.\nGoodwin said the choice for investors boils down to either leaning into the old narrative that benefits cyclical stocks and shorter duration assets or the new one that expects economic growth to prove more sluggish and anemic, much as it was before the pandemic, favoring growth stocks and defensive sectors.\nThe best response, however, may be a little bit of both, Goodwin said.\nReflation likely still has some room to run in the near term. Distribution of child tax credit payments will begin later this month, while labor shortages may be alleviated in coming months as children return to school and additional unemployment benefits expire, she said, while consumers are sitting on sizable savings.\nAt the same time, growth and inflation are peaking, she said, and valuations are stretched across asset classes. While still maintaining a cyclical tilt, the changing backdrop calls for a more balanced approach to portfolios, she said.\nInvestors need to look closely at sectors and individual companies that can leverage changing trends and pass rising prices on to consumers, she said, in a more selective environment rather than one in which a rising tide raises all boats.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":693712913,"gmtCreate":1640078865625,"gmtModify":1640078865830,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693712913","repostId":"1149530831","repostType":4,"repost":{"id":"1149530831","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640078220,"share":"https://www.laohu8.com/m/news/1149530831?lang=zh_CN&edition=full","pubTime":"2021-12-21 17:17","market":"us","language":"en","title":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149530831","media":"Tiger Newspress","summary":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Ma","content":"<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会(EC)已批准Veklury的有条件营销授权变更®（瑞德西韦）纳入不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）科学委员会人用药品委员会（CHMP）于12月16日积极建议扩大Veklury的适应症之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着COVID-19发病率再次攀升以及奥密克戎病毒等新变种的出现，我们需要像Veklury这样的有效工具来治疗该疾病的各个阶段，”传染病科主任Roger Paredes医学博士和IrsiCaixa艾滋病研究所表示。“我们现在可以使用Veklury来帮助防止高危患者进展为更严重的疾病，即使他们不需要氧气，以及继续利用Veklury作为治疗严重疾病的关键工具。这一最新批准也将有助于缓解已经因COVID-19负担而承受巨大压力的医疗保健系统的一些压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>EC的决定得到了一项3期随机、双盲、安慰剂对照试验结果的支持，该试验旨在评估静脉（IV）使用Veklury三天疗程治疗疾病进展高风险的非住院患者COVID-19的疗效和安全性。在一项对以1：1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，与安慰剂（5.3%【15/283】）相比，Veklury在第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），具有统计学意义p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗后出现的不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交给科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症增加了Veklury之前的有条件上市许可，使其能够治疗需要补充氧气（治疗开始时的低流量或高流量氧气或其他无创通气）的肺炎成人和青少年（12岁至18岁以下，体重至少40 kg）的COVID-19。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官、医学博士Merdad Parsey说：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些方法可以在疾病过程的早期使用，以帮助欧洲各地的COVID-19患者。”“随着我们对COVID-19疾病如何进展的了解越来越多，很明显，如果在病程早期使用，像Veklury这样的抗病毒药物可以产生重大影响。作为COVID-19住院患者的抗病毒护理标准，我们对Veklury在大流行前线继续发挥的作用感到自豪，我们相信Veklury现在将能够帮助欧洲更多患者缩短从COVID-19中康复的时间。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>由于欧盟委员会批准了Veklury有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会(EC)已批准Veklury的有条件营销授权变更®（瑞德西韦）纳入不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）科学委员会人用药品委员会（CHMP）于12月16日积极建议扩大Veklury的适应症之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着COVID-19发病率再次攀升以及奥密克戎病毒等新变种的出现，我们需要像Veklury这样的有效工具来治疗该疾病的各个阶段，”传染病科主任Roger Paredes医学博士和IrsiCaixa艾滋病研究所表示。“我们现在可以使用Veklury来帮助防止高危患者进展为更严重的疾病，即使他们不需要氧气，以及继续利用Veklury作为治疗严重疾病的关键工具。这一最新批准也将有助于缓解已经因COVID-19负担而承受巨大压力的医疗保健系统的一些压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>EC的决定得到了一项3期随机、双盲、安慰剂对照试验结果的支持，该试验旨在评估静脉（IV）使用Veklury三天疗程治疗疾病进展高风险的非住院患者COVID-19的疗效和安全性。在一项对以1：1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，与安慰剂（5.3%【15/283】）相比，Veklury在第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），具有统计学意义p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗后出现的不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交给科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症增加了Veklury之前的有条件上市许可，使其能够治疗需要补充氧气（治疗开始时的低流量或高流量氧气或其他无创通气）的肺炎成人和青少年（12岁至18岁以下，体重至少40 kg）的COVID-19。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官、医学博士Merdad Parsey说：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些方法可以在疾病过程的早期使用，以帮助欧洲各地的COVID-19患者。”“随着我们对COVID-19疾病如何进展的了解越来越多，很明显，如果在病程早期使用，像Veklury这样的抗病毒药物可以产生重大影响。作为COVID-19住院患者的抗病毒护理标准，我们对Veklury在大流行前线继续发挥的作用感到自豪，我们相信Veklury现在将能够帮助欧洲更多患者缩短从COVID-19中康复的时间。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149530831","content_text":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.\n\"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"\nThe EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.\nThis expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).\n\"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":1653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846181020,"gmtCreate":1636067995588,"gmtModify":1636067996114,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846181020","repostId":"1128227989","repostType":4,"repost":{"id":"1128227989","kind":"news","pubTimestamp":1636067303,"share":"https://www.laohu8.com/m/news/1128227989?lang=zh_CN&edition=full","pubTime":"2021-11-05 07:08","market":"us","language":"en","title":"S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长股的推动下，标普500和纳斯达克延续了创纪录的连胜纪录</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128227989","media":"Reuters","summary":" - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.Financials dropped 1","content":"<p>(Reuters) - The S&amp;P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p><p><blockquote>（路透社）-标普500和纳斯达克周四上涨，将收盘纪录高位连涨至六个交易日，因高通强劲的财务预测以及投资者消化了美联储开始减少月度债券购买的决定后，芯片制造商股市飙升。</blockquote></p><p> The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase &amp; Co and Goldman Sachs Group weighed on the blue-chip index.</p><p><blockquote>道琼斯工业平均指数小幅下跌，结束了四点收盘的纪录。摩根大通和高盛集团银行股的下跌打压了蓝筹股指数。</blockquote></p><p> Financials dropped 1.3%, most among S&amp;P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p><p><blockquote>金融股下跌1.3%，其中大部分是标普500板块，因美国国债收益率下跌，在美联储表示不急于加息的第二天，市场解除了对美联储更快加息的预期。</blockquote></p><p> “The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p><p><blockquote>John Hancock Investment Management联席首席投资策略师马修·米斯金(Matthew Miskin)表示：“市场的增长方今天看到了更积极的结果，因为它们受益于收益率的下降。”</blockquote></p><p> “The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p><p><blockquote>“鉴于美联储宣布缩减规模，市场总体上一直在为更高的收益率做准备。当我们今天走进来时，这种情况已经发生了逆转。”</blockquote></p><p> The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&amp;P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p><p><blockquote>道琼斯工业平均指数下跌33.35点，跌幅0.09%，至36,124.23点；标普500上涨19.49点，跌幅0.42%，至4,680.06点；纳斯达克综合指数上涨128.72点，跌幅0.81%，至15,940.31点。</blockquote></p><p> The S&amp;P 500 growth index rose 1.2% while the S&amp;P 500 value index fell 0.5%.</p><p><blockquote>标普500增长指数上涨1.2%，标普500价值指数下跌0.5%。</blockquote></p><p> Among S&amp;P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p><p><blockquote>标普500板块中，科技和非必需消费品领涨，均上涨约1.5%。</blockquote></p><p> Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p><p><blockquote>高通股价上涨12.7%，该公司预测本季度利润和收入好于预期，原因是手机、汽车和其他互联网连接设备所用芯片的需求飙升。</blockquote></p><p> The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p><p><blockquote>费城SE半导体指数上涨3.5%，英伟达飙升12%。</blockquote></p><p> Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p><p><blockquote>好于预期的第三季度收益有助于提振股市情绪。根据Refinitiv IBES的数据，约有420家公司发布了财报，预计标普500第三季度盈利将同比增长41.2%。</blockquote></p><p> “The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p><p><blockquote>爱德华·琼斯投资策略师克雷格·费尔表示：“企业盈利情况仍然相当光明。”</blockquote></p><p> “The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p><p><blockquote>“市场正在奖励那些超出预期并上调前景的公司，而市场正在惩罚那些本季度未达到预期的公司，也许更重要的是，这预示着前景更加糟糕。”</blockquote></p><p> Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&amp;P 500 healthcare sector, which fell 0.8%.</p><p><blockquote>Moderna股价暴跌约18%，该公司将其COVID-19疫苗2021年的销售预测削减了多达50亿美元，并努力灌装和分销小瓶，以满足前所未有的全球需求。Moderna股价拖累标普500医疗保健板块，该板块下跌0.8%。</blockquote></p><p> Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p><p><blockquote>数据显示，上周美国新申请失业救济人数降至近20个月来的最低水平，表明经济正在恢复动力。投资者将从周五的月度就业报告中获得对经济的批判性看法。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌股与上涨股的比例为1.12比1；在纳斯达克，1.24比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p><p><blockquote>标普500创下75个52周新高和5个新低；纳斯达克综合指数录得224个新高和38个新低。</blockquote></p><p> About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p><p><blockquote>美国交易所约有113亿股易手，高于过去20个交易日104亿股的日均水平。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长股的推动下，标普500和纳斯达克延续了创纪录的连胜纪录</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长股的推动下，标普500和纳斯达克延续了创纪录的连胜纪录</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-05 07:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - The S&amp;P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p><p><blockquote>（路透社）-标普500和纳斯达克周四上涨，将收盘纪录高位连涨至六个交易日，因高通强劲的财务预测以及投资者消化了美联储开始减少月度债券购买的决定后，芯片制造商股市飙升。</blockquote></p><p> The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase &amp; Co and Goldman Sachs Group weighed on the blue-chip index.</p><p><blockquote>道琼斯工业平均指数小幅下跌，结束了四点收盘的纪录。摩根大通和高盛集团银行股的下跌打压了蓝筹股指数。</blockquote></p><p> Financials dropped 1.3%, most among S&amp;P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p><p><blockquote>金融股下跌1.3%，其中大部分是标普500板块，因美国国债收益率下跌，在美联储表示不急于加息的第二天，市场解除了对美联储更快加息的预期。</blockquote></p><p> “The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p><p><blockquote>John Hancock Investment Management联席首席投资策略师马修·米斯金(Matthew Miskin)表示：“市场的增长方今天看到了更积极的结果，因为它们受益于收益率的下降。”</blockquote></p><p> “The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p><p><blockquote>“鉴于美联储宣布缩减规模，市场总体上一直在为更高的收益率做准备。当我们今天走进来时，这种情况已经发生了逆转。”</blockquote></p><p> The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&amp;P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p><p><blockquote>道琼斯工业平均指数下跌33.35点，跌幅0.09%，至36,124.23点；标普500上涨19.49点，跌幅0.42%，至4,680.06点；纳斯达克综合指数上涨128.72点，跌幅0.81%，至15,940.31点。</blockquote></p><p> The S&amp;P 500 growth index rose 1.2% while the S&amp;P 500 value index fell 0.5%.</p><p><blockquote>标普500增长指数上涨1.2%，标普500价值指数下跌0.5%。</blockquote></p><p> Among S&amp;P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p><p><blockquote>标普500板块中，科技和非必需消费品领涨，均上涨约1.5%。</blockquote></p><p> Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p><p><blockquote>高通股价上涨12.7%，该公司预测本季度利润和收入好于预期，原因是手机、汽车和其他互联网连接设备所用芯片的需求飙升。</blockquote></p><p> The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p><p><blockquote>费城SE半导体指数上涨3.5%，英伟达飙升12%。</blockquote></p><p> Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p><p><blockquote>好于预期的第三季度收益有助于提振股市情绪。根据Refinitiv IBES的数据，约有420家公司发布了财报，预计标普500第三季度盈利将同比增长41.2%。</blockquote></p><p> “The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p><p><blockquote>爱德华·琼斯投资策略师克雷格·费尔表示：“企业盈利情况仍然相当光明。”</blockquote></p><p> “The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p><p><blockquote>“市场正在奖励那些超出预期并上调前景的公司，而市场正在惩罚那些本季度未达到预期的公司，也许更重要的是，这预示着前景更加糟糕。”</blockquote></p><p> Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&amp;P 500 healthcare sector, which fell 0.8%.</p><p><blockquote>Moderna股价暴跌约18%，该公司将其COVID-19疫苗2021年的销售预测削减了多达50亿美元，并努力灌装和分销小瓶，以满足前所未有的全球需求。Moderna股价拖累标普500医疗保健板块，该板块下跌0.8%。</blockquote></p><p> Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p><p><blockquote>数据显示，上周美国新申请失业救济人数降至近20个月来的最低水平，表明经济正在恢复动力。投资者将从周五的月度就业报告中获得对经济的批判性看法。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌股与上涨股的比例为1.12比1；在纳斯达克，1.24比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p><p><blockquote>标普500创下75个52周新高和5个新低；纳斯达克综合指数录得224个新高和38个新低。</blockquote></p><p> About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p><p><blockquote>美国交易所约有113亿股易手，高于过去20个交易日104亿股的日均水平。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".SPX":"S&P 500 Index","UPRO":"三倍做多标普500ETF-ProShares","SPXU":"三倍做空标普500ETF-ProShares","SH":"做空标普500-Proshares",".IXIC":"NASDAQ Composite","OEF":"标普100指数ETF-iShares","SSO":"2倍做多标普500ETF-ProShares",".DJI":"道琼斯","IVV":"标普500ETF-iShares","OEX":"标普100","SDS":"两倍做空标普500 ETF-ProShares"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128227989","content_text":"(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.\nThe Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.\nFinancials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.\n“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\n“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”\nThe Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.\nThe S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.\nAmong S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.\nQualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.\nThe Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.\n“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.\n“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”\nModerna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.\nData showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.\nThe S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.\nAbout 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"SPXU":0.9,"SDS":0.9,".DJI":0.9,".IXIC":0.9,"IVV":0.9,".SPX":0.9,"ESmain":0.9,"OEF":0.9,"OEX":0.9,"SH":0.9,"UPRO":0.9,"SSO":0.9}},"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822013471,"gmtCreate":1634078431219,"gmtModify":1634078431459,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/822013471","repostId":"1198930462","repostType":4,"repost":{"id":"1198930462","kind":"news","pubTimestamp":1634044920,"share":"https://www.laohu8.com/m/news/1198930462?lang=zh_CN&edition=full","pubTime":"2021-10-12 21:22","market":"us","language":"en","title":"Why you won’t know it when a bear market starts<blockquote>为什么熊市何时开始你不会知道</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198930462","media":"MarketWatch","summary":"It’s crucial to devise a strategy that you can live with through a bear market\nAFP via Getty Images\n","content":"<p>It’s crucial to devise a strategy that you can live with through a bear market</p><p><blockquote>制定一个可以度过熊市的策略至关重要</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/82a6b41119b11a31337948b9b003acab\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>AFP via Getty Images</span></p><p><blockquote><p class=\"t-img-caption\"><span>法新社来自盖蒂图片社</span></p></blockquote></p><p> It was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.</p><p><blockquote>2007年10月9日，也就是14年前的这个星期，股市在金融危机引发的熊市开始之前触及牛市高点。</blockquote></p><p> I am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&amp;P 500&nbsp;was 120% higher than where it had stood at the beginning of that bull market, five years previously.</p><p><blockquote>我敢打赌，那天你脑子里想的最后一件事就是新的熊市是否开始了。相反，你无疑分享了伴随另一个牛市新高而来的繁荣。标普500比五年前牛市开始时高出120%。</blockquote></p><p> And, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&amp;P 500 over the subsequent 16 months would <i>lose</i> 55%.</p><p><blockquote>然而，美国历史上最严重的熊市之一就在那一天开始了。标普500在随后的16个月内将<i>失去</i>55%.</blockquote></p><p> This walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.</p><p><blockquote>这种回忆很重要，因为它提醒我们牛市顶部并不是实时识别的。只有在事实发生之后，牛市才明显结束。</blockquote></p><p> Many clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.</p><p><blockquote>许多客户强烈反对我的观点，坚持认为他们实际上对牛市在2007年10月见顶有很好的感觉。但几乎可以肯定，他们正在改写历史，这是可以理解的。重写过去是人类的天性，让事情看起来很明显会像他们一样展开。</blockquote></p><p> But the beginning of the 2007-2009 bear market was anything but obvious in the moment.</p><p><blockquote>但2007-2009年熊市的开始在当时一点也不明显。</blockquote></p><p> If you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.</p><p><blockquote>如果您有任何疑问，请考虑我的公司每天监控的近100个短期股市计时器子集中推荐的平均股票敞口。（这个平均值是赫伯特股票时事通讯情绪指数（HSNSI）所代表的。）平均而言，HSNSI在牛市见顶的当天达到最高水平。</blockquote></p><p> This is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.</p><p><blockquote>这在附图中进行了说明。它对过去40年中每次牛市顶部之前六周和之后六周的HSNSI进行了平均值（根据Ned Davis Research维护的日历）。如您所见，HSNSI在平均牛市的最后六周上涨20个百分点，然后在随后的熊市的前六周暴跌40个百分点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8bc18ef162a6e98217aada4619d99651\" tg-width=\"700\" tg-height=\"488\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> In other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?</p><p><blockquote>换句话说，平均而言，专业市场计时器在他们应该最悲观的日子里最乐观。他们是专业人士，每天都在跟踪市场。如果他们不能做得更好，那你凭什么认为你可以？</blockquote></p><p> <b>Comments of market timers</b></p><p><blockquote><b>市场计时器的评论</b></blockquote></p><p> I think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:</p><p><blockquote>我认为这些统计数据提供了令人信服的理由。但为了锦上添花，请考虑时事通讯编辑在2007年10月市场顶部当天或之前几天发表的具有代表性的评论样本：</blockquote></p><p> <ul>  <li>“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”</li>  <li>“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”</li>  <li>“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”</li>  <li>“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]</li>  <li>“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”</li>  <li>“The longer-term bull market is intact… You should be looking to buy on any weakness.”</li> </ul> Their exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.</p><p><blockquote><ul><li>“如果你仔细听，你可以听到隆隆声。那隆隆声是这场大牛市第三阶段的遥远雷声……我看到了美好的时光在翻滚，我真的看到了。”</li><li>“我已经有一段时间没有对用我们的大笔资金获得巨大收益的潜力充满信心了。因此，如果您还没有这样做，那么您必须尽快将资金投入这个[股票]市场。时间不等人，你的钱在等着你。所以去吧。”</li><li>“全球股市牛市不仅仍在继续，而且……还进入了强劲阶段……既然美联储已经挥舞着利率下降的旗帜，确实没有什么可以阻碍市场。”</li><li>“道琼斯指数16,000点我们来了……在我们看来，股市将在未来3到6个月内展开竞争。”[2007年10月牛市顶部当天道指为14,165点。]</li><li>“周期性熊市跌幅超过20%的风险并未出现在雷达屏幕上。”</li><li>“长期牛市完好无损……你应该在任何疲软时买入。”</li></ul>他们的旺盛是显而易见的，不是吗？很有可能你那天也有这种感觉——不管你今天给自己讲了什么故事。</blockquote></p><p> <b>Investment lesson</b></p><p><blockquote><b>投资课</b></blockquote></p><p> The investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.</p><p><blockquote>投资含义很明确：不要指望能够为了避开熊市而减少股票敞口。</blockquote></p><p> This is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&amp;P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.</p><p><blockquote>这就是为什么你应该设计并遵循一个你可以度过熊市的策略。如果你在牛市期间100%投资，直到标普500顶部的那一天，然后在牛市期间转为100%现金，那么它不一定能赚到理论上最大值那么多钱。熊市的持续时间。但是在现实世界中没有人能达到理论上的最大值。</blockquote></p><p> The perfect is the enemy of the good, in other words.</p><p><blockquote>换句话说，完美是好的敌人。</blockquote></p><p></p><p> For the record, I have no idea whether a bear market has started. It’s been over a month now since the S&amp;P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.</p><p><blockquote>郑重声明，我不知道熊市是否已经开始。距离标普500触及迄今为止的牛市高点已经过去一个多月了，目前的交易价格比该高点低了近3%。</blockquote></p><p> But if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.</p><p><blockquote>但如果它已经开始，我们要到几个月后市场大幅下跌时才能确定。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why you won’t know it when a bear market starts<blockquote>为什么熊市何时开始你不会知道</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy you won’t know it when a bear market starts<blockquote>为什么熊市何时开始你不会知道</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-10-12 21:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It’s crucial to devise a strategy that you can live with through a bear market</p><p><blockquote>制定一个可以度过熊市的策略至关重要</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/82a6b41119b11a31337948b9b003acab\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>AFP via Getty Images</span></p><p><blockquote><p class=\"t-img-caption\"><span>法新社来自盖蒂图片社</span></p></blockquote></p><p> It was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.</p><p><blockquote>2007年10月9日，也就是14年前的这个星期，股市在金融危机引发的熊市开始之前触及牛市高点。</blockquote></p><p> I am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&amp;P 500&nbsp;was 120% higher than where it had stood at the beginning of that bull market, five years previously.</p><p><blockquote>我敢打赌，那天你脑子里想的最后一件事就是新的熊市是否开始了。相反，你无疑分享了伴随另一个牛市新高而来的繁荣。标普500比五年前牛市开始时高出120%。</blockquote></p><p> And, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&amp;P 500 over the subsequent 16 months would <i>lose</i> 55%.</p><p><blockquote>然而，美国历史上最严重的熊市之一就在那一天开始了。标普500在随后的16个月内将<i>失去</i>55%.</blockquote></p><p> This walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.</p><p><blockquote>这种回忆很重要，因为它提醒我们牛市顶部并不是实时识别的。只有在事实发生之后，牛市才明显结束。</blockquote></p><p> Many clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.</p><p><blockquote>许多客户强烈反对我的观点，坚持认为他们实际上对牛市在2007年10月见顶有很好的感觉。但几乎可以肯定，他们正在改写历史，这是可以理解的。重写过去是人类的天性，让事情看起来很明显会像他们一样展开。</blockquote></p><p> But the beginning of the 2007-2009 bear market was anything but obvious in the moment.</p><p><blockquote>但2007-2009年熊市的开始在当时一点也不明显。</blockquote></p><p> If you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.</p><p><blockquote>如果您有任何疑问，请考虑我的公司每天监控的近100个短期股市计时器子集中推荐的平均股票敞口。（这个平均值是赫伯特股票时事通讯情绪指数（HSNSI）所代表的。）平均而言，HSNSI在牛市见顶的当天达到最高水平。</blockquote></p><p> This is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.</p><p><blockquote>这在附图中进行了说明。它对过去40年中每次牛市顶部之前六周和之后六周的HSNSI进行了平均值（根据Ned Davis Research维护的日历）。如您所见，HSNSI在平均牛市的最后六周上涨20个百分点，然后在随后的熊市的前六周暴跌40个百分点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8bc18ef162a6e98217aada4619d99651\" tg-width=\"700\" tg-height=\"488\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> In other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?</p><p><blockquote>换句话说，平均而言，专业市场计时器在他们应该最悲观的日子里最乐观。他们是专业人士，每天都在跟踪市场。如果他们不能做得更好，那你凭什么认为你可以？</blockquote></p><p> <b>Comments of market timers</b></p><p><blockquote><b>市场计时器的评论</b></blockquote></p><p> I think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:</p><p><blockquote>我认为这些统计数据提供了令人信服的理由。但为了锦上添花，请考虑时事通讯编辑在2007年10月市场顶部当天或之前几天发表的具有代表性的评论样本：</blockquote></p><p> <ul>  <li>“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”</li>  <li>“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”</li>  <li>“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”</li>  <li>“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]</li>  <li>“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”</li>  <li>“The longer-term bull market is intact… You should be looking to buy on any weakness.”</li> </ul> Their exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.</p><p><blockquote><ul><li>“如果你仔细听，你可以听到隆隆声。那隆隆声是这场大牛市第三阶段的遥远雷声……我看到了美好的时光在翻滚，我真的看到了。”</li><li>“我已经有一段时间没有对用我们的大笔资金获得巨大收益的潜力充满信心了。因此，如果您还没有这样做，那么您必须尽快将资金投入这个[股票]市场。时间不等人，你的钱在等着你。所以去吧。”</li><li>“全球股市牛市不仅仍在继续，而且……还进入了强劲阶段……既然美联储已经挥舞着利率下降的旗帜，确实没有什么可以阻碍市场。”</li><li>“道琼斯指数16,000点我们来了……在我们看来，股市将在未来3到6个月内展开竞争。”[2007年10月牛市顶部当天道指为14,165点。]</li><li>“周期性熊市跌幅超过20%的风险并未出现在雷达屏幕上。”</li><li>“长期牛市完好无损……你应该在任何疲软时买入。”</li></ul>他们的旺盛是显而易见的，不是吗？很有可能你那天也有这种感觉——不管你今天给自己讲了什么故事。</blockquote></p><p> <b>Investment lesson</b></p><p><blockquote><b>投资课</b></blockquote></p><p> The investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.</p><p><blockquote>投资含义很明确：不要指望能够为了避开熊市而减少股票敞口。</blockquote></p><p> This is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&amp;P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.</p><p><blockquote>这就是为什么你应该设计并遵循一个你可以度过熊市的策略。如果你在牛市期间100%投资，直到标普500顶部的那一天，然后在牛市期间转为100%现金，那么它不一定能赚到理论上最大值那么多钱。熊市的持续时间。但是在现实世界中没有人能达到理论上的最大值。</blockquote></p><p> The perfect is the enemy of the good, in other words.</p><p><blockquote>换句话说，完美是好的敌人。</blockquote></p><p></p><p> For the record, I have no idea whether a bear market has started. It’s been over a month now since the S&amp;P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.</p><p><blockquote>郑重声明，我不知道熊市是否已经开始。距离标普500触及迄今为止的牛市高点已经过去一个多月了，目前的交易价格比该高点低了近3%。</blockquote></p><p> But if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.</p><p><blockquote>但如果它已经开始，我们要到几个月后市场大幅下跌时才能确定。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/why-you-wont-know-it-when-a-bear-market-starts-11633654477?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/why-you-wont-know-it-when-a-bear-market-starts-11633654477?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198930462","content_text":"It’s crucial to devise a strategy that you can live with through a bear market\nAFP via Getty Images\n\nIt was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.\nI am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&P 500 was 120% higher than where it had stood at the beginning of that bull market, five years previously.\nAnd, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&P 500 over the subsequent 16 months would lose 55%.\nThis walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.\nMany clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.\nBut the beginning of the 2007-2009 bear market was anything but obvious in the moment.\nIf you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.\nThis is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.\n\n\nIn other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?\nComments of market timers\nI think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:\n\n“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”\n“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”\n“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”\n“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]\n“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”\n“The longer-term bull market is intact… You should be looking to buy on any weakness.”\n\nTheir exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.\nInvestment lesson\nThe investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.\nThis is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.\nThe perfect is the enemy of the good, in other words.\nFor the record, I have no idea whether a bear market has started. It’s been over a month now since the S&P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.\nBut if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":881106606,"gmtCreate":1631313763405,"gmtModify":1632883288299,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881106606","repostId":"2166137557","repostType":4,"isVote":1,"tweetType":1,"viewCount":393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":699829799,"gmtCreate":1639783265714,"gmtModify":1639783265921,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699829799","repostId":"2192497854","repostType":4,"isVote":1,"tweetType":1,"viewCount":1944,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609690307,"gmtCreate":1638274281322,"gmtModify":1638274281408,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609690307","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","kind":"news","pubTimestamp":1638273550,"share":"https://www.laohu8.com/m/news/1192203085?lang=zh_CN&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>新冠抗体药物受奥密克戎挑战初步检测显示</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司的Covid-19抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明，如果新毒株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家表示，对礼来公司(Eli Lilly&amp;Co.)的另一种授权的Covid-19抗体药物混合物进行的单独测试表明，它对奥密克戎病也没有那么有效。礼来公司表示，正在针对其抗体治疗测试新变种，但不愿猜测结果会是什么。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞相评估新的奥密克戎病毒变种对患者、医生和医院一直依赖的Covid-19治疗的影响的早期结果，以及正在开发的有望让人们远离医院的药物。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它含有再生元和礼来药物所针对的刺突蛋白的突变，而其他药物应该表现良好，因为它们攻击的是变种中未改变的病毒元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来自新冠肺炎幸存者或被改造成具有人类免疫系统的小鼠。当感染后不久给药时，这些药物会附着在冠状病毒的表面，阻止它在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权在需要住院治疗患者之前治疗这些患者的药物，这些患者具有发展为严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何防御病毒，包括产生抗体。去年，前总统唐纳德·特朗普将他从Covid-19中迅速康复归功于再生元的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在进行进一步测试后，它将能够在未来几周内量化该变体的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的Paxlovid等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>该公司总裁兼首席科学官George Yancopoulos表示，如果最终测试表明其抗体药物对奥密克戎病毒的效果较差，再生元已经开发出替代抗体，可以将其推向临床测试，并且认为这些抗体将保留对该变种的有效性。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元的一种替代抗体已经处于临床测试阶段，该公司预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎病毒变种，促使药物研究人员争先恐后地看看，如果新冠肺炎病毒最终广泛传播，相对较小的新冠肺炎治疗药箱是否仍能对抗新毒株。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“我们必须承认的是，在过去的六天里，我们的紧迫性有所增加，”扬科普洛斯博士在接受采访时说。“最初的备用计划现在变得更加紧迫。”</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图Fred Hutchinson癌症研究中心的科学家发现，奥密克戎病毒的个体突变降低或消除了再生元和礼来公司的药物附着在病毒上的能力。该中心和西雅图华盛顿大学的候选人。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对针对整个变种的药物进行更全面的测试，以充分了解其影响。“我不确定效果的确切程度，但效果可能会较差，”格雷尼女士说。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问Nicole Kallewaard表示，礼来公司正在针对其药物测试新变种，该药物是两种抗体的组合，称为bamlanivimab和etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变结合在一起时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“我认为我们需要等待整个病毒的确认，”Kallewaard博士说。“希望数据能在未来几周内公布。”</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病毒患病率的上升可能会给那些表示其药物在初步测试中没有出现的竞争对手带来受到该变种影响的机会，其中包括Vir Biotechnology Inc.和葛兰素史克PLC，其药物sotrovimab早些时候被授权紧急使用今年。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc.是一家正在进行临床试验的新冠肺炎抗体药物的生物技术公司，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、葛兰素史克和Adagio表示，他们正在进行进一步测试，以确认他们的药物不受奥密克戎病的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生了突变，已知抗体经常附着在该部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir和Adagio官员表示，两家公司设计抗体的目的是针对病毒上不同冠状病毒中常见的点，这些点即使在多年多次突变后仍保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>Adagio首席执行官蒂尔曼·格恩格罗斯(Tillman Gerngross)在接受采访时表示：“它们与病毒的一个区域结合，该区域经过数十年的进化并没有发生太大变化。”“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，至少需要两周时间才能创建完整的奥密克戎病毒变种版本并测试针对其的抗体药物。尽管如此，科学家们表示，他们对这种变异逃避疫苗、先前感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“奥密克戎还没有成为下一个三角洲，”Vir首席科学官Skip Virgin在接受采访时表示。但“我们认为突变的程度和数量意味着世界需要非常认真地对待奥密克戎。”</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>洛克菲勒大学免疫学家米歇尔·努森茨威格(Michel Nussenzweig)表示，抗病毒药物，包括默克公司(Merck&amp;Co.)和合作伙伴Ridgeback Biotherapeutics LP以及辉瑞公司(Pfizer Inc.)正在接受授权评估的药物，似乎不受该变种的影响，因为它们针对病毒上的不同位点。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直在期待这种药物的批准，在临床试验中，如果尽早服用，这种药物可以降低住院风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“药物的目标似乎压力较小，可能没问题，但这也需要测试，”努森茨威格博士说。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计他们的药物将有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物Veklury将保持对奥密克戎病毒的有效性，就像它对其他令人担忧的变种一样。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>新冠抗体药物受奥密克戎挑战初步检测显示</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>新冠抗体药物受奥密克戎挑战初步检测显示</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-11-30 19:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司的Covid-19抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明，如果新毒株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家表示，对礼来公司(Eli Lilly&amp;Co.)的另一种授权的Covid-19抗体药物混合物进行的单独测试表明，它对奥密克戎病也没有那么有效。礼来公司表示，正在针对其抗体治疗测试新变种，但不愿猜测结果会是什么。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞相评估新的奥密克戎病毒变种对患者、医生和医院一直依赖的Covid-19治疗的影响的早期结果，以及正在开发的有望让人们远离医院的药物。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它含有再生元和礼来药物所针对的刺突蛋白的突变，而其他药物应该表现良好，因为它们攻击的是变种中未改变的病毒元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来自新冠肺炎幸存者或被改造成具有人类免疫系统的小鼠。当感染后不久给药时，这些药物会附着在冠状病毒的表面，阻止它在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权在需要住院治疗患者之前治疗这些患者的药物，这些患者具有发展为严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何防御病毒，包括产生抗体。去年，前总统唐纳德·特朗普将他从Covid-19中迅速康复归功于再生元的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在进行进一步测试后，它将能够在未来几周内量化该变体的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的Paxlovid等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>该公司总裁兼首席科学官George Yancopoulos表示，如果最终测试表明其抗体药物对奥密克戎病毒的效果较差，再生元已经开发出替代抗体，可以将其推向临床测试，并且认为这些抗体将保留对该变种的有效性。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元的一种替代抗体已经处于临床测试阶段，该公司预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎病毒变种，促使药物研究人员争先恐后地看看，如果新冠肺炎病毒最终广泛传播，相对较小的新冠肺炎治疗药箱是否仍能对抗新毒株。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“我们必须承认的是，在过去的六天里，我们的紧迫性有所增加，”扬科普洛斯博士在接受采访时说。“最初的备用计划现在变得更加紧迫。”</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图Fred Hutchinson癌症研究中心的科学家发现，奥密克戎病毒的个体突变降低或消除了再生元和礼来公司的药物附着在病毒上的能力。该中心和西雅图华盛顿大学的候选人。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对针对整个变种的药物进行更全面的测试，以充分了解其影响。“我不确定效果的确切程度，但效果可能会较差，”格雷尼女士说。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问Nicole Kallewaard表示，礼来公司正在针对其药物测试新变种，该药物是两种抗体的组合，称为bamlanivimab和etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变结合在一起时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“我认为我们需要等待整个病毒的确认，”Kallewaard博士说。“希望数据能在未来几周内公布。”</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病毒患病率的上升可能会给那些表示其药物在初步测试中没有出现的竞争对手带来受到该变种影响的机会，其中包括Vir Biotechnology Inc.和葛兰素史克PLC，其药物sotrovimab早些时候被授权紧急使用今年。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc.是一家正在进行临床试验的新冠肺炎抗体药物的生物技术公司，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、葛兰素史克和Adagio表示，他们正在进行进一步测试，以确认他们的药物不受奥密克戎病的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生了突变，已知抗体经常附着在该部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir和Adagio官员表示，两家公司设计抗体的目的是针对病毒上不同冠状病毒中常见的点，这些点即使在多年多次突变后仍保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>Adagio首席执行官蒂尔曼·格恩格罗斯(Tillman Gerngross)在接受采访时表示：“它们与病毒的一个区域结合，该区域经过数十年的进化并没有发生太大变化。”“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，至少需要两周时间才能创建完整的奥密克戎病毒变种版本并测试针对其的抗体药物。尽管如此，科学家们表示，他们对这种变异逃避疫苗、先前感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“奥密克戎还没有成为下一个三角洲，”Vir首席科学官Skip Virgin在接受采访时表示。但“我们认为突变的程度和数量意味着世界需要非常认真地对待奥密克戎。”</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>洛克菲勒大学免疫学家米歇尔·努森茨威格(Michel Nussenzweig)表示，抗病毒药物，包括默克公司(Merck&amp;Co.)和合作伙伴Ridgeback Biotherapeutics LP以及辉瑞公司(Pfizer Inc.)正在接受授权评估的药物，似乎不受该变种的影响，因为它们针对病毒上的不同位点。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直在期待这种药物的批准，在临床试验中，如果尽早服用，这种药物可以降低住院风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“药物的目标似乎压力较小，可能没问题，但这也需要测试，”努森茨威格博士说。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计他们的药物将有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物Veklury将保持对奥密克戎病毒的有效性，就像它对其他令人担忧的变种一样。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1,"symbols_score_info":{"LLY":0.9,"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866126804,"gmtCreate":1632749416008,"gmtModify":1632798135036,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/866126804","repostId":"1143393352","repostType":4,"repost":{"id":"1143393352","kind":"news","pubTimestamp":1632747727,"share":"https://www.laohu8.com/m/news/1143393352?lang=zh_CN&edition=full","pubTime":"2021-09-27 21:02","market":"us","language":"en","title":"Tesla and General Motors picked by Goldman Sachs as auto winners in tough environment<blockquote>高盛评选特斯拉和通用汽车为严峻环境下的汽车赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143393352","media":"Seeking Alpha","summary":"Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand envi","content":"<p><ul>  <li>Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand environment that is anticipated to last several more quarters as the global chip shortage and other supply chain issues impact production. The firm now sees 75M autos produced in 2021 vs. 83M prior forecast and 85M in 2022 vs. 90M prior forecast.t</li>  <li>The unexpected backdrop sets up some automakers to outperform, per Goldman. \"Several of our Buy rated stocks strike a good balance in our opinion of having strong financial models (e.g., attractive margins and/or [free cash flow]) that we think can provide resiliency in a difficult supply chain environment,\" notes analyst Mark Delaney. In particular, Tesla&nbsp;is called an industry leader that is well positioned for growth and General Motors&nbsp;is seen as an attractive stock that captures the benefit from an industry recovery in production as well as opportunities to benefit from EVs and advanced driver-assistance systems. Both stocks have a Buy rating at Goldman and price targets that imply double-digit upside. The setup is seen being not nearly as favorable for Lordstown Motors, which was cut to a Sell rating.</li> </ul></p><p><blockquote><ul><li>高盛下调了全球汽车产量预期，以反映由于全球芯片短缺和其他供应链问题影响生产，预计供需紧张环境将持续几个季度。该公司目前预计2021年汽车产量为7500万辆，而之前预测为8300万辆；2022年汽车产量为8500万辆，而之前预测为9000万辆。t</li><li>高盛表示，这种意想不到的背景使一些汽车制造商跑赢大盘。分析师指出：“我们认为，我们的几只买入评级股票在拥有强大的财务模型（例如，有吸引力的利润率和/或[自由现金流]）方面取得了良好的平衡，我们认为这些模型可以在困难的供应链环境中提供弹性。”马克·德莱尼。特别是，特斯拉被称为处于良好增长地位的行业领导者，而通用汽车被视为一只有吸引力的股票，它受益于行业生产复苏以及从电动汽车和先进驾驶辅助系统中受益的机会。这两只股票均获得高盛的买入评级，目标价意味着两位数的上涨空间。这种设置被认为对洛兹敦汽车公司不利，该公司被下调至卖出评级。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla and General Motors picked by Goldman Sachs as auto winners in tough environment<blockquote>高盛评选特斯拉和通用汽车为严峻环境下的汽车赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla and General Motors picked by Goldman Sachs as auto winners in tough environment<blockquote>高盛评选特斯拉和通用汽车为严峻环境下的汽车赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-09-27 21:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand environment that is anticipated to last several more quarters as the global chip shortage and other supply chain issues impact production. The firm now sees 75M autos produced in 2021 vs. 83M prior forecast and 85M in 2022 vs. 90M prior forecast.t</li>  <li>The unexpected backdrop sets up some automakers to outperform, per Goldman. \"Several of our Buy rated stocks strike a good balance in our opinion of having strong financial models (e.g., attractive margins and/or [free cash flow]) that we think can provide resiliency in a difficult supply chain environment,\" notes analyst Mark Delaney. In particular, Tesla&nbsp;is called an industry leader that is well positioned for growth and General Motors&nbsp;is seen as an attractive stock that captures the benefit from an industry recovery in production as well as opportunities to benefit from EVs and advanced driver-assistance systems. Both stocks have a Buy rating at Goldman and price targets that imply double-digit upside. The setup is seen being not nearly as favorable for Lordstown Motors, which was cut to a Sell rating.</li> </ul></p><p><blockquote><ul><li>高盛下调了全球汽车产量预期，以反映由于全球芯片短缺和其他供应链问题影响生产，预计供需紧张环境将持续几个季度。该公司目前预计2021年汽车产量为7500万辆，而之前预测为8300万辆；2022年汽车产量为8500万辆，而之前预测为9000万辆。t</li><li>高盛表示，这种意想不到的背景使一些汽车制造商跑赢大盘。分析师指出：“我们认为，我们的几只买入评级股票在拥有强大的财务模型（例如，有吸引力的利润率和/或[自由现金流]）方面取得了良好的平衡，我们认为这些模型可以在困难的供应链环境中提供弹性。”马克·德莱尼。特别是，特斯拉被称为处于良好增长地位的行业领导者，而通用汽车被视为一只有吸引力的股票，它受益于行业生产复苏以及从电动汽车和先进驾驶辅助系统中受益的机会。这两只股票均获得高盛的买入评级，目标价意味着两位数的上涨空间。这种设置被认为对洛兹敦汽车公司不利，该公司被下调至卖出评级。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3744831-tesla-and-general-motors-picked-by-goldman-sachs-as-auto-winners-in-tough-environment\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","GM":"通用汽车"},"source_url":"https://seekingalpha.com/news/3744831-tesla-and-general-motors-picked-by-goldman-sachs-as-auto-winners-in-tough-environment","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143393352","content_text":"Goldman Sachs lowers its global auto production forecast to reflect the tight supply and demand environment that is anticipated to last several more quarters as the global chip shortage and other supply chain issues impact production. The firm now sees 75M autos produced in 2021 vs. 83M prior forecast and 85M in 2022 vs. 90M prior forecast.t\nThe unexpected backdrop sets up some automakers to outperform, per Goldman. \"Several of our Buy rated stocks strike a good balance in our opinion of having strong financial models (e.g., attractive margins and/or [free cash flow]) that we think can provide resiliency in a difficult supply chain environment,\" notes analyst Mark Delaney. In particular, Tesla is called an industry leader that is well positioned for growth and General Motors is seen as an attractive stock that captures the benefit from an industry recovery in production as well as opportunities to benefit from EVs and advanced driver-assistance systems. Both stocks have a Buy rating at Goldman and price targets that imply double-digit upside. The setup is seen being not nearly as favorable for Lordstown Motors, which was cut to a Sell rating.","news_type":1,"symbols_score_info":{"GM":0.9,"TSLA":0.9,"RIDE":0.9}},"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698851498,"gmtCreate":1640347839561,"gmtModify":1640347839791,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698851498","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":2530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871950051,"gmtCreate":1637021099591,"gmtModify":1637021099673,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871950051","repostId":"2183907418","repostType":4,"isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868026181,"gmtCreate":1632556506043,"gmtModify":1632657801629,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868026181","repostId":"1188909032","repostType":4,"repost":{"id":"1188909032","kind":"news","pubTimestamp":1632531451,"share":"https://www.laohu8.com/m/news/1188909032?lang=zh_CN&edition=full","pubTime":"2021-09-25 08:57","market":"us","language":"en","title":"5 Top Consumer Stocks To Watch Ahead Of October 2021<blockquote>2021年10月之前值得关注的5只顶级消费股</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188909032","media":"Nasdaq","summary":"Do You Have These Top Consumer Stocks On Your Radar Now?\nThe past trading week has been exciting, to","content":"<p>Do You Have These Top Consumer Stocks On Your Radar Now?</p><p><blockquote>您现在关注这些顶级消费股吗？</blockquote></p><p> The past trading week has been exciting, to say the least. Despite all of the ups and downs,consumer stockscontinue to make waves in thestock market today. If anything, the consumer-focused industry continues to hold strong now. This is evident as August’s retail sales figures smashed expectations, rising by 0.7% versus an estimated drop of 0.8%. Moreover, the current broad-based rebound in thestock marketcould indicate that investors’ sentiment on the economy is improving.</p><p><blockquote>至少可以说，过去的交易周令人兴奋。尽管经历了大起大落，消费类股今天继续在股市上掀起波澜。如果说有什么不同的话，那就是以消费者为中心的行业现在继续保持强劲。这一点很明显，8月份零售额数据超出预期，增长0.7%，而预期下降0.8%。此外，当前股市的广泛反弹可能表明投资者对经济的信心正在改善。</blockquote></p><p> Evidently, we could look at the likes of<b>Roku</b>(NASDAQ: ROKU) right now. Just yesterday, Guggenheim analyst Michael Morris provided a positive update on the stock. Namely, Morris hit ROKU stock with a Buy rating and a price target of $395. Morris cites Roku’s aggressive expansion of its original content and penetration of international markets as core reasons for the upgrade.</p><p><blockquote>显然，我们可以看看<b>Roku</b>（纳斯达克：ROKU）现在。就在昨天，古根海姆分析师迈克尔·莫里斯提供了该股的积极更新。也就是说，Morris给予ROKU股票买入评级，目标价为395美元。Morris将Roku对其原创内容的积极扩张和对国际市场的渗透作为升级的核心原因。</blockquote></p><p> At the same time, there is some interesting movement going on with<b>Nike’s</b>(NYSE: NKE) shares as well. Yesterday, the company posted its first-quarter earnings after the closing bell. In short, Nike reported an earnings per share of $1.16 on revenue of $12.25 billion for the quarter. This is against estimates of $1.11 and $12.46 billion. Investors appear to be focusing on Nike’s revenue miss which is mostly due to temporary supply chain pressures. Regardless, as one of the biggest names in the sports apparel industry globally, some could see opportunity in NKE stocks’ current weakness. With all this activity in the space now, could one of these consumer stocks be worth investing in?</p><p><blockquote>与此同时，有一些有趣的运动正在进行<b>耐克的</b>（纽约证券交易所代码：NKE）的股票也是如此。昨天，该公司在收盘后公布了第一季度财报。简而言之，耐克报告本季度每股收益为1.16美元，营收为122.5亿美元。相比之下，估计为11.1亿美元和124.6亿美元。投资者似乎关注耐克的营收下滑，这主要是由于暂时的供应链压力。无论如何，作为全球运动服装行业最大的品牌之一，一些人可能会从NKE股票当前的疲软中看到机会。鉴于目前该领域的所有活动，这些消费股中的一只值得投资吗？</blockquote></p><p> Best Consumer Stocks To Buy [Or Sell] Today</p><p><blockquote>今天最值得买入[或卖出]的消费股</blockquote></p><p> <ul>  <li><b>Beyond Meat Inc.</b>(NASDAQ: BYND)</li>  <li><b>Trip.com Group Ltd.</b>(NASDAQ: TCOM)</li>  <li><b>Vail Resorts Inc.</b>(NYSE: MTN)</li>  <li><b>Costco Wholesale Corporation</b>(NASDAQ: COST)</li>  <li><b>Stitch Fix Inc.</b>(NASDAQ: SFIX)</li> </ul> Beyond Meat Inc.</p><p><blockquote><ul><li><b>Beyond Meat公司。</b>（纳斯达克：BYND）</li><li><b>携程集团有限公司。</b>（纳斯达克：TCOM）</li><li><b>韦尔度假村公司。</b>（纽约证券交易所代码：MTN）</li><li><b>好市多批发公司</b>（纳斯达克：成本）</li><li><b>缝合修复公司。</b>（纳斯达克：SFIX）</li></ul>Beyond Meat公司。</blockquote></p><p> <b>Beyond Meat</b>is a plant-based meat substitutes retailer with headquarters in California. The company offers plant-based options in the beef, poultry, and pork categories. In fact, it is one of the fastest-growing food companies in the U.S. as more people are increasingly alternating to plant-based options. Its products are designed to have the same taste and texture as animal-based meat while being the better option for the environment. BYND stock has almost doubled in valuation since its pandemic era low.</p><p><blockquote><b>Beyond Meat</b>是一家植物性肉类替代品零售商，总部位于加利福尼亚州。该公司提供牛肉、家禽和猪肉类别的植物性选择。事实上，随着越来越多的人越来越多地转向植物性食品，它是美国发展最快的食品公司之一。它的产品被设计成具有与动物性肉类相同的味道和质地，同时也是更好的环境选择。自大流行时代低点以来，BYND股票的估值几乎翻了一番。</blockquote></p><p> In August, the company reported its second-quarter financials. Diving in, net revenue for the quarter was $149.4 million, increasing by 31.8% year-over-year. Furthermore, gross profit for the quarter was $47.4 million. The company saw record net revenues and also continues to return to growth in the foodservice industry as its customers welcome consumers back to their venues. Not resting on its laurels, the company also continues to make substantial investments in its long-term growth in the U.S. and abroad. Given all of this, will you consider investing in BYND stock right now?</p><p><blockquote>8月，该公司公布了第二季度财务数据。该季度净收入为1.494亿美元，同比增长31.8%。此外，该季度毛利润为4740万美元。该公司实现了创纪录的净收入，并且随着客户欢迎消费者回到他们的场所，餐饮服务行业也继续恢复增长。该公司并没有固步自封，还继续为其在美国和海外的长期增长进行大量投资。鉴于所有这些，您现在会考虑投资BYND股票吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/875119289e70dc28e620fb5eeb2d291b\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p><p><blockquote>资料来源：德美利证券TOS</blockquote></p><p> <b>[Read More]</b>&nbsp;What Stocks To Buy Today? 5 Tech Stocks To Watch</p><p><blockquote><b>[阅读更多]</b>今天买什么股票？5只值得关注的科技股</blockquote></p><p> Trip.com Group Ltd</p><p><blockquote>携程集团有限公司</blockquote></p><p> Following that, we have multinational online travel company<b>Trip.com</b>, a leading one-stop travel platform globally. It integrates a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for travelers in China and around the world. Impressively, it is currently one of the largest online travel agencies in China and also one of the largest travel service providers in the world.</p><p><blockquote>接下来，我们有跨国在线旅游公司<b>Trip.com</b>，全球领先的一站式旅游平台。它整合了一套全面的旅游产品和服务以及差异化的旅游内容。它是中国和世界各地游客的首选目的地。令人印象深刻的是，它是目前中国最大的在线旅行社之一，也是全球最大的旅游服务提供商之一。</blockquote></p><p> After yesterday’s closing bell, Trip.com posted solid figures in its second fiscal quarter earnings report. In it, the company saw a total revenue of $912 million for the quarter. This marks a significant year-over-year jump of 86%. In terms of net income, the company saw a 43% increase over the same period. CEO Jane Sun cites Trip.com’s focus on the domestic market as a core contributor to this solid quarter for the company. Overall, given this piece of news, will you consider adding TCOM stock to your portfolio right now?</p><p><blockquote>昨天收盘后，携程在第二财季财报中公布了稳健的数据。该公司本季度总收入为9.12亿美元。这标志着同比大幅增长86%。净利润方面，该公司同期增长了43%。首席执行官Jane Sun表示，携程对国内市场的关注是该公司本季度业绩强劲的核心贡献者。总体而言，鉴于这条消息，您现在会考虑将TCOM股票添加到您的投资组合中吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/781e08ea2e30a4f9c94020727b3e77bc\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOSVail Resorts Inc.</p><p><blockquote>资料来源：德美利证券TOSVail Resorts Inc.</blockquote></p><p> <b>Vail Resorts</b>is a leading global mountain resort operator. The company and its subsidiaries operate 37 destination mountain resorts and regional ski areas. In essence, it owns and/or manages a collection of casually elegant hotels under the RockResorts brand. It also has a development company that is in the real estate planning and development business. MTN stock is up by over 40% in the past year alone.</p><p><blockquote><b>韦尔度假村</b>是全球领先的山地度假村运营商。该公司及其子公司经营着37个目的地山地度假村和区域滑雪场。本质上，它拥有和/或管理RockResorts品牌下的一系列休闲优雅的酒店。它还拥有一家从事房地产规划和开发业务的开发公司。仅去年一年，MTN股价就上涨了40%以上。</blockquote></p><p></p><p> Recently, KeyBanc Capital Markets upgraded Vail Resorts to an Overweight rating from Sector Weight and hit it with a price target of $355. Analyst Brett Andreas says that demand for skiing vacations was exceeding expectations with some bookings already at record levels. Not to mention, the company continues to gain momentum on the financial front. In its fourth fiscal quarterearnings call, Vail reported a net income of $127.9 million, marking a sizable 29.4% year-over-year increase. After considering that pandemic-related factors still weigh on its key operations, the company’s fundamentals are admirable. Moreover, the company also declared a cash dividend of $0.88 per share, to investors’ delight. All things considered, will you buy MTN stock?</p><p><blockquote>最近，KeyBanc Capital Markets将Vail Resorts的评级从行业权重上调至跑赢大盘，并将其目标价定为355美元。分析师布雷特·安德烈亚斯表示，滑雪度假的需求超出了预期，一些预订量已经达到创纪录水平。更不用说，该公司在财务方面继续获得动力。在第四财季收益看涨期权中，韦尔公布净利润为1.279亿美元，同比大幅增长29.4%。在考虑到大流行相关因素仍然拖累其关键业务后，该公司的基本面令人钦佩。此外，该公司还宣布派发每股0.88美元的现金股息，令投资者感到高兴。综合考虑，您会购买MTN股票吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c596fd2c2dc3ef4d15e9c9dfa89b8147\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p><p><blockquote>资料来源：德美利证券TOS</blockquote></p><p> <b>[Read More]</b>&nbsp;4 Semiconductor Stocks To Watch Right Now</p><p><blockquote><b>[阅读更多]</b>目前值得关注的4只半导体股票</blockquote></p><p> Costco Wholesale Corporation</p><p><blockquote>好市多批发公司</blockquote></p><p> Next up, we will be taking a look at<b>Costco</b>. For the most part, the multinational consumer staples giant would be another player to consider in thestock market today. The main factor differentiating Costco from its retail competitors would be its membership-only big-box operations. Simply put, the company only caters to members and sells daily necessities in bulk. Amidst the ongoing pandemic and climate crises, Costco’s offerings could see greater demand from consumers.</p><p><blockquote>接下来，我们将看看<b>Costco</b>在很大程度上，这家跨国消费品巨头将是当今股市中另一个值得考虑的参与者。Costco区别于零售竞争对手的主要因素是其仅限会员的大卖场业务。简单来说，公司只迎合会员，散装销售日用品。在持续的大流行和气候危机中，好市多的产品可能会受到消费者更大的需求。</blockquote></p><p> By and large, with COST stock sitting on year-to-date gains of over 19%, could it be worth investing in? Well, for one thing, the company beat Wall Streets’ projections across the board in its latest quarterly earnings report. In detail, Costco posted an earnings per share of $3.76 on revenue of $62.7 billion for the quarter. For some perspective, consensus estimates suggest an earnings per share of $3.59 on revenue of $61.6 billion. All in all, would you consider adding COST stock to your portfolio?</p><p><blockquote>总的来说，成本股今年迄今的涨幅超过19%，值得投资吗？一方面，该公司在最新的季度收益报告中全面超出了华尔街的预测。具体而言，Costco公布本季度每股收益为3.76美元，营收为627亿美元。从某种角度来看，普遍预期每股收益为3.59美元，营收为616亿美元。总而言之，您会考虑将成本股票添加到您的投资组合中吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0412ae414ccd0df0d5f93302bd037b56\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p><p><blockquote>资料来源：德美利证券TOS</blockquote></p><p> <b>[Read More]</b>&nbsp;Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist</p><p><blockquote><b>[阅读更多]</b>现在最值得购买的股票？值得您关注的4只可再生能源股票</blockquote></p><p> Stitch Fix Inc.</p><p><blockquote>缝合修复公司。</blockquote></p><p> Another name to know in the consumer stock space now would be<b>Stitch Fix</b>. In brief, it is an online personal styling service. Through a combination of artificial intelligence and data science, Stitch Fix provides customers with personalized e-commerce experiences. Given the prevalence of online shopping throughout the pandemic, SFIX stock could be in focus among investors. In fact, the company’s shares are up by over 15% just this week on account of its solid earnings report.</p><p><blockquote>现在消费股领域另一个值得了解的名字是<b>缝合固定</b>简而言之，它是一种在线个人造型服务。通过人工智能和数据科学的结合，Stitch Fix为客户提供个性化的电子商务体验。鉴于在线购物在整个大流行期间的盛行，SFIX股票可能会成为投资者关注的焦点。事实上，由于其稳健的盈利报告，该公司股价仅本周就上涨了15%以上。</blockquote></p><p> Notably, Stitch Fix raked in a total revenue of $571.16 million for the quarter, marking a 28% year-over-year increase. Additionally, the company also reported massive year-over-year spikes of over 145% in both its net income and earnings per share. Despite beating analyst estimates on these fronts, Stitch Fix does not seem to be slowing down anytime soon. This appears to be the case as the company is expanding its services with Stitch Fix Freestyle, a “differentiated shopping experience”. This would give customers a more instant and flexible means of shopping on its platform. As such, could SFIX stock be a top pick in the stock market now?</p><p><blockquote>值得注意的是，Stitch Fix本季度总收入为5.7116亿美元，同比增长28%。此外，该公司还报告称，其净利润和每股收益同比大幅增长超过145%。尽管在这些方面超出了分析师的预期，但Stitch Fix似乎不会很快放缓。这似乎是因为该公司正在通过Stitch Fix Freestyle扩展其服务，这是一种“差异化的购物体验”。这将为客户提供一种更即时、更灵活的方式在其平台上购物。因此，SFIX股票现在能成为股市的首选吗？</blockquote></p><p></p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Top Consumer Stocks To Watch Ahead Of October 2021<blockquote>2021年10月之前值得关注的5只顶级消费股</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Top Consumer Stocks To Watch Ahead Of October 2021<blockquote>2021年10月之前值得关注的5只顶级消费股</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Nasdaq</strong><span class=\"h-time small\">2021-09-25 08:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Do You Have These Top Consumer Stocks On Your Radar Now?</p><p><blockquote>您现在关注这些顶级消费股吗？</blockquote></p><p> The past trading week has been exciting, to say the least. Despite all of the ups and downs,consumer stockscontinue to make waves in thestock market today. If anything, the consumer-focused industry continues to hold strong now. This is evident as August’s retail sales figures smashed expectations, rising by 0.7% versus an estimated drop of 0.8%. Moreover, the current broad-based rebound in thestock marketcould indicate that investors’ sentiment on the economy is improving.</p><p><blockquote>至少可以说，过去的交易周令人兴奋。尽管经历了大起大落，消费类股今天继续在股市上掀起波澜。如果说有什么不同的话，那就是以消费者为中心的行业现在继续保持强劲。这一点很明显，8月份零售额数据超出预期，增长0.7%，而预期下降0.8%。此外，当前股市的广泛反弹可能表明投资者对经济的信心正在改善。</blockquote></p><p> Evidently, we could look at the likes of<b>Roku</b>(NASDAQ: ROKU) right now. Just yesterday, Guggenheim analyst Michael Morris provided a positive update on the stock. Namely, Morris hit ROKU stock with a Buy rating and a price target of $395. Morris cites Roku’s aggressive expansion of its original content and penetration of international markets as core reasons for the upgrade.</p><p><blockquote>显然，我们可以看看<b>Roku</b>（纳斯达克：ROKU）现在。就在昨天，古根海姆分析师迈克尔·莫里斯提供了该股的积极更新。也就是说，Morris给予ROKU股票买入评级，目标价为395美元。Morris将Roku对其原创内容的积极扩张和对国际市场的渗透作为升级的核心原因。</blockquote></p><p> At the same time, there is some interesting movement going on with<b>Nike’s</b>(NYSE: NKE) shares as well. Yesterday, the company posted its first-quarter earnings after the closing bell. In short, Nike reported an earnings per share of $1.16 on revenue of $12.25 billion for the quarter. This is against estimates of $1.11 and $12.46 billion. Investors appear to be focusing on Nike’s revenue miss which is mostly due to temporary supply chain pressures. Regardless, as one of the biggest names in the sports apparel industry globally, some could see opportunity in NKE stocks’ current weakness. With all this activity in the space now, could one of these consumer stocks be worth investing in?</p><p><blockquote>与此同时，有一些有趣的运动正在进行<b>耐克的</b>（纽约证券交易所代码：NKE）的股票也是如此。昨天，该公司在收盘后公布了第一季度财报。简而言之，耐克报告本季度每股收益为1.16美元，营收为122.5亿美元。相比之下，估计为11.1亿美元和124.6亿美元。投资者似乎关注耐克的营收下滑，这主要是由于暂时的供应链压力。无论如何，作为全球运动服装行业最大的品牌之一，一些人可能会从NKE股票当前的疲软中看到机会。鉴于目前该领域的所有活动，这些消费股中的一只值得投资吗？</blockquote></p><p> Best Consumer Stocks To Buy [Or Sell] Today</p><p><blockquote>今天最值得买入[或卖出]的消费股</blockquote></p><p> <ul>  <li><b>Beyond Meat Inc.</b>(NASDAQ: BYND)</li>  <li><b>Trip.com Group Ltd.</b>(NASDAQ: TCOM)</li>  <li><b>Vail Resorts Inc.</b>(NYSE: MTN)</li>  <li><b>Costco Wholesale Corporation</b>(NASDAQ: COST)</li>  <li><b>Stitch Fix Inc.</b>(NASDAQ: SFIX)</li> </ul> Beyond Meat Inc.</p><p><blockquote><ul><li><b>Beyond Meat公司。</b>（纳斯达克：BYND）</li><li><b>携程集团有限公司。</b>（纳斯达克：TCOM）</li><li><b>韦尔度假村公司。</b>（纽约证券交易所代码：MTN）</li><li><b>好市多批发公司</b>（纳斯达克：成本）</li><li><b>缝合修复公司。</b>（纳斯达克：SFIX）</li></ul>Beyond Meat公司。</blockquote></p><p> <b>Beyond Meat</b>is a plant-based meat substitutes retailer with headquarters in California. The company offers plant-based options in the beef, poultry, and pork categories. In fact, it is one of the fastest-growing food companies in the U.S. as more people are increasingly alternating to plant-based options. Its products are designed to have the same taste and texture as animal-based meat while being the better option for the environment. BYND stock has almost doubled in valuation since its pandemic era low.</p><p><blockquote><b>Beyond Meat</b>是一家植物性肉类替代品零售商，总部位于加利福尼亚州。该公司提供牛肉、家禽和猪肉类别的植物性选择。事实上，随着越来越多的人越来越多地转向植物性食品，它是美国发展最快的食品公司之一。它的产品被设计成具有与动物性肉类相同的味道和质地，同时也是更好的环境选择。自大流行时代低点以来，BYND股票的估值几乎翻了一番。</blockquote></p><p> In August, the company reported its second-quarter financials. Diving in, net revenue for the quarter was $149.4 million, increasing by 31.8% year-over-year. Furthermore, gross profit for the quarter was $47.4 million. The company saw record net revenues and also continues to return to growth in the foodservice industry as its customers welcome consumers back to their venues. Not resting on its laurels, the company also continues to make substantial investments in its long-term growth in the U.S. and abroad. Given all of this, will you consider investing in BYND stock right now?</p><p><blockquote>8月，该公司公布了第二季度财务数据。该季度净收入为1.494亿美元，同比增长31.8%。此外，该季度毛利润为4740万美元。该公司实现了创纪录的净收入，并且随着客户欢迎消费者回到他们的场所，餐饮服务行业也继续恢复增长。该公司并没有固步自封，还继续为其在美国和海外的长期增长进行大量投资。鉴于所有这些，您现在会考虑投资BYND股票吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/875119289e70dc28e620fb5eeb2d291b\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p><p><blockquote>资料来源：德美利证券TOS</blockquote></p><p> <b>[Read More]</b>&nbsp;What Stocks To Buy Today? 5 Tech Stocks To Watch</p><p><blockquote><b>[阅读更多]</b>今天买什么股票？5只值得关注的科技股</blockquote></p><p> Trip.com Group Ltd</p><p><blockquote>携程集团有限公司</blockquote></p><p> Following that, we have multinational online travel company<b>Trip.com</b>, a leading one-stop travel platform globally. It integrates a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for travelers in China and around the world. Impressively, it is currently one of the largest online travel agencies in China and also one of the largest travel service providers in the world.</p><p><blockquote>接下来，我们有跨国在线旅游公司<b>Trip.com</b>，全球领先的一站式旅游平台。它整合了一套全面的旅游产品和服务以及差异化的旅游内容。它是中国和世界各地游客的首选目的地。令人印象深刻的是，它是目前中国最大的在线旅行社之一，也是全球最大的旅游服务提供商之一。</blockquote></p><p> After yesterday’s closing bell, Trip.com posted solid figures in its second fiscal quarter earnings report. In it, the company saw a total revenue of $912 million for the quarter. This marks a significant year-over-year jump of 86%. In terms of net income, the company saw a 43% increase over the same period. CEO Jane Sun cites Trip.com’s focus on the domestic market as a core contributor to this solid quarter for the company. Overall, given this piece of news, will you consider adding TCOM stock to your portfolio right now?</p><p><blockquote>昨天收盘后，携程在第二财季财报中公布了稳健的数据。该公司本季度总收入为9.12亿美元。这标志着同比大幅增长86%。净利润方面，该公司同期增长了43%。首席执行官Jane Sun表示，携程对国内市场的关注是该公司本季度业绩强劲的核心贡献者。总体而言，鉴于这条消息，您现在会考虑将TCOM股票添加到您的投资组合中吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/781e08ea2e30a4f9c94020727b3e77bc\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOSVail Resorts Inc.</p><p><blockquote>资料来源：德美利证券TOSVail Resorts Inc.</blockquote></p><p> <b>Vail Resorts</b>is a leading global mountain resort operator. The company and its subsidiaries operate 37 destination mountain resorts and regional ski areas. In essence, it owns and/or manages a collection of casually elegant hotels under the RockResorts brand. It also has a development company that is in the real estate planning and development business. MTN stock is up by over 40% in the past year alone.</p><p><blockquote><b>韦尔度假村</b>是全球领先的山地度假村运营商。该公司及其子公司经营着37个目的地山地度假村和区域滑雪场。本质上，它拥有和/或管理RockResorts品牌下的一系列休闲优雅的酒店。它还拥有一家从事房地产规划和开发业务的开发公司。仅去年一年，MTN股价就上涨了40%以上。</blockquote></p><p></p><p> Recently, KeyBanc Capital Markets upgraded Vail Resorts to an Overweight rating from Sector Weight and hit it with a price target of $355. Analyst Brett Andreas says that demand for skiing vacations was exceeding expectations with some bookings already at record levels. Not to mention, the company continues to gain momentum on the financial front. In its fourth fiscal quarterearnings call, Vail reported a net income of $127.9 million, marking a sizable 29.4% year-over-year increase. After considering that pandemic-related factors still weigh on its key operations, the company’s fundamentals are admirable. Moreover, the company also declared a cash dividend of $0.88 per share, to investors’ delight. All things considered, will you buy MTN stock?</p><p><blockquote>最近，KeyBanc Capital Markets将Vail Resorts的评级从行业权重上调至跑赢大盘，并将其目标价定为355美元。分析师布雷特·安德烈亚斯表示，滑雪度假的需求超出了预期，一些预订量已经达到创纪录水平。更不用说，该公司在财务方面继续获得动力。在第四财季收益看涨期权中，韦尔公布净利润为1.279亿美元，同比大幅增长29.4%。在考虑到大流行相关因素仍然拖累其关键业务后，该公司的基本面令人钦佩。此外，该公司还宣布派发每股0.88美元的现金股息，令投资者感到高兴。综合考虑，您会购买MTN股票吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c596fd2c2dc3ef4d15e9c9dfa89b8147\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p><p><blockquote>资料来源：德美利证券TOS</blockquote></p><p> <b>[Read More]</b>&nbsp;4 Semiconductor Stocks To Watch Right Now</p><p><blockquote><b>[阅读更多]</b>目前值得关注的4只半导体股票</blockquote></p><p> Costco Wholesale Corporation</p><p><blockquote>好市多批发公司</blockquote></p><p> Next up, we will be taking a look at<b>Costco</b>. For the most part, the multinational consumer staples giant would be another player to consider in thestock market today. The main factor differentiating Costco from its retail competitors would be its membership-only big-box operations. Simply put, the company only caters to members and sells daily necessities in bulk. Amidst the ongoing pandemic and climate crises, Costco’s offerings could see greater demand from consumers.</p><p><blockquote>接下来，我们将看看<b>Costco</b>在很大程度上，这家跨国消费品巨头将是当今股市中另一个值得考虑的参与者。Costco区别于零售竞争对手的主要因素是其仅限会员的大卖场业务。简单来说，公司只迎合会员，散装销售日用品。在持续的大流行和气候危机中，好市多的产品可能会受到消费者更大的需求。</blockquote></p><p> By and large, with COST stock sitting on year-to-date gains of over 19%, could it be worth investing in? Well, for one thing, the company beat Wall Streets’ projections across the board in its latest quarterly earnings report. In detail, Costco posted an earnings per share of $3.76 on revenue of $62.7 billion for the quarter. For some perspective, consensus estimates suggest an earnings per share of $3.59 on revenue of $61.6 billion. All in all, would you consider adding COST stock to your portfolio?</p><p><blockquote>总的来说，成本股今年迄今的涨幅超过19%，值得投资吗？一方面，该公司在最新的季度收益报告中全面超出了华尔街的预测。具体而言，Costco公布本季度每股收益为3.76美元，营收为627亿美元。从某种角度来看，普遍预期每股收益为3.59美元，营收为616亿美元。总而言之，您会考虑将成本股票添加到您的投资组合中吗？</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0412ae414ccd0df0d5f93302bd037b56\" tg-width=\"759\" tg-height=\"468\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Source: TD Ameritrade TOS</p><p><blockquote>资料来源：德美利证券TOS</blockquote></p><p> <b>[Read More]</b>&nbsp;Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist</p><p><blockquote><b>[阅读更多]</b>现在最值得购买的股票？值得您关注的4只可再生能源股票</blockquote></p><p> Stitch Fix Inc.</p><p><blockquote>缝合修复公司。</blockquote></p><p> Another name to know in the consumer stock space now would be<b>Stitch Fix</b>. In brief, it is an online personal styling service. Through a combination of artificial intelligence and data science, Stitch Fix provides customers with personalized e-commerce experiences. Given the prevalence of online shopping throughout the pandemic, SFIX stock could be in focus among investors. In fact, the company’s shares are up by over 15% just this week on account of its solid earnings report.</p><p><blockquote>现在消费股领域另一个值得了解的名字是<b>缝合固定</b>简而言之，它是一种在线个人造型服务。通过人工智能和数据科学的结合，Stitch Fix为客户提供个性化的电子商务体验。鉴于在线购物在整个大流行期间的盛行，SFIX股票可能会成为投资者关注的焦点。事实上，由于其稳健的盈利报告，该公司股价仅本周就上涨了15%以上。</blockquote></p><p> Notably, Stitch Fix raked in a total revenue of $571.16 million for the quarter, marking a 28% year-over-year increase. Additionally, the company also reported massive year-over-year spikes of over 145% in both its net income and earnings per share. Despite beating analyst estimates on these fronts, Stitch Fix does not seem to be slowing down anytime soon. This appears to be the case as the company is expanding its services with Stitch Fix Freestyle, a “differentiated shopping experience”. This would give customers a more instant and flexible means of shopping on its platform. As such, could SFIX stock be a top pick in the stock market now?</p><p><blockquote>值得注意的是，Stitch Fix本季度总收入为5.7116亿美元，同比增长28%。此外，该公司还报告称，其净利润和每股收益同比大幅增长超过145%。尽管在这些方面超出了分析师的预期，但Stitch Fix似乎不会很快放缓。这似乎是因为该公司正在通过Stitch Fix Freestyle扩展其服务，这是一种“差异化的购物体验”。这将为客户提供一种更即时、更灵活的方式在其平台上购物。因此，SFIX股票现在能成为股市的首选吗？</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.nasdaq.com/articles/5-top-consumer-stocks-to-watch-ahead-of-october-2021-2021-09-24\">Nasdaq</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克","BYND":"Beyond Meat, Inc.","SFIX":"Stitch Fix Inc.","ROKU":"Roku Inc","COST":"好市多","TCOM":"携程网"},"source_url":"https://www.nasdaq.com/articles/5-top-consumer-stocks-to-watch-ahead-of-october-2021-2021-09-24","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188909032","content_text":"Do You Have These Top Consumer Stocks On Your Radar Now?\nThe past trading week has been exciting, to say the least. Despite all of the ups and downs,consumer stockscontinue to make waves in thestock market today. If anything, the consumer-focused industry continues to hold strong now. This is evident as August’s retail sales figures smashed expectations, rising by 0.7% versus an estimated drop of 0.8%. Moreover, the current broad-based rebound in thestock marketcould indicate that investors’ sentiment on the economy is improving.\nEvidently, we could look at the likes ofRoku(NASDAQ: ROKU) right now. Just yesterday, Guggenheim analyst Michael Morris provided a positive update on the stock. Namely, Morris hit ROKU stock with a Buy rating and a price target of $395. Morris cites Roku’s aggressive expansion of its original content and penetration of international markets as core reasons for the upgrade.\nAt the same time, there is some interesting movement going on withNike’s(NYSE: NKE) shares as well. Yesterday, the company posted its first-quarter earnings after the closing bell. In short, Nike reported an earnings per share of $1.16 on revenue of $12.25 billion for the quarter. This is against estimates of $1.11 and $12.46 billion. Investors appear to be focusing on Nike’s revenue miss which is mostly due to temporary supply chain pressures. Regardless, as one of the biggest names in the sports apparel industry globally, some could see opportunity in NKE stocks’ current weakness. With all this activity in the space now, could one of these consumer stocks be worth investing in?\nBest Consumer Stocks To Buy [Or Sell] Today\n\nBeyond Meat Inc.(NASDAQ: BYND)\nTrip.com Group Ltd.(NASDAQ: TCOM)\nVail Resorts Inc.(NYSE: MTN)\nCostco Wholesale Corporation(NASDAQ: COST)\nStitch Fix Inc.(NASDAQ: SFIX)\n\nBeyond Meat Inc.\nBeyond Meatis a plant-based meat substitutes retailer with headquarters in California. The company offers plant-based options in the beef, poultry, and pork categories. In fact, it is one of the fastest-growing food companies in the U.S. as more people are increasingly alternating to plant-based options. Its products are designed to have the same taste and texture as animal-based meat while being the better option for the environment. BYND stock has almost doubled in valuation since its pandemic era low.\nIn August, the company reported its second-quarter financials. Diving in, net revenue for the quarter was $149.4 million, increasing by 31.8% year-over-year. Furthermore, gross profit for the quarter was $47.4 million. The company saw record net revenues and also continues to return to growth in the foodservice industry as its customers welcome consumers back to their venues. Not resting on its laurels, the company also continues to make substantial investments in its long-term growth in the U.S. and abroad. Given all of this, will you consider investing in BYND stock right now?\nSource: TD Ameritrade TOS\n[Read More] What Stocks To Buy Today? 5 Tech Stocks To Watch\nTrip.com Group Ltd\nFollowing that, we have multinational online travel companyTrip.com, a leading one-stop travel platform globally. It integrates a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for travelers in China and around the world. Impressively, it is currently one of the largest online travel agencies in China and also one of the largest travel service providers in the world.\nAfter yesterday’s closing bell, Trip.com posted solid figures in its second fiscal quarter earnings report. In it, the company saw a total revenue of $912 million for the quarter. This marks a significant year-over-year jump of 86%. In terms of net income, the company saw a 43% increase over the same period. CEO Jane Sun cites Trip.com’s focus on the domestic market as a core contributor to this solid quarter for the company. Overall, given this piece of news, will you consider adding TCOM stock to your portfolio right now?\nSource: TD Ameritrade TOSVail Resorts Inc.\nVail Resortsis a leading global mountain resort operator. The company and its subsidiaries operate 37 destination mountain resorts and regional ski areas. In essence, it owns and/or manages a collection of casually elegant hotels under the RockResorts brand. It also has a development company that is in the real estate planning and development business. MTN stock is up by over 40% in the past year alone.\nRecently, KeyBanc Capital Markets upgraded Vail Resorts to an Overweight rating from Sector Weight and hit it with a price target of $355. Analyst Brett Andreas says that demand for skiing vacations was exceeding expectations with some bookings already at record levels. Not to mention, the company continues to gain momentum on the financial front. In its fourth fiscal quarterearnings call, Vail reported a net income of $127.9 million, marking a sizable 29.4% year-over-year increase. After considering that pandemic-related factors still weigh on its key operations, the company’s fundamentals are admirable. Moreover, the company also declared a cash dividend of $0.88 per share, to investors’ delight. All things considered, will you buy MTN stock?\nSource: TD Ameritrade TOS\n[Read More] 4 Semiconductor Stocks To Watch Right Now\nCostco Wholesale Corporation\nNext up, we will be taking a look atCostco. For the most part, the multinational consumer staples giant would be another player to consider in thestock market today. The main factor differentiating Costco from its retail competitors would be its membership-only big-box operations. Simply put, the company only caters to members and sells daily necessities in bulk. Amidst the ongoing pandemic and climate crises, Costco’s offerings could see greater demand from consumers.\nBy and large, with COST stock sitting on year-to-date gains of over 19%, could it be worth investing in? Well, for one thing, the company beat Wall Streets’ projections across the board in its latest quarterly earnings report. In detail, Costco posted an earnings per share of $3.76 on revenue of $62.7 billion for the quarter. For some perspective, consensus estimates suggest an earnings per share of $3.59 on revenue of $61.6 billion. All in all, would you consider adding COST stock to your portfolio?\nSource: TD Ameritrade TOS\n[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist\nStitch Fix Inc.\nAnother name to know in the consumer stock space now would beStitch Fix. In brief, it is an online personal styling service. Through a combination of artificial intelligence and data science, Stitch Fix provides customers with personalized e-commerce experiences. Given the prevalence of online shopping throughout the pandemic, SFIX stock could be in focus among investors. In fact, the company’s shares are up by over 15% just this week on account of its solid earnings report.\nNotably, Stitch Fix raked in a total revenue of $571.16 million for the quarter, marking a 28% year-over-year increase. Additionally, the company also reported massive year-over-year spikes of over 145% in both its net income and earnings per share. Despite beating analyst estimates on these fronts, Stitch Fix does not seem to be slowing down anytime soon. This appears to be the case as the company is expanding its services with Stitch Fix Freestyle, a “differentiated shopping experience”. This would give customers a more instant and flexible means of shopping on its platform. As such, could SFIX stock be a top pick in the stock market now?","news_type":1,"symbols_score_info":{"SFIX":0.9,"NKE":0.9,"ROKU":0.9,"COST":0.9,"TCOM":0.9,"BYND":0.9}},"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":888703280,"gmtCreate":1631524608140,"gmtModify":1631890295722,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"hmm","listText":"hmm","text":"hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/888703280","repostId":"1111145722","repostType":4,"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889050456,"gmtCreate":1631094554875,"gmtModify":1632884675205,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"good thought","listText":"good thought","text":"good thought","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/889050456","repostId":"1175171654","repostType":4,"repost":{"id":"1175171654","kind":"news","pubTimestamp":1631093315,"share":"https://www.laohu8.com/m/news/1175171654?lang=zh_CN&edition=full","pubTime":"2021-09-08 17:28","market":"us","language":"en","title":"5 Stock Ideas From an Investor Who Predicted Tesla Would Rise to $1,000<blockquote>预测特斯拉将升至1,000美元的投资者的5个股票想法</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1175171654","media":"Barron's","summary":"Investors listen to what Gary Black has to say about Tesla. But the investing veteran is more than j","content":"<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> listen to what Gary Black has to say about Tesla. But the investing veteran is more than just a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-trick, or one-stock, pony.</p><p><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>听听Gary Black对特斯拉的看法。但这位投资老手不仅仅是一位<a href=\"https://laohu8.com/S/AONE.U\">一</a>-诡计，或一只股票，小马。</blockquote></p><p> He has other picks for growth investors as well as a new actively managed ETF: The Future Fund (ticker: FFND), designed to capitalized on 10 megatrends he sees changing the world.</p><p><blockquote>他为成长型投资者提供了其他选择，以及一只新的主动管理型ETF：未来基金（股票代码：FFND），旨在利用他认为正在改变世界的10个大趋势。</blockquote></p><p> That fund is only a couple of weeks old. Black has been at the investing game for about 30 years, starting as a research analyst at Bernstein in 1992.</p><p><blockquote>该基金才成立几周。布莱克从1992年开始在伯恩斯坦担任研究分析师，从事投资行业已有大约30年的历史。</blockquote></p><p> After Bernstein, Black moved to the buy-side with stints at <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> Asset Management, Janus and Aegon, among others. After a brief respite following Aegon, Black jumped into the world of actively managed ETFs.</p><p><blockquote>在伯恩斯坦之后，布莱克转向买方，曾在<a href=\"https://laohu8.com/S/GS\">高盛</a>资产管理公司、骏利和全球保险集团等。在Aegon之后短暂休息后，Black进入了主动管理型ETF的领域。</blockquote></p><p> He sat down with Barron’s to talk about his new fund, his approach to investing and some of the stocks he’s invested in. An edited version of the conversation follows.</p><p><blockquote>他与《巴伦周刊》坐下来谈论他的新基金、他的投资方法以及他投资的一些股票。以下是对话的编辑版本。</blockquote></p><p> <b>Barron’s: </b>We probably have to start with Tesla (TSLA). How do you value Tesla stock?</p><p><blockquote><b>巴伦周刊：</b>我们可能要从特斯拉（TSLA）开始。您如何评估特斯拉股票？</blockquote></p><p> <b>Black:</b> I take where I think global [car sales are] going to be in about five years, and I take the EV adoption–it will get to 25% by 2025. This is the big investment controversy on Tesla: As competitors enter the market, can it keep its roughly 25% EV share? If it can, I get about $32 or so of earnings in 2025. And if I even put a 50 multiple on it, which is pretty low given projected 55% average annual earnings growth. I get a $1,600 price. And that’s worth about $1,100 today.</p><p><blockquote><b>黑色：</b>我认为全球[汽车销量]将在大约五年内达到什么水平，以及电动汽车的采用率——到2025年将达到25%。这就是特斯拉最大的投资争议：随着竞争对手进入市场，它能否保持大约25%的电动汽车份额？如果可以的话，到2025年我将获得大约32美元左右的收入。即使我给它打50倍，考虑到预计55%的平均年盈利增长率，这个数字也相当低。我得到1600美元的价格。今天这大约值1100美元。</blockquote></p><p> <b>Market share is the big controversy? What about self-driving cars?</b></p><p><blockquote><b>市场份额是最大的争议？自动驾驶汽车呢？</b></blockquote></p><p> Stop saying Tesla has valuation equal to $1,000 a share because of the EV business. And then another $1,000 because of robotaxis.</p><p><blockquote>不要因为电动汽车业务而说特斯拉的估值相当于每股1,000美元。然后又是1000美元，因为机器人出租车。</blockquote></p><p> <b>Tesla robotaxis like Waymo won’t be a thing?</b></p><p><blockquote><b>像Waymo这样的特斯拉机器人出租车不会成为现实？</b></blockquote></p><p> I think you’re going to have commercial robotaxi. And you’re going to have consumer robotaxi.</p><p><blockquote>我认为你将拥有商业机器人出租车。你将拥有消费者机器人出租车。</blockquote></p><p> Tesla has a head start, but competitors, especially those from <a href=\"https://laohu8.com/S/CAAS\">China</a>, are offering more expensive systems with vision, lidar, radar and HD mapping allowing them to close the gap. Everyone will get there eventually–which Elon has said. Tesla’s features will still let Tesla sell more Teslas.</p><p><blockquote>特斯拉处于领先地位，但竞争对手，尤其是来自<a href=\"https://laohu8.com/S/CAAS\">中国</a>，正在提供具有视觉、激光雷达、雷达和高清测绘功能的更昂贵的系统，使他们能够缩小差距。每个人最终都会到达那里——埃隆已经说过了。特斯拉的功能仍然会让特斯拉卖出更多的特斯拉。</blockquote></p><p> <b>Why did you start the Future Fund ETF?</b></p><p><blockquote><b>为什么要启动未来基金ETF？</b></blockquote></p><p> Secular growth [is] its cornerstone. We’re looking to capitalize on 10 secular megatrends that are changing the world.</p><p><blockquote>长期增长是其基石。我们希望利用正在改变世界的10个长期大趋势。</blockquote></p><p> <b>What are they?</b></p><p><blockquote><b>它们是什么？</b></blockquote></p><p> They are: [1] 24/7 information and entertainment, [2] social networking, [3] mobility–working from anywhere–[4] e-commerce, [5] fintech innovation, [6] big data and security, [7] people living longer, [8] lifestyle betterment, [9] automation and [10] sustainability. Those are the 10.</p><p><blockquote>它们是：[1]24/7信息和娱乐，[2]社交网络，[3]移动性-随时随地工作-[4]电子商务，[5]金融科技创新，[6]大数据和安全，[7]人们寿命更长，[8]生活方式改善，[9]自动化和[10]可持续发展。那是10个。</blockquote></p><p> And so what we try to do is find companies that [have] the megatrends as tailwinds. No. 1, we’re looking for high growth, 20% revenue growth. We’re looking for unlevered brands, meaning, brands that are very successful in, say, one segment, and they bring them into other segments, or brands that are successful in one geography, and can go global.</p><p><blockquote>因此，我们试图做的是找到那些以大趋势为推动力的公司。第一，我们寻求高增长，20%的收入增长。我们正在寻找无杠杆品牌，即在一个细分市场非常成功的品牌，并将其带入其他细分市场，或者在一个地区取得成功并可以走向全球的品牌。</blockquote></p><p> No. 2, we’re looking for investment controversy. We’re looking for something where there is a fight, and where investors don’t agree. And that’s what creates opportunity.</p><p><blockquote>第二，我们在寻找投资争议。我们正在寻找存在争斗且投资者不同意的地方。这就是创造机会的原因。</blockquote></p><p> <b>What’s your research process like?</b></p><p><blockquote><b>你的研究过程是怎样的？</b></blockquote></p><p> We go out, and I talk. We talk to a lot of competitors. When I was an analyst, I used to do focus groups. For 2,000 bucks, you could get 10 people in a room, and ask them why they don’t like about Beyond Meat [BYND] versus Impossible [Foods]. We can usually find information that gives me a research edge to answer the controversy.</p><p><blockquote>我们出去，我说话。我们和很多竞争对手谈过。当我还是分析师的时候，我经常做焦点小组。花2000美元，你可以让10个人呆在一个房间里，问他们为什么不喜欢Beyond Meat[BYND]和Impossible[Foods]。我们通常可以找到给我研究优势的信息来回答争议。</blockquote></p><p> <b>And how do you build your portfolio?</b></p><p><blockquote><b>你如何建立你的投资组合？</b></blockquote></p><p> We want a portfolio that’s high conviction, meaning no more than about 40 names. The top 10 names are about 40% of the portfolio. So that’s high conviction to me.</p><p><blockquote>我们想要一个高度可信的投资组合，这意味着不超过40个名字。排名前10的名字约占投资组合的40%。所以这对我来说是高度的信念。</blockquote></p><p> We think we have very strong buy and sell discipline. When we put something in the portfolio, we want it to have at least 2:1 risk-adjusted upside versus downside.</p><p><blockquote>我们认为我们有非常严格的买卖纪律。当我们将某样东西放入投资组合时，我们希望它的风险调整后上行空间与下行空间至少为2：1。</blockquote></p><p> <b>What else do you like, besides Tesla?</b></p><p><blockquote><b>除了特斯拉，你还喜欢什么？</b></blockquote></p><p> We have Google [parent <a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> ], which is changing the world. Google is a mega cap stock just like Tesla is. But we think You Tube is 24/7 information and entertainment. YouTube is way undervalued. They’re still monetizing [search]. It has good 15% to 20% revenue growth. At 22 times projected earnings, it’s still [an attractive] price to us.</p><p><blockquote>我们有谷歌[父<a href=\"https://laohu8.com/S/GOOG\">Alphabet</a>]，这正在改变世界。谷歌和特斯拉一样都是大盘股。但我们认为You Tube是24/7的信息和娱乐。YouTube被严重低估了。他们仍在通过[搜索]赚钱。它有15%到20%的良好收入增长。预计市盈率为22倍，对我们来说仍然是一个[有吸引力的]价格。</blockquote></p><p> Another name we have is <a href=\"https://laohu8.com/S/CMG\">Chipotle Mexican Grill</a> [CMG]. It fits with this megatrend of eating healthy, staying fit. We call it lifestyle betterment. Their product innovation has been superb–they launched these rolled quesadillas, which are going to have monster 15% same-store sales comps for them in the third quarter. It’s a great stock for us. Not cheap. But it has high growth.</p><p><blockquote>另一个名字是<a href=\"https://laohu8.com/S/CMG\">墨西哥烤肉店</a>[CMG]。它符合健康饮食、保持身材的大趋势。我们看涨期权it生活方式的改善。他们的产品创新非常出色——他们推出了这些卷油炸玉米饼，第三季度同店销售额将达到15%。这对我们来说是一只很棒的股票。不便宜。但它有很高的成长性。</blockquote></p><p> <b>How about a couple more?</b></p><p><blockquote><b>再来几个怎么样？</b></blockquote></p><p></p><p> One of the names that’s controversial we own is Tencent [TCEHY]. It’s one of the largest Internet companies in the world. It has 1.2 billion WeChat users. We believe that Chinese regulatory fears are overdone. Tencent is now trading at about 25 times next year’s earnings. We view it as having probably 20% revenue growth for at least the next few years.</p><p><blockquote>我们拥有的一个有争议的名字是腾讯控股[TCEHY]。它是世界上最大的互联网公司之一。它拥有12亿微信用户。我们认为，中国监管的担忧有些过头了。腾讯控股目前的市盈率约为明年市盈率的25倍。我们认为至少在未来几年内，它的收入可能会增长20%。</blockquote></p><p> <a href=\"https://laohu8.com/S/GNRC\">Generac</a> [GNRC] is another one. We’ll call it a climate change stock. Because climate change is happening, you have a lot of wildfires. You have a lot of weather patterns that aren’t normal. And in new homes today, one of the most common features that people are putting is a generator.</p><p><blockquote><a href=\"https://laohu8.com/S/GNRC\">通用</a>[GNRC]是另一个。我们将其看涨期权为气候变化股票。因为气候变化正在发生，所以有很多野火。你有很多不正常的天气模式。在今天的新房子里，人们最常见的特征之一就是发电机。</blockquote></p><p> <b>Can Generac sales be disrupted by battery storage in homes?</b></p><p><blockquote><b>家庭中的电池存储会扰乱Generac的销售吗？</b></blockquote></p><p> Battery and solar powered walls and roofs are still expensive–$40,000. A Generac system starts at $2,000.</p><p><blockquote>电池和太阳能供电的墙壁和屋顶仍然很贵——4万美元。Generac系统起价为2,000美元。</blockquote></p><p> <b>One more?</b></p><p><blockquote><b>再来一个？</b></blockquote></p><p> Snap [SNAP] is another name. If you have kids, Snap is one of the [apps] everybody’s using. The ARPU [or average revenue per user] is $13 annually, up about 30% over a year ago. Active users will be up about 20% this year. Do you use Tik Tok?</p><p><blockquote>SNAP【SNAP】是另一个名字。如果你有孩子，Snap是每个人都在使用的应用程序之一。ARPU（或每用户平均收入）为每年13美元，比一年前增长约30%。今年活跃用户将增长约20%。你用抖音吗？</blockquote></p><p> <b>No.</b></p><p><blockquote><b>没有。</b></blockquote></p><p> The biggest risk to Snap is something else comes along that the 18 to 25-year-old crowd wants to use that’s better. And Tik Tok is a disrupter to Snap. But I have kids in this age group, three of them, and they all use Snap.</p><p><blockquote>Snap面临的最大风险是18至25岁人群想要使用的更好的其他东西。而Tik Tok是Snap的颠覆者。但是我有这个年龄段的孩子，他们三个，他们都用Snap。</blockquote></p><p> The monetization has just begun. The global expansion has just begun. I think you have got at least three or four years of [growth].</p><p><blockquote>货币化才刚刚开始。全球扩张才刚刚开始。我认为你至少有三四年的[增长]。</blockquote></p><p> Thanks, Gary.</p><p><blockquote>谢谢，加里。</blockquote></p><p></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stock Ideas From an Investor Who Predicted Tesla Would Rise to $1,000<blockquote>预测特斯拉将升至1,000美元的投资者的5个股票想法</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stock Ideas From an Investor Who Predicted Tesla Would Rise to $1,000<blockquote>预测特斯拉将升至1,000美元的投资者的5个股票想法</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barron's</strong><span class=\"h-time small\">2021-09-08 17:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> listen to what Gary Black has to say about Tesla. But the investing veteran is more than just a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-trick, or one-stock, pony.</p><p><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>听听Gary Black对特斯拉的看法。但这位投资老手不仅仅是一位<a href=\"https://laohu8.com/S/AONE.U\">一</a>-诡计，或一只股票，小马。</blockquote></p><p> He has other picks for growth investors as well as a new actively managed ETF: The Future Fund (ticker: FFND), designed to capitalized on 10 megatrends he sees changing the world.</p><p><blockquote>他为成长型投资者提供了其他选择，以及一只新的主动管理型ETF：未来基金（股票代码：FFND），旨在利用他认为正在改变世界的10个大趋势。</blockquote></p><p> That fund is only a couple of weeks old. Black has been at the investing game for about 30 years, starting as a research analyst at Bernstein in 1992.</p><p><blockquote>该基金才成立几周。布莱克从1992年开始在伯恩斯坦担任研究分析师，从事投资行业已有大约30年的历史。</blockquote></p><p> After Bernstein, Black moved to the buy-side with stints at <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> Asset Management, Janus and Aegon, among others. After a brief respite following Aegon, Black jumped into the world of actively managed ETFs.</p><p><blockquote>在伯恩斯坦之后，布莱克转向买方，曾在<a href=\"https://laohu8.com/S/GS\">高盛</a>资产管理公司、骏利和全球保险集团等。在Aegon之后短暂休息后，Black进入了主动管理型ETF的领域。</blockquote></p><p> He sat down with Barron’s to talk about his new fund, his approach to investing and some of the stocks he’s invested in. An edited version of the conversation follows.</p><p><blockquote>他与《巴伦周刊》坐下来谈论他的新基金、他的投资方法以及他投资的一些股票。以下是对话的编辑版本。</blockquote></p><p> <b>Barron’s: </b>We probably have to start with Tesla (TSLA). How do you value Tesla stock?</p><p><blockquote><b>巴伦周刊：</b>我们可能要从特斯拉（TSLA）开始。您如何评估特斯拉股票？</blockquote></p><p> <b>Black:</b> I take where I think global [car sales are] going to be in about five years, and I take the EV adoption–it will get to 25% by 2025. This is the big investment controversy on Tesla: As competitors enter the market, can it keep its roughly 25% EV share? If it can, I get about $32 or so of earnings in 2025. And if I even put a 50 multiple on it, which is pretty low given projected 55% average annual earnings growth. I get a $1,600 price. And that’s worth about $1,100 today.</p><p><blockquote><b>黑色：</b>我认为全球[汽车销量]将在大约五年内达到什么水平，以及电动汽车的采用率——到2025年将达到25%。这就是特斯拉最大的投资争议：随着竞争对手进入市场，它能否保持大约25%的电动汽车份额？如果可以的话，到2025年我将获得大约32美元左右的收入。即使我给它打50倍，考虑到预计55%的平均年盈利增长率，这个数字也相当低。我得到1600美元的价格。今天这大约值1100美元。</blockquote></p><p> <b>Market share is the big controversy? What about self-driving cars?</b></p><p><blockquote><b>市场份额是最大的争议？自动驾驶汽车呢？</b></blockquote></p><p> Stop saying Tesla has valuation equal to $1,000 a share because of the EV business. And then another $1,000 because of robotaxis.</p><p><blockquote>不要因为电动汽车业务而说特斯拉的估值相当于每股1,000美元。然后又是1000美元，因为机器人出租车。</blockquote></p><p> <b>Tesla robotaxis like Waymo won’t be a thing?</b></p><p><blockquote><b>像Waymo这样的特斯拉机器人出租车不会成为现实？</b></blockquote></p><p> I think you’re going to have commercial robotaxi. And you’re going to have consumer robotaxi.</p><p><blockquote>我认为你将拥有商业机器人出租车。你将拥有消费者机器人出租车。</blockquote></p><p> Tesla has a head start, but competitors, especially those from <a href=\"https://laohu8.com/S/CAAS\">China</a>, are offering more expensive systems with vision, lidar, radar and HD mapping allowing them to close the gap. Everyone will get there eventually–which Elon has said. Tesla’s features will still let Tesla sell more Teslas.</p><p><blockquote>特斯拉处于领先地位，但竞争对手，尤其是来自<a href=\"https://laohu8.com/S/CAAS\">中国</a>，正在提供具有视觉、激光雷达、雷达和高清测绘功能的更昂贵的系统，使他们能够缩小差距。每个人最终都会到达那里——埃隆已经说过了。特斯拉的功能仍然会让特斯拉卖出更多的特斯拉。</blockquote></p><p> <b>Why did you start the Future Fund ETF?</b></p><p><blockquote><b>为什么要启动未来基金ETF？</b></blockquote></p><p> Secular growth [is] its cornerstone. We’re looking to capitalize on 10 secular megatrends that are changing the world.</p><p><blockquote>长期增长是其基石。我们希望利用正在改变世界的10个长期大趋势。</blockquote></p><p> <b>What are they?</b></p><p><blockquote><b>它们是什么？</b></blockquote></p><p> They are: [1] 24/7 information and entertainment, [2] social networking, [3] mobility–working from anywhere–[4] e-commerce, [5] fintech innovation, [6] big data and security, [7] people living longer, [8] lifestyle betterment, [9] automation and [10] sustainability. Those are the 10.</p><p><blockquote>它们是：[1]24/7信息和娱乐，[2]社交网络，[3]移动性-随时随地工作-[4]电子商务，[5]金融科技创新，[6]大数据和安全，[7]人们寿命更长，[8]生活方式改善，[9]自动化和[10]可持续发展。那是10个。</blockquote></p><p> And so what we try to do is find companies that [have] the megatrends as tailwinds. No. 1, we’re looking for high growth, 20% revenue growth. We’re looking for unlevered brands, meaning, brands that are very successful in, say, one segment, and they bring them into other segments, or brands that are successful in one geography, and can go global.</p><p><blockquote>因此，我们试图做的是找到那些以大趋势为推动力的公司。第一，我们寻求高增长，20%的收入增长。我们正在寻找无杠杆品牌，即在一个细分市场非常成功的品牌，并将其带入其他细分市场，或者在一个地区取得成功并可以走向全球的品牌。</blockquote></p><p> No. 2, we’re looking for investment controversy. We’re looking for something where there is a fight, and where investors don’t agree. And that’s what creates opportunity.</p><p><blockquote>第二，我们在寻找投资争议。我们正在寻找存在争斗且投资者不同意的地方。这就是创造机会的原因。</blockquote></p><p> <b>What’s your research process like?</b></p><p><blockquote><b>你的研究过程是怎样的？</b></blockquote></p><p> We go out, and I talk. We talk to a lot of competitors. When I was an analyst, I used to do focus groups. For 2,000 bucks, you could get 10 people in a room, and ask them why they don’t like about Beyond Meat [BYND] versus Impossible [Foods]. We can usually find information that gives me a research edge to answer the controversy.</p><p><blockquote>我们出去，我说话。我们和很多竞争对手谈过。当我还是分析师的时候，我经常做焦点小组。花2000美元，你可以让10个人呆在一个房间里，问他们为什么不喜欢Beyond Meat[BYND]和Impossible[Foods]。我们通常可以找到给我研究优势的信息来回答争议。</blockquote></p><p> <b>And how do you build your portfolio?</b></p><p><blockquote><b>你如何建立你的投资组合？</b></blockquote></p><p> We want a portfolio that’s high conviction, meaning no more than about 40 names. The top 10 names are about 40% of the portfolio. So that’s high conviction to me.</p><p><blockquote>我们想要一个高度可信的投资组合，这意味着不超过40个名字。排名前10的名字约占投资组合的40%。所以这对我来说是高度的信念。</blockquote></p><p> We think we have very strong buy and sell discipline. When we put something in the portfolio, we want it to have at least 2:1 risk-adjusted upside versus downside.</p><p><blockquote>我们认为我们有非常严格的买卖纪律。当我们将某样东西放入投资组合时，我们希望它的风险调整后上行空间与下行空间至少为2：1。</blockquote></p><p> <b>What else do you like, besides Tesla?</b></p><p><blockquote><b>除了特斯拉，你还喜欢什么？</b></blockquote></p><p> We have Google [parent <a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> ], which is changing the world. Google is a mega cap stock just like Tesla is. But we think You Tube is 24/7 information and entertainment. YouTube is way undervalued. They’re still monetizing [search]. It has good 15% to 20% revenue growth. At 22 times projected earnings, it’s still [an attractive] price to us.</p><p><blockquote>我们有谷歌[父<a href=\"https://laohu8.com/S/GOOG\">Alphabet</a>]，这正在改变世界。谷歌和特斯拉一样都是大盘股。但我们认为You Tube是24/7的信息和娱乐。YouTube被严重低估了。他们仍在通过[搜索]赚钱。它有15%到20%的良好收入增长。预计市盈率为22倍，对我们来说仍然是一个[有吸引力的]价格。</blockquote></p><p> Another name we have is <a href=\"https://laohu8.com/S/CMG\">Chipotle Mexican Grill</a> [CMG]. It fits with this megatrend of eating healthy, staying fit. We call it lifestyle betterment. Their product innovation has been superb–they launched these rolled quesadillas, which are going to have monster 15% same-store sales comps for them in the third quarter. It’s a great stock for us. Not cheap. But it has high growth.</p><p><blockquote>另一个名字是<a href=\"https://laohu8.com/S/CMG\">墨西哥烤肉店</a>[CMG]。它符合健康饮食、保持身材的大趋势。我们看涨期权it生活方式的改善。他们的产品创新非常出色——他们推出了这些卷油炸玉米饼，第三季度同店销售额将达到15%。这对我们来说是一只很棒的股票。不便宜。但它有很高的成长性。</blockquote></p><p> <b>How about a couple more?</b></p><p><blockquote><b>再来几个怎么样？</b></blockquote></p><p></p><p> One of the names that’s controversial we own is Tencent [TCEHY]. It’s one of the largest Internet companies in the world. It has 1.2 billion WeChat users. We believe that Chinese regulatory fears are overdone. Tencent is now trading at about 25 times next year’s earnings. We view it as having probably 20% revenue growth for at least the next few years.</p><p><blockquote>我们拥有的一个有争议的名字是腾讯控股[TCEHY]。它是世界上最大的互联网公司之一。它拥有12亿微信用户。我们认为，中国监管的担忧有些过头了。腾讯控股目前的市盈率约为明年市盈率的25倍。我们认为至少在未来几年内，它的收入可能会增长20%。</blockquote></p><p> <a href=\"https://laohu8.com/S/GNRC\">Generac</a> [GNRC] is another one. We’ll call it a climate change stock. Because climate change is happening, you have a lot of wildfires. You have a lot of weather patterns that aren’t normal. And in new homes today, one of the most common features that people are putting is a generator.</p><p><blockquote><a href=\"https://laohu8.com/S/GNRC\">通用</a>[GNRC]是另一个。我们将其看涨期权为气候变化股票。因为气候变化正在发生，所以有很多野火。你有很多不正常的天气模式。在今天的新房子里，人们最常见的特征之一就是发电机。</blockquote></p><p> <b>Can Generac sales be disrupted by battery storage in homes?</b></p><p><blockquote><b>家庭中的电池存储会扰乱Generac的销售吗？</b></blockquote></p><p> Battery and solar powered walls and roofs are still expensive–$40,000. A Generac system starts at $2,000.</p><p><blockquote>电池和太阳能供电的墙壁和屋顶仍然很贵——4万美元。Generac系统起价为2,000美元。</blockquote></p><p> <b>One more?</b></p><p><blockquote><b>再来一个？</b></blockquote></p><p> Snap [SNAP] is another name. If you have kids, Snap is one of the [apps] everybody’s using. The ARPU [or average revenue per user] is $13 annually, up about 30% over a year ago. Active users will be up about 20% this year. Do you use Tik Tok?</p><p><blockquote>SNAP【SNAP】是另一个名字。如果你有孩子，Snap是每个人都在使用的应用程序之一。ARPU（或每用户平均收入）为每年13美元，比一年前增长约30%。今年活跃用户将增长约20%。你用抖音吗？</blockquote></p><p> <b>No.</b></p><p><blockquote><b>没有。</b></blockquote></p><p> The biggest risk to Snap is something else comes along that the 18 to 25-year-old crowd wants to use that’s better. And Tik Tok is a disrupter to Snap. But I have kids in this age group, three of them, and they all use Snap.</p><p><blockquote>Snap面临的最大风险是18至25岁人群想要使用的更好的其他东西。而Tik Tok是Snap的颠覆者。但是我有这个年龄段的孩子，他们三个，他们都用Snap。</blockquote></p><p> The monetization has just begun. The global expansion has just begun. I think you have got at least three or four years of [growth].</p><p><blockquote>货币化才刚刚开始。全球扩张才刚刚开始。我认为你至少有三四年的[增长]。</blockquote></p><p> Thanks, Gary.</p><p><blockquote>谢谢，加里。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/stock-ideas-gary-black-tesla-51631058814?mod=hp_LATEST\">Barron's</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","TCEHY":"腾讯控股ADR","FFND":"One Global ETF","GNRC":"Generac控股","SNAP":"Snap Inc"},"source_url":"https://www.barrons.com/articles/stock-ideas-gary-black-tesla-51631058814?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175171654","content_text":"Investors listen to what Gary Black has to say about Tesla. But the investing veteran is more than just a one-trick, or one-stock, pony.\nHe has other picks for growth investors as well as a new actively managed ETF: The Future Fund (ticker: FFND), designed to capitalized on 10 megatrends he sees changing the world.\nThat fund is only a couple of weeks old. Black has been at the investing game for about 30 years, starting as a research analyst at Bernstein in 1992.\nAfter Bernstein, Black moved to the buy-side with stints at Goldman Sachs Asset Management, Janus and Aegon, among others. After a brief respite following Aegon, Black jumped into the world of actively managed ETFs.\nHe sat down with Barron’s to talk about his new fund, his approach to investing and some of the stocks he’s invested in. An edited version of the conversation follows.\nBarron’s: We probably have to start with Tesla (TSLA). How do you value Tesla stock?\nBlack: I take where I think global [car sales are] going to be in about five years, and I take the EV adoption–it will get to 25% by 2025. This is the big investment controversy on Tesla: As competitors enter the market, can it keep its roughly 25% EV share? If it can, I get about $32 or so of earnings in 2025. And if I even put a 50 multiple on it, which is pretty low given projected 55% average annual earnings growth. I get a $1,600 price. And that’s worth about $1,100 today.\nMarket share is the big controversy? What about self-driving cars?\nStop saying Tesla has valuation equal to $1,000 a share because of the EV business. And then another $1,000 because of robotaxis.\nTesla robotaxis like Waymo won’t be a thing?\nI think you’re going to have commercial robotaxi. And you’re going to have consumer robotaxi.\nTesla has a head start, but competitors, especially those from China, are offering more expensive systems with vision, lidar, radar and HD mapping allowing them to close the gap. Everyone will get there eventually–which Elon has said. Tesla’s features will still let Tesla sell more Teslas.\nWhy did you start the Future Fund ETF?\nSecular growth [is] its cornerstone. We’re looking to capitalize on 10 secular megatrends that are changing the world.\nWhat are they?\nThey are: [1] 24/7 information and entertainment, [2] social networking, [3] mobility–working from anywhere–[4] e-commerce, [5] fintech innovation, [6] big data and security, [7] people living longer, [8] lifestyle betterment, [9] automation and [10] sustainability. Those are the 10.\nAnd so what we try to do is find companies that [have] the megatrends as tailwinds. No. 1, we’re looking for high growth, 20% revenue growth. We’re looking for unlevered brands, meaning, brands that are very successful in, say, one segment, and they bring them into other segments, or brands that are successful in one geography, and can go global.\nNo. 2, we’re looking for investment controversy. We’re looking for something where there is a fight, and where investors don’t agree. And that’s what creates opportunity.\nWhat’s your research process like?\nWe go out, and I talk. We talk to a lot of competitors. When I was an analyst, I used to do focus groups. For 2,000 bucks, you could get 10 people in a room, and ask them why they don’t like about Beyond Meat [BYND] versus Impossible [Foods]. We can usually find information that gives me a research edge to answer the controversy.\nAnd how do you build your portfolio?\nWe want a portfolio that’s high conviction, meaning no more than about 40 names. The top 10 names are about 40% of the portfolio. So that’s high conviction to me.\nWe think we have very strong buy and sell discipline. When we put something in the portfolio, we want it to have at least 2:1 risk-adjusted upside versus downside.\nWhat else do you like, besides Tesla?\nWe have Google [parent Alphabet ], which is changing the world. Google is a mega cap stock just like Tesla is. But we think You Tube is 24/7 information and entertainment. YouTube is way undervalued. They’re still monetizing [search]. It has good 15% to 20% revenue growth. At 22 times projected earnings, it’s still [an attractive] price to us.\nAnother name we have is Chipotle Mexican Grill [CMG]. It fits with this megatrend of eating healthy, staying fit. We call it lifestyle betterment. Their product innovation has been superb–they launched these rolled quesadillas, which are going to have monster 15% same-store sales comps for them in the third quarter. It’s a great stock for us. Not cheap. But it has high growth.\nHow about a couple more?\nOne of the names that’s controversial we own is Tencent [TCEHY]. It’s one of the largest Internet companies in the world. It has 1.2 billion WeChat users. We believe that Chinese regulatory fears are overdone. Tencent is now trading at about 25 times next year’s earnings. We view it as having probably 20% revenue growth for at least the next few years.\nGenerac [GNRC] is another one. We’ll call it a climate change stock. Because climate change is happening, you have a lot of wildfires. You have a lot of weather patterns that aren’t normal. And in new homes today, one of the most common features that people are putting is a generator.\nCan Generac sales be disrupted by battery storage in homes?\nBattery and solar powered walls and roofs are still expensive–$40,000. A Generac system starts at $2,000.\nOne more?\nSnap [SNAP] is another name. If you have kids, Snap is one of the [apps] everybody’s using. The ARPU [or average revenue per user] is $13 annually, up about 30% over a year ago. Active users will be up about 20% this year. Do you use Tik Tok?\nNo.\nThe biggest risk to Snap is something else comes along that the 18 to 25-year-old crowd wants to use that’s better. And Tik Tok is a disrupter to Snap. But I have kids in this age group, three of them, and they all use Snap.\nThe monetization has just begun. The global expansion has just begun. I think you have got at least three or four years of [growth].\nThanks, Gary.","news_type":1,"symbols_score_info":{"TCEHY":0.9,"TSLA":0.9,"SNAP":0.9,"FFND":0.9,"GNRC":0.9}},"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141039321,"gmtCreate":1625822924263,"gmtModify":1633936980157,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/141039321","repostId":"2150037500","repostType":4,"isVote":1,"tweetType":1,"viewCount":303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":605090515,"gmtCreate":1639090391250,"gmtModify":1639090391439,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605090515","repostId":"1165217477","repostType":4,"repost":{"id":"1165217477","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639067136,"share":"https://www.laohu8.com/m/news/1165217477?lang=zh_CN&edition=full","pubTime":"2021-12-10 00:25","market":"us","language":"en","title":"Grab and Lucid stocks plunged more than 10%<blockquote>Grab和Lucid股价暴跌逾10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165217477","media":"Tiger Newspress","summary":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","content":"<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p><p><blockquote>Grab和Lucid股价在周四交易中暴跌超过10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab and Lucid stocks plunged more than 10%<blockquote>Grab和Lucid股价暴跌逾10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab and Lucid stocks plunged more than 10%<blockquote>Grab和Lucid股价暴跌逾10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 00:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p><p><blockquote>Grab和Lucid股价在周四交易中暴跌超过10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165217477","content_text":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","news_type":1,"symbols_score_info":{"GRAB":0.9,"LCID":0.9}},"isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868022399,"gmtCreate":1632556564711,"gmtModify":1632657774616,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"best","listText":"best","text":"best","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/868022399","repostId":"2170619785","repostType":4,"isVote":1,"tweetType":1,"viewCount":312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":884396807,"gmtCreate":1631853767309,"gmtModify":1631890295658,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/884396807","repostId":"2168528707","repostType":4,"isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}